<SEC-DOCUMENT>0001641172-25-016163.txt : 20250624
<SEC-HEADER>0001641172-25-016163.hdr.sgml : 20250624
<ACCEPTANCE-DATETIME>20250623182323
ACCESSION NUMBER:		0001641172-25-016163
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		12
FILED AS OF DATE:		20250624
DATE AS OF CHANGE:		20250623

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LIXTE BIOTECHNOLOGY HOLDINGS, INC.
		CENTRAL INDEX KEY:			0001335105
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				202903526
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-288120
		FILM NUMBER:		251066190

	BUSINESS ADDRESS:	
		STREET 1:		248 ROUTE 25A
		STREET 2:		NO. 2
		CITY:			EAST SETAUKET
		STATE:			NY
		ZIP:			11733
		BUSINESS PHONE:		310 203 2902

	MAIL ADDRESS:	
		STREET 1:		248 ROUTE 25A
		STREET 2:		NO. 2
		CITY:			EAST SETAUKET
		STATE:			NY
		ZIP:			11733

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SRKP 7 INC
		DATE OF NAME CHANGE:	20050803
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>forms-1a.htm
<DESCRIPTION>S-1/A
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>As
filed with the Securities and Exchange Commission on June 23, 2025</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration
No. 333-288120 </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <B>AMENDMENT NO. 1</B> </P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <B>TO</B> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>FORM
S-1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REGISTRATION
STATEMENT UNDER THE SECURITIES ACT OF 1933</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>LIXTE
    BIOTECHNOLOGY HOLDINGS, INC.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
    name of registrant as specified in its charter)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2834</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>20-2903526</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
                                            or other jurisdiction of</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">incorporation
    or organization)</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Primary
                                            standard industrial</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">classification
    code number)</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
                                            employer</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">identification
    number)</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>680
East Colorado Boulevard, Suite 180</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pasadena,
CA 91101</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(631)
830-7092</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address,
including zip code, and telephone number, including area code, of registrant&rsquo;s principal executive offices)</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <B>Geordan Pursglove</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Chief
Executive Officer</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>680
East Colorado Boulevard, Suite 180</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pasadena,
CA 91101</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(631)
830-7092</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name,
address, including zip code, and telephone number, including area code, of agent for service)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Copies
to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>David
                                            L. Ficksman, Esq.</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TroyGould
    PC</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1801
    Century Park East, 16<SUP>th</SUP> Floor</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Los
    Angeles, CA 90067</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tel:
    (310) 789-1290</B></FONT></P></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Anthony
                                            W. Basch, Esq.</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Kaufman
    &amp; Canoles</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Two
    James Center, 14<SUP>th</SUP> Floor</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Richmond,
    VA 23219</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tel:
    (804) 771-5700</B></FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 33.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Approximate
date of commencement of proposed sale to the public:</B> As soon as practicable after the effective date of this registration statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 33.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 33.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act of 1933 check the following box. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 33.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 33.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the
following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 33.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 33.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 33.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 33.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 33.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 33.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of &ldquo;large accelerated filer&rdquo;, &ldquo;accelerated filer&rdquo;,
&ldquo;smaller reporting company&rdquo;, and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 33%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 17%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 40%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated
    filer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 33.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 33.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 33.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the
registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective
in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date
as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 33.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement
filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not
soliciting an offer to buy these securities in any state where the offer or sale is not permitted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: red"><B>The information in this prospectus
is not complete and may be changed. The securities may not be sold until the registration statement filed with the SEC is declared effective.
This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where
the offer or sale is not permitted.</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: red"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: red"><B>Subject to Completion, dated June 23,
2025</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PRELIMINARY
PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <B>Up to 7,692,308</B> <B> Shares of Common
Stock, and/or up to</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <B>7,692,308</B> <B> Pre-Funded Warrants to
purchase up to 7,692,308 Shares of Common Stock</B></P>

<P STYLE="text-align: center; margin-top: 0; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0"><B>(and up to 7,692,308
shares of Common Stock underlying the Pre-Funded Warrants)</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LIXTE
BIOTECHNOLOGY HOLDINGS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are offering on a best efforts basis up to 7.692,308 </FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
of common stock, par value $0.0001 per share (the &ldquo;common stock&rdquo;) at an assumed public offering price of $0.78
per share of common stock, which is the last reported sales price of our common stock on the Nasdaq Capital Market on June 20,
2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
public offering price per share of common stock will be negotiated between us and the investors in consultation with the placement
agent based on market conditions at the time of pricing, and may be at a discount to the then current market price of our common
stock. Therefore, the recent market price of our common stock referenced throughout this preliminary prospectus may not be indicative
of the final offering price per share of common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on the Nasdaq Capital Market under the symbol &ldquo;LIXT&rdquo;. The closing price of our common stock on the
Nasdaq Capital Market on June 20, 2025 was $0.78 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also offering to investors in shares of common stock that would otherwise result in the investor&rsquo;s beneficial ownership exceeding
4.99% (or, at the election of the purchaser, 9.99%) of our outstanding shares of common stock immediately following the consummation
of this offering the opportunity to purchase pre-funded warrants (&ldquo;Pre-Funded Warrants&rdquo;) in lieu of common stock. Each Pre-Funded
Warrant consists of one pre-funded warrant to purchase one share of our common stock. The purchase price of each Pre-Funded Warrant is
$0.77999 (which is equal to the assumed public offering price per share of common stock of $0.78 minus $0.00001). Subject
to limited exceptions, a holder of Pre-Funded Warrants will not have the right to exercise any portion of its Pre-Funded Warrants if
the holder, together with its affiliates, would beneficially own in excess of 4.99% (or, at the election of the holder, such limit may
be increased to up to 9.99%) of the common stock outstanding immediately after giving effect to such exercise. The Pre-Funded Warrants
will be immediately exercisable (subject to the beneficial ownership cap) and may be exercised at any time until all of the Pre-Funded
Warrants are exercised in full. For each Pre-Funded Warrant purchased, the number of shares of common stock will be decreased on a one-for-one
basis. The Pre-Funded Warrants have no stand-alone rights and will not be certificated or issued as stand-alone securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have engaged Spartan Capital Securities, LLC to act as our exclusive placement agent (the &ldquo;Placement Agent&rdquo;) in connection
with this offering. The Placement Agent has agreed to use its reasonable best efforts to arrange for the sale of the securities
offered by this prospectus. The Placement Agent is not purchasing or selling any of the securities we are offering, and the Placement
Agent is not required to arrange the purchase or sale of any specific number of securities or dollar amount. We have agreed to pay to
the Placement Agent the fees set forth in the table below, which assumes that we sell all of the securities offered by this prospectus.
See &ldquo;Plan of Distribution&rdquo;. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no established trading market for the Pre-Funded Warrants and we do not expect an active trading market to develop. We do not intend
to list the Pre-Funded Warrants on any securities exchange or other trading market. Without an active trading market, the liquidity of
these securities will be limited.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
securities are expected to be issued in a single closing and the public offering price per share of common stock and Pre-Funded Warrant
will be fixed for the duration of this offering. We will deliver all of the securities to be issued in connection with this offering
delivery versus payment (&ldquo;DVP&rdquo;)/receipt versus payment (&ldquo;RVP&rdquo;) upon receipt of investor funds received by us.
There is no minimum offering requirement as a condition of closing of this offering. Because there is no minimum offering amount required
as a condition to closing this offering, we may sell fewer than all of the securities offered hereby, which may significantly reduce
the amount of proceeds received by us, and investors in this offering will not receive a refund in the event that we do not sell an amount
of securities sufficient to pursue our business goals described in this prospectus. Further, any proceeds from the sale of securities
offered by us will be available for our immediate use, despite uncertainty about whether we would be able to use such funds to effectively
implement our business plan. See &ldquo;Risk Factors&rdquo; on page 16 of this prospectus for more information.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
offering will terminate on July 15, 2025, unless the offering is fully subscribed before that date, or we decide to terminate the offering
(which we may do at any time in our discretion) prior to that date. We will bear all costs associated with the offering. No escrow agent
has been appointed or will be involved in this offering.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investing
in our securities is speculative and involves a high degree of risk. You should carefully consider the risk factors beginning on page
16 of this prospectus before purchasing our securities.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined
if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;<B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>Per Share of Common Stock<SUP></SUP> &nbsp;&nbsp;&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>Total &nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%">Public offering price </TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-size: 10pt"> &nbsp;&nbsp;&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt"> <FONT STYLE="font-size: 10pt">Placement Agent fees<SUP>(1)</SUP></FONT> <FONT STYLE="font-size: 10pt"><SUP>
    </SUP>&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt"> &nbsp;&nbsp;&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">Proceeds to us, before expenses </TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&nbsp;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have agreed to pay the Placement Agent a cash fee equal to 8.0% of the aggregate gross proceeds raised in this offering. We
    have also agreed to provide the Placement Agent with a 1.0% non-accountable expense allowance and to reimburse the Placement
    Agent for certain of its offering-related expenses, including its legal fees, up to a maximum of $125,000, which are not included
    in the above table. We have agreed to issue to the Placement Agent five-year warrants (the &ldquo;Placement Agent Warrants&rdquo;)
    to purchase up to 5.0% of the number of shares of common stock sold in this offering at an exercise price of 125% of the offering
    price per share of common stock. See &ldquo;Plan of Distribution&rdquo; for a description of the compensation to be received
    by the Placement Agent. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to deliver the shares of</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> common stock
(and Pre-Funded Warrants, if any) on or about June __, 2025, subject to the satisfaction of customary closing conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Sole
Placement Agent </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>Spartan
Capital Securities, LLC</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
date of this prospectus is June 23, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TABLE
OF CONTENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Page No.</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_001">ABOUT THIS PROSPECTUS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: center">1</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_002">PROSPECTUS SUMMARY</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">2</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_003">THE OFFERING</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">14</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_004">RISK FACTORS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">16</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_005">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">23</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_006">USE OF PROCEEDS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">26</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_007">CAPITALIZATION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">27</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_008">SELECTED HISTORICAL FINANCIAL DATA</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">30</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_009">DESCRIPTION OF SECURITIES</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">32</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <A HREF="#vi_001">PLAN OF DISTRIBUTION</A> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> 36 </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_011">LEGAL MATTERS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">39</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_012">EXPERTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">39</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_013">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">39</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_014">WHERE YOU CAN FIND MORE INFORMATION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">39</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_001"></A>ABOUT
THIS PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should rely only on the information contained in or incorporated by reference into this prospectus and in any free writing prospectus.
We have not authorized anyone to provide you with information different from that contained in this prospectus. The sale of our securities
will only be made in jurisdictions where offers and sales are permitted. The information in this prospectus is accurate only as of the
date of this prospectus, and any information we have incorporated by reference is accurate only as of the date of the document incorporated
by reference, regardless of the time of delivery of this prospectus or any sale of our securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action
for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus
must inform themselves about, and observe any restrictions relating to, the offering of our securities and the distribution of this prospectus
outside of the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
own or have rights to trademarks or trade names that we use in connection with the operation of our business, including our corporate
names, logos and website names. In addition, we own or have the rights to copyrights, trade secrets and other proprietary rights that
protect the content of our products. This prospectus may also contain trademarks, service marks and trade names of other companies, which
are the property of their respective owners. Our use or display of third parties&rsquo; trademarks, service marks, trade names or products
in this prospectus is not intended to, and should not be read to, imply a relationship with or endorsement or sponsorship of us. Solely
for convenience, some of the copyrights, trade names and trademarks referred to in this prospectus are listed without their &copy;, &reg;
and <SUP>TM</SUP> symbols, but we will assert, to the fullest extent under applicable law, our rights to our copyrights, trade names
and trademarks. All other trademarks are the property of their respective owners.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_002"></A>PROSPECTUS
SUMMARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
following summary highlights information contained or incorporated by reference elsewhere in this prospectus and does not contain all
of the information that you should consider in making your investment decision. Before investing in our securities, you should carefully
read this entire prospectus, including our consolidated financial statements and the related notes and other documents incorporated by
reference herein, as well as the information under the caption &ldquo;Risk Factors&rdquo; herein and under similar headings in the other
documents that are incorporated by reference into this prospectus including documents that are filed after the date hereof. Some of the
statements in this prospectus constitute forward-looking statements that involve risks and uncertainties. See &ldquo;Cautionary Note
Regarding Forward-Looking Statements&rdquo;. Our actual results could differ materially from those anticipated in such forward-looking
statements as a result of certain factors, including those discussed in the &ldquo;Risk Factors&rdquo; and other sections included in
or incorporated by reference herein. In this prospectus, unless otherwise stated or the context otherwise requires, references to &ldquo;Lixte&rdquo;,
the &ldquo;Company&rdquo;, &ldquo;we&rdquo;, &ldquo;us&rdquo;, &ldquo;our&rdquo;, or similar references mean Lixte Biotechnology Holdings,
Inc.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Company
Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage biopharmaceutical company focused on identifying new targets for cancer drug development and developing and commercializing
cancer therapies. Our product pipeline is primarily focused on inhibitors of protein phosphatase 2A, which are used to enhance cytotoxic
agents, radiation, immune checkpoint blockers and other cancer therapies. We believe that inhibitors of protein phosphatases have significant
therapeutic potential for a broad range of cancers. We are focusing on the clinical development of a specific protein phosphatase inhibitor,
referred to as LB-100, which has been shown to have clinical anti-cancer activity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that the mechanism by which LB-100 affects cancer cell growth is different from cancer agents currently approved for clinical
use. LB-100 is currently being tested in clinical trials in Ovarian Clear Cell Carcinoma, Metastatic Micro Satellite Stable (MSS) Colon
Cancer, and Advanced Soft Tissue Sarcoma. LB-100 has shown anti-cancer activity in animal models of glioblastoma multiforme, neuroblastoma,
and medulloblastoma, all cancers of neural tissue. LB-100 has also been shown to enhance the effectiveness of commonly used anti-cancer
drugs in animal models of melanoma, breast cancer and sarcoma. The enhancement of anti-cancer activity of these anti-cancer drugs occurs
at doses of LB-100 that do not significantly increase toxicity in animals. It is therefore hoped that, when combined with standard anti-cancer
regimens against many tumor types, LB-100 will improve therapeutic benefit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a compound moves through the FDA-approval process, it becomes an increasingly valuable property, but at a cost of additional investment
at each stage. As the potential effectiveness of LB-100 has been documented at the clinical trial level, we have allocated resources
to expand the breadth and depth of its patent portfolio. Our approach has been to operate with a minimum of overhead, moving compounds
forward as efficiently and inexpensively as possible, and to raise funds to support each of these stages as certain milestones are reached.
Our longer-term objective is to secure one or more strategic partnerships or licensing agreements with pharmaceutical companies with
major programs in cancer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
activities are subject to significant risks and uncertainties, including the need for additional capital. We have not yet commenced any
revenue-generating operations, do not have positive cash flows from operations, rely on stock-based compensation for a
substantial portion of employee and consultant compensation, and are dependent on periodic access to equity capital to fund its
operating requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description
of Business</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Most
cancer patients are treated with either chemotherapy or immunotherapy or both. These therapies often have limited benefit and there is
a high unmet medical need to enhance their effects. In many preclinical models we have shown that LB-100 enhances the effect of both
chemotherapy and Immunotherapy</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="forms-1_001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LB-100,
a small molecule potent inhibitor of PP2A, was designed and developed by us. Numerous preclinical studies have documented that LB-100
potentiates most if not all anti-cancer drugs that damage DNA. LB-100 is not associated with any increase in cytotoxicity when given
with cytotoxic drugs. This synergy involves transient interruption of several DNA damage repair pathways by LB-100 and an increase in
cell division rate. LB-100 has FDA Investigational New Drug status in the US and Investigational Medicinal Product Dossier approval in
the European Union.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
its initial Phase 1 clinical trial, LB-100 given alone daily for 3 days was non-toxic, except for a transient increase in serum creatinine
believed to be caused by inhibition of PP2A in the renal tubules. In the Phase 1 clinical trial, the Maximum Tolerated Dose (&ldquo;MTD&rdquo;)
was 2.33mg/m2 daily for 3 days every 3 weeks. Of the 25 patients with heavily-treated advanced solid tumors with measurable disease,
3 patients had stable disease for 2 cycles, 3 patients had stable disease for 4 cycles, and 3 patients had stable disease for 6 cycles.
One patient with pancreatic cancer had a partial response after 12 cycles lasting 534 days.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Low
doses of LB-100 have now been shown to enhance immune checkpoint inhibition (&ldquo;ICI&rdquo;) by several different mechanisms affecting
the tumor compartment and immune T-cell compartment. LB-100 increases CD8+T-cell infiltration and CD8-Treg ratio, CD8+T-cell proliferation,
and cytokine production induces microsatellite instability, neoantigen production and immune responsiveness, converting immunologically
&ldquo;cold&rdquo; to &ldquo;hot&rdquo; cancers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="forms-1_002.jpg" ALT="" STYLE="width: 576px; height: 573px"></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ovarian
clear cell carcinoma patients with inactivating mutations in PPP2R1A, a gene coding for a scaffold component of PP2A, and treated with
immune checkpoint inhibitors, were recently found to have markedly longer survival than patients without the mutation in their cancers.
Retrospective reviews of patients with a variety of cancers treated with ICI or chemotherapy show much longer survival of ICI-treated
patients with a PPP2R1A mutation in their tumors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="forms-1_003.jpg" ALT=""></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the observations in ovarian clear cell carcinoma, we have initiated a clinical trial in this disease combining LB-100 with a monoclonal
antibody blocking PD-1, a protein found on T-cells (NCT06065462).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
these preclinical and clinical observations, it is likely that LB-100 may be a general way to enhance immunotherapy responses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="forms-1_004.jpg" ALT=""></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
research on the LB-100 series was initiated in 2006 under a Cooperative Research and Development Agreement (&ldquo;CRADA&rdquo;) with
the National Institute of Neurologic Disorders and Stroke or NINDS of the National Institutes of Health or NIH dated March 22, 2006 that
was subsequently extended through a series of amendments until it terminated on April 1, 2013.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have also designed and developed the LB-200 series, which consists of histone deacetylase inhibitors (HDACi). LB-200 has not advanced
to the clinical stage and would require additional capital to fund further development. Accordingly, because of our focus on the clinical
development of LB-100 and analogs for cancer therapy as described below in more detail, we have decided not to actively pursue the preclinical
development of our LB-200 series of compounds at this time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Clinical
Trial Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Spanish
Sarcoma Group Collaboration Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
July 31, 2019, we entered into a Collaboration Agreement for an Investigator-Initiated Clinical Trial with the Spanish Sarcoma Group
(Grupo Espa&ntilde;ol de Investigaci&oacute;n en Sarcomas or &ldquo;GEIS&rdquo;), Madrid, Spain, to carry out a study entitled &ldquo;Randomized
phase I/II trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue sarcoma&rdquo;. The purpose of
this clinical trial is to obtain information with respect to the efficacy and safety of LB-100 combined with doxorubicin in soft tissue
sarcomas. Doxorubicin is the global standard for initial treatment of advanced soft tissue sarcomas (&ldquo;ASTS&rdquo;). Doxorubicin
alone has been the mainstay of first line treatment of ASTS for over 40 years, with little improvement in survival from adding cytotoxic
compounds to or substituting other cytotoxic compounds for doxorubicin. In animal models, LB-100 consistently enhances the anti-tumor
activity of doxorubicin without apparent increases in toxicity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GEIS
has a network of referral centers in Spain and across Europe that have an impressive track record of efficiently conducting innovative
studies in ASTS. We agreed to provide GEIS with a supply of LB-100 to be utilized in the conduct of this clinical trial, as well as to
provide funding for the clinical trial. The goal is to enter approximately 150 to 170 patients in this clinical trial over a period of
two to four years. The Phase 1 portion of the study began in the quarter ended June 30, 2023 to determine the recommended Phase 2 dose
of the combination of doxorubicin and LB-100. As advanced sarcoma is a very aggressive disease, the design of the Phase 2 portion of
the study assumes a median progression-free survival (&ldquo;PFS&rdquo;), no evidence of disease progression or death from any cause)
of 4.5 months in the doxorubicin arm and an alternative median PFS of 7.5 months in the doxorubicin plus LB-100 arm to demonstrate a
statistically significant decrease in relative risk of progression or death by adding LB-100. There is a planned interim analysis of
the primary endpoint when approximately 50% of the 102 events required for final analysis is reached.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 13, 2022, we announced that the Spanish Agency for Medicines and Health Products (Agencia Espa&ntilde;ola de Medicamentos y Productos
Sanitarios or &ldquo;AEMPS&rdquo;) had authorized a Phase 1b/randomized Phase 2 study of LB-100, our lead clinical compound, plus doxorubicin,
versus doxorubicin alone, the global standard for initial treatment of advanced soft tissue sarcomas (ASTS). Consequently, this clinical
trial commenced during the quarter ended June 30, 2023 and to be completed and a report prepared by December 31, 2026. In April 2023,
GEIS completed its first site initiation visit in preparation for the clinical trial at Fundaci&oacute;n Jim&eacute;nez D&iacute;az University
Hospital (Madrid). Up to 170 patents will be entered into the clinical trial. The recruitment phase of the Phase 1b portion of the protocol
was completed during the quarter ended September 30, 2024. We expect to have data on toxicity and preliminary efficacy from this portion
of the clinical trial during the quarter ending December 31, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
the focus on the combination of LB-100 with immunotherapy in ovarian clear cell carcinoma and colorectal cancer and the availability
of capital resources, we entered into Amendment No. 1 to the Collaboration Agreement effective March 11, 2025 that relieved us of the
financial obligation to support the randomized Phase 2 portion of the clinical trial contemplated in the Collaboration Agreement of approximately
$3,095,000. As a result, it is uncertain as to whether the Phase 2 portion of this clinical trial will proceed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
Research Support Agreement Relating to Small Cell Lung Cancer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
had executed a Clinical Research Support Agreement with the City of Hope National Medical Center to carry out a Phase 1b clinical trial
of LB-100 combined with an FDA-approved standard regiment for treatment of untreated extensive-stage disease small cell lung cancer.
The clinical trial was initiated on March 9, 2021. However, due to the lack of patient accrual, the Company provided notice to the City
of Hope National Medical Center of our intent to terminate the Clinical Research Support Agreement effective as of July 8, 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MD
Anderson Cancer Center Clinical Trial</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 20, 2023, we announced an investigator-initiated Phase 1b/2 collaborative clinical trial to assess whether adding LB-100 to
a human programmed death receptor-1 (&ldquo;PD-1&rdquo;) blocking antibody of GSK plc (&ldquo;GSK&rdquo;), dostarlimab-gxly, may enhance
the effectiveness of immunotherapy in the treatment of ovarian clear cell carcinoma (&ldquo;OCCC&rdquo;). The clinical trial is being
sponsored by The University of Texas MD Anderson Cancer Center (&ldquo;MD Anderson&rdquo;) and is being conducted at The University of
Texas &ndash; MD Anderson Cancer Center. We are providing LB-100 and GSK is providing dostarlimab-gxly and financial support for the
clinical trial. On January 29, 2024, we announced the entry of the first patient into this clinical trial. We currently expect that this
clinical trial will be completed by December 31, 2027.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 25, 2025, we announced that we had added the Robert H. Lurie Comprehensive Cancer Center (Lurie Cancer Center) of Northwestern
University as a second site in a clinical trial combining the Company&rsquo;s proprietary compound LB-100 with GSK&rsquo;s dostarlimab
to treat ovarian clear cell cancer. Patient recruitment is underway, and the first patient has been dosed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Netherlands
Cancer Institute Clinical Trial</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
June 10, 2024, we entered into a Clinical Trial Agreement with the Netherlands Cancer Institute (&ldquo;NKI&rdquo;) to conduct a Phase
1b clinical trial of the Company&rsquo;s protein phosphatase inhibitor, LB-100, combined with atezolizumab, a PD-L1 inhibitor, the proprietary
molecule of F. Hoffman-La Roche Ltd. (&ldquo;Roche&rdquo;), for patients with microsatellite stable metastatic colon cancer. Under the
agreement, we will provide our lead clinical compound, LB-100, and under a separate agreement between NKI and Roche, Roche will provide
atezolizumab and financial support for the clinical trial. We have no obligation to and will not provide any reimbursement of clinical
trial costs. Pursuant to the agreement and the protocol set forth in the agreement, the clinical trial will be conducted by NKI at NKI&rsquo;s
site in Amsterdam by principal investigator Neeltje Steeghs, MD, PhD, and NKI will be responsible for the recruitment of patients. The
agreement provides for the protection of the respective intellectual property rights of each of Lixte, NKI and Roche.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Phase 1b clinical trial will evaluate safety, optimal dose and preliminary efficacy of LB-100 combined with atezolizumab for the treatment
of patients with metastatic microsatellite stable colorectal cancer. Immunotherapy using monoclonal antibodies like atezolizumab can
enhance the body&rsquo;s immune response against cancer and hinder tumor growth and spread. LB-100 has been found to improve the effectiveness
of anticancer drugs in killing cancer cells by inhibiting a protein called PP2A on cell surfaces. Blocking PP2A increases stress signals
in tumor cells expressing the PP2A protein. Accordingly, combining atezolizumab with LB-100 may enhance treatment efficacy for metastatic
colorectal cancer, as cancer cells with heightened stress signals are more vulnerable to immunotherapy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
study comprises a dose escalation phase and a dose expansion phase. The objective of the dose escalation phase is to determine the recommended
Phase 2 dose (RP2D) of LB-100 when combined with the standard dosage of atezolizumab. The dose expansion phase will further investigate
the preliminary efficacy, safety, tolerability, and pharmacokinetics/dynamics of the LB-100 and atezolizumab combination. The clinical
trial opened in August 2024 with the enrollment of the first patient. Patient accrual is expected to take up to 24 months, with a maximum
of 37 patients with advanced colorectal cancer to be enrolled in this study.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shelf life of the batch of LB-100 being utilized in this clinical trial was scheduled to expire on December 25, 2025, but has been extended
for a final time for a period of 12 months through December 25, 2026, after which date no new patients can be recruited into this clinical
trial and no patients can be treated with the current batch of LB-100. Although we do not currently intend to commission the production
of a new batch of LB-100 for this clinical trial, we believe that it is likely that we will be able to recruit enough patients in sufficient
time into this clinical trial to be able to reach an evaluable outcome for all end points in this clinical trial by December 25, 2026.
The expiration of the shelf life of this batch of LB-100 represents an effective termination date of this clinical trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal investigator of the colorectal study testing LB-100 in combination with atezolizumab is currently investigating two Serious
Adverse Events (&ldquo;SAEs&rdquo;) observed in the clinical trial that was launched in August 2024. The Investigational Review Board
(IRB) of the Netherlands Cancer Institute has requested additional information with respect to these SAEs and the study has been paused
for enrollment until the IRB&rsquo;s questions have been, as more fully discussed below at &ldquo;Risks Related to the Development and
Regulatory Approval of Our Product Candidates - <I>A clinical trial hold due to serious adverse events could delay or halt the development
of our product candidate&rdquo;.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I></I></FONT></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">National
Cancer Institute Pharmacologic Clinical Trial</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2019, the National Cancer Institute (NCI) initiated a glioblastoma (GBM) pharmacologic clinical trial. This study was being conducted
and funded by the NCI under a Cooperative Research and Development Agreement, with the Company being required to provide the LB-100 clinical
compound.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Primary
malignant brain tumors (gliomas) are very challenging to treat. Radiation combined with the chemotherapeutic drug temozolomide has been
the mainstay of therapy of the most aggressive gliomas (glioblastoma multiforme or GBM) for decades, with little further benefit gained
by the addition of one or more anti-cancer drugs, but without major advances in overall survival for the majority of patients. In animal
models of GBM, the Company&rsquo;s novel protein phosphatase inhibitor, LB-100, has been found to enhance the effectiveness of radiation,
temozolomide chemotherapy treatments and immunotherapy, raising the possibility that LB-100 may improve outcomes of standard GBM treatment
in the clinic. Although LB-100 has proven safe in patients at doses associated with apparent anti-tumor activity against several human
cancers arising outside the brain, the ability of LB-100 to penetrate tumor tissue arising in the brain was not known. Many drugs potentially
useful for GBM treatment do not enter the brain in amounts necessary for anti-cancer action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
NCI study was designed to determine the extent to which LB-100 enters recurrent malignant gliomas. Patients having surgery to remove
one or more tumors received one dose of LB-100 prior to surgery and had blood and tumor tissue analyzed to determine the amount of LB-100
present and to determine whether the cells in the tumors showed the biochemical changes expected to be present if LB-100 reached its
molecular target. As a result of the innovative design of the NCI study, it was believed that data from a few patients would be sufficient
to provide a sound rationale for conducting a larger clinical trial to determine the effectiveness of adding LB-100 to the standard treatment
regimen for GBMs. Blood and brain tumor tissue were analyzed from seven patients after intravenous infusion of a single dose of LB-100.
Results of the investigation demonstrated that there was virtually no entry of LB-100 into the brain tumor tissue. Accordingly, alternative
methods of drug delivery will be required to determine if LB-100 has meaningful clinical anti-cancer activity against glioblastoma multiforme
and other aggressive brain tumors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Patent
and License Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">National
Institute of Health</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
February 23, 2024, we entered into a Patent License Agreement (the &ldquo;License Agreement&rdquo;) with the National Institute of Neurological
Disorders and Stroke (&ldquo;NINDS&rdquo;) and the National Cancer Institute (&ldquo;NCI&rdquo;), each an institute or center of the
National Institute of Health (&ldquo;NIH&rdquo;). Pursuant to the License Agreement, we have licensed exclusively NIH&rsquo;s intellectual
property rights claimed for a Cooperative Research and Development Agreement (&ldquo;CRADA&rdquo;) subject invention co-developed with
the Company, and the licensed field of use, which focuses on promoting anti-cancer activity alone, or in combination with standard anti-cancer
drugs. The scope of this clinical research extends to checkpoint inhibitors, immunotherapy, and radiation for the treatment of cancer.
The License Agreement is effective, and shall extend, on a licensed product, licensed process, and country basis, until the expiration
of the last-to-expire valid claim of the jointly owned licensed patent rights in each such country in the licensed territory, unless
sooner terminated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
License Agreement contemplates that we will seek to work with pharmaceutical companies and clinical trial sites (including comprehensive
cancer centers) to initiate clinical trials within timeframes that will meet certain benchmarks. Data from the clinical trials will be
the subject of various regulatory filings for marketing approval in applicable countries in the licensed territories. Subject to the
receipt of marketing approval, we would be expected to commercialize the licensed products in markets where regulatory approval has been
obtained.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
Significant Agreements and Contracts</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Netherlands
Cancer Institute</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 8, 2021, we entered into a Development Collaboration Agreement with the Netherlands Cancer Institute, Amsterdam (&ldquo;NKI&rdquo;),
one of the world&rsquo;s leading comprehensive cancer centers, and Oncode Institute, Utrecht, a major independent cancer research center,
for a term of three years. The Development Collaboration Agreement was subsequently modified by Amendment No. 1 thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Development Collaboration Agreement is a preclinical study intended to identify the most promising drugs to be combined with LB-100,
and potentially LB-100 analogues, to be used to treat a range of cancers, as well as to identify the specific molecular mechanisms underlying
the identified combinations. We agreed to fund the preclinical study, at an approximate cost of 391,000 Euros and provide a sufficient
supply of LB-100 to conduct the preclinical study.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 3, 2023, we entered into Amendment No. 2 to the Development Collaboration Agreement with NKI, which provides for additional research
activities, extends the termination date of the Development Collaboration Agreement by two years to October 8, 2026, and added 500,000
Euros to the operating budget being funded by us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 4, 2024, we entered into Amendment No. 3 to the Development Collaboration Agreement with NKI, which suspended Amendment No. 2
and provided for a new study term of one year and starts upon the dosing of the first patient in the clinical trial at a project cost
of 100,000 Euros.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
as of June 15, 2022, Dr. Ren&eacute; Bernards was appointed to our Board of Directors as an independent director. Dr. Bernards is a leader
in the field of molecular carcinogenesis and is employed by NKI.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Intellectual
Property</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
intellectual property includes proprietary know-how, proprietary methodologies and extensive clinical validation data and publications.
To provide legal protection of our intellectual property, we rely on a combination of patents, licenses, trade secrets, trademarks, confidentiality
and non-disclosure clauses and agreements, and other forms of intellectual property protection to define and protect our rights to our
products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
products are expected to be covered by our patents. These patents now cover sole rights to the composition and synthesis of our LB-100
series of drugs, which is the Company&rsquo;s lead clinical compound in development. Lixte has filed patent applications covering the
treatment of cancer with LB-100. Lixte has also filed joint patent applications with the NIH and the Netherlands Cancer Institute for
the treatment of cancer using LB-100 in combination with other drugs like immune checkpoint inhibitors and WEE1 inhibitors (a class of
drugs that target and inhibit the WEE1 kinase enzyme that plays a crucial role in regulating cell division).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent
applications for the LB-100 series (oxabicycloheptanes and oxabicycloheptenes) have been filed in the United States and internationally
under the Patent Cooperation Treaty. Patents for composition of matter and for several uses of the LB-100 series have been issued in
the United States, Mexico, Australia, Japan, China, Hong Kong, Canada, and by the European Patent Office</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
strive to protect and enhance the proprietary technology, inventions, and improvements that are commercially important to the development
of our business, including seeking, maintaining, and defending its patent rights, which are owned solely by our wholly-owned Delaware
subsidiary, Lixte Biotechnology, Inc., except in several instances jointly with one of many of our collaborators. We also rely on trade
secrets relating to its proprietary pipeline of product candidates and on know-how and continuing technological innovation to develop
and strengthen its pipeline. We intend to rely on regulatory protection afforded by regulatory agencies through data exclusivity, market
exclusivity, and patent term extensions, where available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success will depend in large part on its ability to obtain and maintain patent and other proprietary protection for commercially important
technology, inventions and know-how related to its business; defend and enforce its patents; preserve the confidentiality of its trade
secrets; and operate without infringing valid and enforceable patents or proprietary rights of third parties. Our ability to stop third
parties from making, using, selling, offering to sell, or importing our technology may depend on the extent to which we have rights under
valid and enforceable licenses, patents, or trade secrets that cover these activities. In some cases, enforcement of these rights may
depend on cooperation of the joint owners of our jointly owned patents and patent applications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to both our solely and jointly owned intellectual property, we cannot be sure that patents will be granted on any of its pending
patent applications or on any patent applications filed solely or jointly by us in the future; we cannot be sure that any of our existing
patents or any patents that may be granted to us in the future will be commercially useful in protecting our intended commercial products
or therapeutic methods; and we cannot be sure that an agency or court would determine that the our solely or jointly owned patents are
valid and enforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nasdaq
Compliance</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 19, 2024, we received a letter from the Listing Qualifications Department (the &ldquo;Staff&rdquo;) of the Nasdaq Stock Market
LLC indicating that we were not in compliance with the minimum stockholders&rsquo; equity requirement of $2,500,000 for continued listing
on the Nasdaq Capital Market under Listing Rule 5550(b) (the &ldquo;Equity Rule&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 3, 2024, we submitted a plan to the Staff to regain compliance with the Equity Rule, which outlined our proposed initiatives
to regain compliance by raising equity capital through various registered equity offerings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 21, 2024, the Staff provided notice to us that it had granted an extension through February 18, 2025 to regain compliance with
the Equity Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of February 18, 2025, we had not regained compliance with the Equity Rule. Accordingly, on February 19, 2025, we received a Staff determination
letter from the Staff stating that we did not meet the terms of the extension because we did not complete our proposed financing initiatives
to regain compliance. We timely requested a Hearing before a Nasdaq Hearings Panel (the &ldquo;Panel&rdquo;), which automatically stayed
Nasdaq&rsquo;s suspension or delisting of our common stock and public warrants pending the Panel&rsquo;s decision.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 17, 2025, we received notice that the Panel had granted us an extension in which to regain compliance with all continued listing
rules of the Nasdaq Capital Market. The Panel&rsquo;s determination followed a hearing on April 3, 2025, at which time the Panel considered
our plan to regain compliance with the Equity Rule. As a result of the extension, the Panel granted our request for continued listing
on the Nasdaq Capital Market, provided that we demonstrate compliance with the Equity Rule and all other continued listing requirements
for the Nasdaq Capital Market by July 3, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
offering is being conducted in order for us to satisfy the decision of the Panel and to provide the working capital resources to fund
our operations. However, there can be no assurances that the Panel will deem the proceeds from this offering as sufficient to comply
with the Equity Rule and all other continued listing requirements for the Nasdaq Capital Market. Accordingly, even if we complete this
offering, there can be no assurances that we will be able to regain compliance during the extension period and thus be able to maintain
our listing on the Nasdaq Capital Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the extension period, our common stock and public warrants will continue to trade on the Nasdaq Capital Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were incorporated as a Delaware Corporation on May 24, 2005 under the name SRKP7, Inc. On June 30, 2006, pursuant to a share exchange
agreement, we acquired all of the outstanding shares of Lixte Biotechnology, Inc. which then became a wholly owned subsidiary. On December
7, 2006, we changed our name to Lixte Biotechnology Holdings, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
September 26, 2023, Bastiaan van der Baan, a director of the Company since June 17, 2022, replaced our founder, John S. Kovach, as President
and Chief Executive Officer. Dr. Kovach passed away on October 5, 2023. Effective October 6, 2023, Mr. van der Baan was appointed as
Chairman of the Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
discussed below, effective June 16, 2025, Mr. van der Baan resigned as Chairman of the Board of Directors and Chief Executive Officer,
but remained as President and as a member of the Board of Directors, and was appointed as the Company&rsquo;s Chief Scientific Officer,
and Geordan Pursglove was appointed as Chairman of the Board of Directors and Chief Executive Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock and public warrants are traded on the Nasdaq Capital Market under the symbols &ldquo;LIXT&rdquo; and &ldquo;LIXTW&rdquo;,
respectively. On June 2, 2023, we effected a one-for-ten reverse split of our outstanding shares of common stock in order to remain in
compliance with the $1.00 minimum closing bid price requirement of the Nasdaq Capital Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
principal address is 680 East Colorado Boulevard, Suite 180, Pasadena, CA 91101. Our telephone number is (631) 830-7092. We maintain
a website at <U>https://lixte.com</U>. The information contained on our website is not, and should not be interpreted to be, incorporated
into this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>July
2023 Financing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 20, 2023, we sold 583,334 shares of common stock at a price of $6.00 per share to an institutional investor and raised gross proceeds
of approximately $3,500,000. As part of this financing, we sold warrants to the institutional investor to purchase 583,334 shares of
common stock (the &ldquo;2023 Warrants&rdquo;). The 2023 Warrants had an initial exercise price of $6.00 per share, were immediately
exercisable upon issuance, and expire five years thereafter on July 20, 2028. We also issued warrants to the placement agent to purchase
35,000 shares of common stock at an exercise price of $6.60 per share and expiring on July 20, 2028 (the &ldquo;2023 Placement Agent
Warrants&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise prices of the warrants issued to the institutional investor and to the placement agent are subject to customary adjustments
for stock splits, stock dividends, stock combinations, reclassifications, reorganizations, or similar events affecting our common stock.
In addition, the warrants issued to the institutional investor contain a &ldquo;fundamental transaction&rdquo; provision whereby in the
event of a fundamental transaction (including a sale or transfer of assets or ownership of the Company as defined in the warrant agreement)
within our control, the holder of the unexercised common stock warrants would be entitled to receive, in exchange for extinguishment
of the warrants, cash consideration equal to a Black-Scholes valuation, as defined in the warrant agreement. If such fundamental transaction
is not within our control, the warrant holder would only be entitled to receive the same form of consideration (and in the same proportion)
as the holders of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly,
in the event of a change in control of the Company or a sale or transfer of all or substantially all of our assets, as defined in the
2023 Warrants, to the extent that the warrants issued to the institutional investor are outstanding at the effective date that such a
transaction is closed, this &ldquo;fundamental transaction&rdquo; provision would entitle the holder to substantial cash consideration,
thus reducing the amounts to be retained by us or potentially distributable to our stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>February
2025 Financing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 11, 2025, we entered into a Securities Purchase Agreement (the &ldquo;Purchase Agreement&rdquo;) with two institutional investors
(the &ldquo;Selling Stockholders&rdquo;). Pursuant to the Purchase Agreement, on February 13, 2025, we sold 434,784 shares of common
stock at a price of $2.415 per share and raised gross proceeds of approximately $1,050,000. As part of this financing, we sold warrants
to the institutional investors to purchase 434,784 shares of common stock (the &ldquo;2025 Warrants&rdquo;). Such Warrants had an initial
exercise price of $2.29 per share, were immediately exercisable upon issuance, and expire five years thereafter on February 12, 2030.
We also issued warrants to the placement agent to purchase 32,609 shares of common stock at an exercise price of $3.0188 per share and
expiring on February 12, 2030 (the &ldquo;2025 Placement Agent Warrants&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise prices of the warrants issued to the institutional investors and to the placement agent are subject to customary adjustments
for stock splits, stock dividends, stock combinations, reclassifications, reorganizations, or similar events affecting our common stock.
In addition, the warrants issued to the institutional investors contain a &ldquo;fundamental transaction&rdquo; provision whereby in
the event of a fundamental transaction (including a sale or transfer of assets or ownership of the Company as defined in the warrant
agreement) within our control, the holders of the unexercised common stock warrants would be entitled to receive, in exchange for extinguishment
of the warrants, cash consideration equal to a Black-Scholes valuation, as defined in the warrant agreement. If such fundamental transaction
is not within our control, the warrant holders would only be entitled to receive the same form of consideration (and in the same proportion)
as the holders of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly,
in the event of a change in control of the Company or a sale or transfer of all or substantially all of our assets, as defined in the
2025 Warrants, to the extent that the warrants issued to the institutional investors are outstanding at the effective date that such
a transaction is closed, this &ldquo;fundamental transaction&rdquo; provision would entitle the holders to substantial cash consideration,
thus reducing the amounts to be retained by us or potentially distributable to our stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Executive
Management and Director Changes</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to and effective as of the consummation of this public offering, there will be several changes with respect to our executive management
and the Board of Directors as described herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Bastiaan
van der Baan. </B>Effective June 16, 2025, Bastiaan van der Baan resigned as Chairman of the Board of Directors and as Chief Executive
Officer, but remained as President and as a member of the Board of Directors, and was appointed as Chief Scientific Officer. Mr. van
der Baan&rsquo;s principal responsibility as President will be related to the clinical development of our LB-100 lead compound. His responsibility
as Chief Scientific Officer (CSO) will be for shaping and executing the scientific vision and research and development strategy of the
Company, with a focus on discovering and developing innovative cancer therapeutics. The CSO leads all research functions, oversees preclinical
and translational programs, supervises the Chief Medical Officer, and ensures alignment with clinical and regulatory development goals.
The CSO provides scientific leadership to internal teams and external partners, supports fundraising and business development, and serves
as a key member of executive management.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
conjunction with such resignation, the stock option that Mr. van der Baan was previously granted on September 26, 2023 to acquire 250,000
shares of common stock was deemed fully vested effective with Mr. van der Baan&rsquo;s resignation as described herein, and the time
period for Mr. van der Baan to exercise his stock option at any time in the future that he is no longer providing his services to the
Company as a consultant, employee or otherwise was increased from ninety (90) days to one (1) year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
for the previously described changes in Mr. van der Baan&rsquo;s management duties and the modifications to the terms of the stock option,
Mr. van der Baan&rsquo;s three (3) year employment agreement dated September 26, 2023 will remain in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Company does not complete a successful financing that enables it to maintain its listing on the Nasdaq Small Cap Market by
July 3, 2025, the amendment to Mr. van der Baan&rsquo;s employment agreement as described herein will be automatically terminated
retroactive to the amendment date and Mr. van der Baan will be reinstated as Chairman of the Board of Directors and Chief Executive
Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Geordan
Pursglove.</B> Effective June 16, 2025, Geordan Pursglove was appointed as our new Chairman of the Board of Directors and Chief Executive
Officer. His responsibilities include the oversight of our business operations and strategic planning, and he will be the primary contact
between our executive team and the Board of Directors. He will also be the principal spokesperson of the Company and have final say on
all corporate matters, subject only to the authority of the Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into an employment agreement with Mr. Pursglove for a term of three (3) years effective June 16, 2025. Mr. Pursglove will
receive an annual salary of $240,000 which may be increased from time to time in the sole discretion of the Board of Directors. At his
election, his compensation will be payable in cash and/or restricted shares, or a combination thereof. He is also eligible to receive
an annual bonus as determined in the sole discretion of the Board of Directors in the form of cash or equity, or a combination thereof.
Mr. Pursglove will not receive any additional compensation for serving as the Chairman of the Board of Directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
as of the end of the first trading day for the Company&rsquo;s common stock immediately following the consummation of this offering,
as an inducement to Mr. Pursglove to join our Company, as a signing bonus, he will be granted a stock option to purchase 350,000 shares
of our common stock at an exercise price equal to the closing price on the Nasdaq Stock Market on such date, which shall be exercisable
for a term of five (5) years, shall provide for cashless exercise, and shall vest 50% on the grant date, 25% on September 30, 2025, and
25% on December 31, 2025, subject to continued service.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
stock option grant will not be issued under the Company&rsquo;s 2020 Stock Incentive Plan. The stock option agreement will provide for
certain registration rights (including on Form S-8) and for accelerated vesting upon the occurrence of certain events, including early
termination of the employment agreement that is not the result of the voluntary termination, gross negligence or willful misconduct of
Mr. Pursglove, a sale or change in control of the Company, or a sale, licensing or other disposition of all or substantially all of the
assets of the Company, as defined in such stock option agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Company does not complete a successful financing that enables it to maintain its listing on the Nasdaq Capital Market by July 3, 2025, the employment agreement with Mr. Pursglove as described herein will be deemed automatically
terminated retroactively as of June 16, 2025 and the stock option grant will be cancelled, and Mr. Pursglove will promptly resign from
the Board of Directors. In such event, Mr. van der Baan will be reinstated as Chairman of the Board of Directors and Chief Executive
Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to joining the Company, Mr. Pursglove served as President, Chief Executive Officer and Chairman of the Board of Directors at Beyond Commerce,
Inc. He was also President of Service 800, Inc., a leading phone and online customer satisfaction survey service that provides the most
actionable customer feedback, to the most recognizable Fortune 500 companies globally, in which he led operations, scaled revenue, and
oversaw the company&rsquo;s strategic vision. Mr. Pursglove held a board position at SemiCab Holdings, an emerging leader in the global
logistics and distribution industry that was part of Algorhythm Holdings (NASDAQ: RIME). Currently Mr. Pursglove serves as the managing
director of The 2GP Group LLC. During his time as the Managing Director of The 2GP Group, Mr. Pursglove has built multiple businesses
in Sports, Sales, Marketing and Logistics. Mr. Pursglove has over a decade of experience in M&amp;A, public markets space, capital raising,
funding, growth, scaling businesses and driving innovation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Peter
Stazzone</B>. Effective upon the closing of the public offering, Peter Stazzone will be appointed as a member of the Board of Directors
and as the Chair of the Audit Committee, replacing Regina Brown, the current Chair of the Audit Committee, who will resign from the Board
of Directors effective upon Mr. Stazzone&rsquo;s appointment. Mr. Stazzone is a senior finance and business development executive with
over 20 years of experience in finance and operations management within start-ups, high-growth and multi-billion dollar organizations.
Mr. Stazzone is an experienced board member in both the public and non-profit sectors. He earned his Master of Business Administration
(Finance) from DePaul University and his Bachelor of Science (Accounting) from the University of Illinois. He also is a member of the
American Institute of Certified Public Accountants. From 2021 to the present, Mr. Stazzone has acted as the Chief Financial Officer of
Beyond Commerce, Inc., a publicly traded company operating in the Business-to-Business Internet Marketing Technology and Services, electric
vehicles and logistics markets. From 2016 to 2021, Mr. Stazzone was the Chief Financial Officer of Strainz, Inc., a leading cannabis
brand and manufacturing company operating in Colorado, Washington, and Nevada.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_003"></A>THE
OFFERING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 30%"> <I>Issuer:</I> </TD>
    <TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="vertical-align: top; width: 68%"> Lixte Biotechnology Holdings, Inc. </TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="vertical-align: top"> &nbsp; </TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"> <FONT STYLE="font-size: 10pt"><I>Securities offered by us:</I></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> 7,692,308 shares of common stock </P>
    <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> We are also offering to investors in shares
    of common stock that would otherwise result in the investor&rsquo;s beneficial ownership exceeding 4.99% (or, at the election of
    the purchaser, 9.99%) of our outstanding shares of common stock immediately following the consummation of this offering the opportunity
    to purchase Pre-Funded Warrants in lieu of common stock. Each Pre-Funded Warrant consists of one pre-funded warrant (&ldquo;Pre-Funded
    Warrant&rdquo;) to purchase one share of our common stock. The purchase price of each Pre-Funded Warrant is $0.77999 (which is equal
    to the assumed public offering price per share of common stock of $0.78 minus $0.00001). Subject to limited exceptions, a holder
    of Pre-Funded Warrants will not have the right to exercise any portion of its Pre-Funded Warrants if the holder, together with its
    affiliates, would beneficially own in excess of 4.99% (or, at the election of the holder, such limit may be increased to up to 9.99%)
    of the common stock outstanding immediately after giving effect to such exercise. The Pre-Funded Warrants will be immediately exercisable
    (subject to the beneficial ownership cap) and may be exercised at any time until all of the Pre-Funded Warrants are exercised in
    full. For each Pre-Funded Warrant purchased, the number of common stock we are offering will be decreased on a one-for-one basis.
    The Pre-Funded Warrants have no stand-alone rights and will not be certificated or issued as stand-alone securities. </P>
    <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P></TD></TR>
  <TR>
    <TD> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"> <FONT STYLE="font-size: 10pt"><I>Placement Agent Warrants:</I></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> We have also granted the Placement Agent five-year
    warrants to purchase up to 5.0% of the shares of common stock and Pre-Funded Warrants at an exercise price of 125% of the offering
    price per share of common stock. The Placement Agent Warrants may not be exercised, sold, transferred, assigned, pledged or hypothecated,
    or be the subject of any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition
    of such securities for a period of one hundred eighty (180) days beginning on the commencement of sales of the offering. </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"> <FONT STYLE="font-size: 10pt"><I>Assumed public offering price:</I></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="vertical-align: top; text-align: justify"> <FONT STYLE="font-size: 10pt">$0.78 per share of common stock, which is the
    closing price of our common stock on the Nasdaq Capital Market on June 20, 2025.</FONT> </TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="vertical-align: top; text-align: justify"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"> <FONT STYLE="font-size: 10pt"><I>Common stock outstanding immediately prior to this offering:</I></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="vertical-align: top; text-align: justify"> <FONT STYLE="font-size: 10pt">2,756,991 shares of common stock. </FONT> </TD></TR>
  <TR>
    <TD> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"> <FONT STYLE="font-size: 10pt"><I>Common stock to be outstanding immediately after this offering:</I></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="vertical-align: top; text-align: justify"> <FONT STYLE="font-size: 10pt">10,449,299 shares<SUP>(1)</SUP> of our common
    stock, assuming no issuance of Pre-Funded Warrants, and no exercise of any of the Placement Agent Warrants issued in this offering.</FONT> </TD></TR>
  <TR>
    <TD> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"> <FONT STYLE="font-size: 10pt"><I>Use of proceeds:</I></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="vertical-align: top; text-align: justify"> <FONT STYLE="font-size: 10pt">We currently intend to use the net proceeds
    of this offering for working capital and for general corporate purposes, including funding our research and development activities,
    consisting primarily of our ongoing clinical trials, and the legal, accounting and various other costs of being a public company.&nbsp;&nbsp;Subject
    to the availability of adequate operating capital, from this offering or from other sources, we also plan to expand our investor
    relations and public relations programs over the next twelve to eighteen months, at a cost of up to approximately $2,000,000, to
    improve communications with the financial community, create targeted profiles, expand media distribution, and build a digital community
    with an ongoing interest in our business prospects and activities. &nbsp;See &ldquo;Use of Proceeds&rdquo;.</FONT> </TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"> <FONT STYLE="font-size: 10pt"><I>Reasonable Best Efforts:</I></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="vertical-align: top; text-align: justify"> <FONT STYLE="font-size: 10pt">We have agreed to offer and sell the securities
    offered hereby to the purchasers through the Placement Agent. The Placement Agent is not required to buy or sell any securities offered
    hereby, but rather has agreed to use its reasonable best efforts to solicit offers to purchase the securities offered by this prospectus.
    See &ldquo;Plan of Distribution&rdquo;.</FONT> </TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="vertical-align: top; text-align: justify"> &nbsp; </TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"> <FONT STYLE="font-size: 10pt"><I>Nasdaq Capital Market trading symbol:</I></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="vertical-align: top; text-align: justify"> <FONT STYLE="font-size: 10pt">Our common stock currently trades on the Nasdaq
    Capital Market under the symbol &ldquo;LIXT&rdquo;. We do not intend to list the Pre-Funded Warrants offered hereunder on any stock
    exchange.</FONT> </TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="vertical-align: top; text-align: justify"> &nbsp; </TD></TR>
  <TR>
    <TD> <FONT STYLE="font-size: 10pt"><I>Transfer agent and registrar:</I></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="vertical-align: top; text-align: justify"> <FONT STYLE="font-size: 10pt">The transfer agent and registrar for our common
    stock is Computershare Trust Company, N.A.</FONT> </TD></TR>
  <TR>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="vertical-align: top; text-align: justify"> &nbsp; </TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"> <FONT STYLE="font-size: 10pt"><I>Risk factors:</I></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">The securities offered by this prospectus are speculative and involve
    a high degree of risk. Investors purchasing securities should not purchase the securities unless they can afford the loss of their
    entire investment. See &ldquo;Risk Factors&rdquo;.</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT> </TD>
    <TD COLSPAN="2" STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immediately
    after this offering, the Company will have 10,449,299 shares of common stock outstanding as set forth above, and will exclude:</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">662,078
    shares of common stock issuable upon the exercise of common stock options issued to members of management, consultants and directors
    at a weighted average exercise price of $11.526 per share; </FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,275,758
                                            shares of common stock issuable upon exercise of outstanding common stock warrants at an
                                            average exercise price of $11.254 per share of common stock, including 434,784 shares of
                                            common stock issuable upon exercise of 434,784 common stock warrants exercisable at $2.29
                                            per share issued in our February 13, 2025 offering, 32,609 shares of common stock issuable
                                            upon exercise of 32,609 common stock warrants exercisable at $3.1088 per share issued to
                                            the placement agent in our February 13, 2025 offering, and 149,700 shares of common stock
                                            issuable upon exercise of 149,700 publicly traded warrants at $57.00 per share of common
                                            stock through November 30, 2025;</FONT> </P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">133,339
    shares of common stock reserved for future grants pursuant to our 2020 Stock Incentive Plan, as amended (the &ldquo;2020 Plan&rdquo;);
    and</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">384,615
                                            shares of common stock issuable upon exercise of the Placement Agent Warrants at an exercise
                                            price of $0.975 per share of common stock issuable to the Placement Agent in this offering.</FONT> </P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Unless otherwise indicated, this prospectus also assumes
no sale of Pre-Funded Warrants, and no exercise of any of the Placement Agent Warrants. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_004"></A>RISK
FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Investing
in our common stock is highly speculative and involves a significant degree of risk. You should carefully consider the following risks
and uncertainties as well as the risks and uncertainties described in the section entitled &ldquo;Risk Factors&rdquo; contained in our
Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in our Quarterly Report on Form 10-Q for the quarterly period
ended March 31, 2025, filed with the Securities and Exchange Commission, which filings are incorporated in this prospectus by reference
in their entirety, as well as in any prospectus supplement hereto. These risk factors could materially and adversely affect our business,
results of operations or financial condition. Our business faces significant risks and the risks described below or incorporated by reference
herein may not be the only risks we face. Additional risks not presently known to us or that we currently believe are immaterial may
materially affect our business, results of operations, or financial condition. If any of these risks occur, the trading price of our
common stock could decline and you may lose all or part of your investment.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to the Development and Regulatory Approval of Our Product Candidates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>A
clinical trial hold due to serious adverse events could delay or halt the development of our product candidate. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
lead drug candidate, LB-100, is currently undergoing various clinical trials, and there is a risk that one or more of these trials could
be placed on hold by regulatory authorities due to serious adverse events (SAEs) related to our drug candidate or to another company&rsquo;s
drug used in combination in one of our clinical trials. It is possible that the SAEs could be attributable to our drug candidate and
could include, but not be limited to, unexpected severe side effects, treatment-related deaths, or long-term health complications. A
dose given could result in non-tolerable adverse events defined as dose-limiting toxicity (DLT). When two DLTs occur at the same dose-level
that dose-level is considered too high and unsafe. Further treatment is only allowed at lower dose-levels that have previously been found
safe.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 33.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an SAE or a pattern of SAEs is observed during the course of a clinical trial involving our drug candidate, the U.S. Food and Drug Administration
(FDA), European Medicines Agency (EMA), or other regulatory authorities may issue a clinical hold, requiring us to pause or discontinue
further enrollment and dosing in our clinical trial. It is also possible that the clinical trial could be terminated. Any of these actions
could delay or halt the development of our drug candidate, increase development costs, and negatively impact our ability to ultimately
achieve regulatory approval. Additionally, if an SAE is confirmed to be drug-related, we may be required to conduct additional studies,
modify the study design, or abandon further development of the drug candidate altogether, which could materially impact our business,
financial condition, and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 33.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
occurrence of an SAE and any resulting clinical hold could also harm our reputation with patients, physicians, health institutions, and
investors, diminish our ability to attract clinical trial participants, and damage our ability to interest investors and obtain financing
in the future. There can be no assurances that we will not experience such SAEs in the future or that any related clinical hold will
be lifted in a timely manner, or at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 33.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal investigator of the colorectal study testing LB-100 in combination with atezolizumab (Roche PD-L1 inhibitor) is currently investigating
two SAEs observed in the clinical trial that was launched in August 2024. The Institutional Review Board (the &ldquo;IRB&rdquo;) of the
Netherlands Cancer Institute (&ldquo;NKI&rdquo;) has put the colorectal cancer study on hold. The adverse reactions that developed in
the two patients were dyspnea (shortness of breath) due to lung toxicity possibly or probably related to the combination of LB-100 and
atezolizumab in one patient and fever and aphasia possibly or probably related to the combination of LB-100 and atezolizumab in the second
patient. The patient who developed lung toxicity deceased due to the combination of lung metastases of colorectal cancer and dyspnea.
The patient with fever and aphasia fully recovered from the adverse events with supportive medication.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 33.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
the identified adverse events in the two patients in the clinical trial, the IRB requested from the principal investigator of the study
at the NKI information as to whether the adverse events could have been caused by the combination of LB-100 and atezolizumab and information
about the mode of action of the combination of LB-100 and atezolizumab. The principal investigator prepared a response to the IRB detailing
the safety experience with LB-100 given alone and in combination with other cancer drugs, especially doxorubicin and dostarlimab. Doxorubicin
is a well-known chemotherapy, and dostarlimab is a well-known immunotherapy of which the mode of action is closely related to that of
atezolizumab.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
reported adverse events in the colorectal cancer study have not been seen in any other patients thus far treated with LB-100 alone or
in combination with other cancer drugs. Through May 2025, the Company has been informed that a total of 79 patients had received or were
receiving experimental treatment with LB-100.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 33.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2025, the Company updated the safety overview of LB-100 and delivered the updated version 5.0 of the Investigator&rsquo;s Brochure
(the &ldquo;IB&rdquo;), which contains all of the relevant preclinical, clinical and pharmacologic data with respect to the study of
the LB-100 clinical compound in humans, to the investigators of all ongoing clinical trials. The investigators of the study in colorectal
cancer (<FONT STYLE="background-color: white">NCT06012734)</FONT> submitted a detailed response to the IRB, including the updated IB.
The Company is currently awaiting the outcome of the IRB review.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 33.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to this Offering and Ownership of our Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have a history of losses, expect to continue to incur losses in the near term and may not achieve or sustain profitability in the future,
and as a result, our management has identified, and our auditors agreed that there is a substantial doubt about our ability to continue
as a going concern.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have incurred significant losses since our inception. We experienced net losses of $3,585,965 and $5,087,029 for the years ended December
31, 2024 and 2023, respectively, and $709,555 and $971,322 for the three months ended March 31, 2025 and 2024, respectively. We expect
our operating losses will continue, or even increase, at least through the near term. You should not rely upon our past results as indicative
of future performance. We will not reach profitability in the near future or at any specific time in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 33.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
report of our independent registered public accounting firm that accompanies our audited consolidated financial statements in our Annual
Report on Form 10-K for the fiscal year ended December 31, 2024 contains an explanatory paragraph regarding substantial doubt about our
ability to continue as a going concern. Our consolidated financial statements do not include any adjustments that might result if we
are unable to continue as a going concern. If we are unable to continue as a going concern, holders of our securities might lose their
entire investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 33.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are currently not in compliance with the Nasdaq Capital Market&rsquo;s continued listing requirements. If we are unable to regain compliance
with the Nasdaq Capital Market&rsquo;s listing requirements, our securities could be delisted, which could affect our common stock&rsquo;s
market price and liquidity and reduce our ability to raise capital.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 19, 2024, we received a letter from the Listing Qualifications Department (the &ldquo;Staff&rdquo;) of the Nasdaq Stock Market
LLC indicating that we were not in compliance with the minimum stockholders&rsquo; equity requirement of $2,500,000 for continued listing
on the Nasdaq Capital Market under Listing Rule 5550(b) (the &ldquo;Equity Rule&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 3, 2024, we submitted a plan to the Staff to regain compliance with the Equity Rule, which outlined our proposed initiatives
to regain compliance by raising equity capital through various registered equity offerings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 21, 2024, the Staff provided notice to us that it had granted an extension through February 18, 2025 to regain compliance with
the Equity Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of February 18, 2025, we had not regained compliance with the Equity Rule. Accordingly, on February 19, 2025, we received a Staff determination
letter from the Staff stating that we did not meet the terms of the extension because we did not complete our proposed financing initiatives
to regain compliance. We timely requested a Hearing before a Nasdaq Hearings Panel (the &ldquo;Panel&rdquo;), which automatically stayed
Nasdaq&rsquo;s suspension or delisting of our common stock and public warrants pending the Panel&rsquo;s decision.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 17, 2025, we received notice that the Panel had granted us an extension in which to regain compliance with all continued listing
rules of the Nasdaq Capital Market. The Panel&rsquo;s determination followed a hearing on April 3, 2025, at which time the Panel considered
our plan to regain compliance with the Equity Rule. As a result of the extension, the Panel granted our request for continued listing
on the Nasdaq Capital Market, provided that we demonstrate compliance with the Equity Rule and all other continued listing requirements
for the Nasdaq Capital Market by July 3, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
offering is being conducted in order for us to satisfy the decision of the Panel and to provide the working capital resources to fund
our operations. However, there can be no assurances that the Panel will deem the proceeds from this offering as sufficient to comply
with the Equity Rule and all other continued listing requirements for the Nasdaq Capital Market. Accordingly, even if we complete this
offering, there can be no assurances that we will be able to regain compliance during the extension period and thus be able to maintain
our listing on the Nasdaq Capital Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the extension period, our common stock and public warrants will continue to trade on the Nasdaq Capital Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot assure you that we will be able to regain compliance with the Nasdaq Capital Market&rsquo;s listing standards. Our failure to
continue to meet these requirements would result in our common stock being delisted from Nasdaq, and if our common stock is delisted,
the warrants issued in our public offering would also be delisted. We and holders of our securities could be materially adversely impacted
if our securities are delisted from the Nasdaq Capital Market. In particular:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be unable to raise equity capital on acceptable terms or at all;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may lose the confidence of our clinical partners, which would jeopardize our ability to continue our clinical trials as currently
    conducted;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    price of our common stock will likely decrease as a result of the loss of market efficiencies associated with the Nasdaq Capital
    Market and the loss of federal pre-emption of state securities laws;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">holders
    may be unable to sell or purchase our securities when they wish to do so;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may become subject to stockholder litigation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be unable to attract, or we may lose the interest of, institutional investors in our common stock;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may lose media and analyst coverage;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    common stock could be considered a &ldquo;penny stock&rdquo;, which would likely limit the level of trading activity in the secondary
    market for our common stock; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    would likely lose any active trading market for our common stock, as it may only be traded on one of the over-the-counter markets,
    if at all.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
will have to seek to raise additional funds to fund our operations, including the various clinical trials being currently conducted or
will be conducted in the future. Depending on the terms available to us, if these fund raising activities result in significant dilution,
they may negatively impact the trading price of our common stock.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
additional financing that we secure may require the granting of rights, preferences or privileges senior to, or <I>pari passu </I>with,
those of our common stock. Any issuances by us of equity securities may be at or below the prevailing market price of our common stock
and in any event may have a dilutive impact on your ownership interest, which could cause the market price of our common stock to decline.
We may also raise additional funds through the incurrence of debt or the issuance or sale of other securities or instruments senior to
our shares of common stock, which may be highly dilutive. The holders of any securities or instruments we may issue may have rights superior
to the rights of our common stockholders. If we experience dilution from the issuance of additional securities and we grant superior
rights to new securities over holders of our common stock, it may negatively impact the trading price of our common stock and you may
lose all or part of your investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.35pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>As
part of the Company&rsquo;s ongoing process of evaluating various alternatives to obtain the capital required to fund its operations
and maintain its listing on the Nasdaq Capital Market, management may decide to consider a wide variety of strategic alternatives, and
there can be no assurances that any such transaction, if implemented, would enhance stockholder value, and could be highly dilutive to
existing stockholders.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is evaluating various alternatives to obtain the capital required to fund its operations and maintain its listing on the Nasdaq
Capital Market, including merger or acquisition opportunities (including reverse mergers) and funding transactions involving a change
in control. There can be no assurances that the evaluation process will result in the identification of an appropriate transaction, the
negotiation and execution of a definitive agreement to effect such a transaction, or that any such transaction will ultimately be approved
by the Company&rsquo;s stockholders and then be consummated. Depending on various factors, many of which are outside the control of the
Company, our failure to enter into and consummate a strategic transaction could have a material adverse effect on our ability to continue
to operate and finance our business, and on the market price of our common stock. Even if such a strategic transaction is consummated,
there can be no assurances that it will enhance stockholder value, and it may result in substantial dilution to existing stockholders.
Any potential transaction would be dependent on a number of factors that may be outside of our control, including, among other things,
market conditions, industry trends, the interest of third parties in a potential transaction with the Company, and the availability of
appropriate financing for such a transaction. If we are unable to raise the required capital to fund our operations, or to enter into
a strategic transaction in the near future, we may not be able to maintain our listing on the Nasdaq Capital Market, and we may need
to curtail or cease operations, which could result in a total loss of stockholders&rsquo; investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
price of our common stock might fluctuate substantially.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should consider an investment in our common stock to be risky. Some factors that might cause the market price of our common stock or
public warrants to fluctuate, in addition to the other risks mentioned in this &ldquo;Risk Factors&rdquo; section, are:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sale
    of our common stock by our stockholders, executives, and directors and our stockholders;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">volatility
    and limitations in trading volumes of our shares of common stock;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain financings to conduct and complete research and development activities including, but not limited to, our clinical
    trials, and other business activities;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing and success of introductions of new products by us or our competitors or any other change in the competitive dynamics of our
    industry, including consolidation among competitors, customers or strategic partners;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">network
    outages or security breaches;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to secure resources and the necessary personnel to conduct clinical trials on our desired schedule;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">commencement,
    enrollment or results of our clinical trials for our lead product candidate or any future clinical trials we might conduct;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in the development status of our lead product candidate;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    delays or adverse developments or perceived adverse developments with respect to the FDA&rsquo;s review of our planned preclinical
    and clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    delay in our submission for studies or product approvals or adverse regulatory decisions, including failure to receive regulatory
    approval for our lead product candidate;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unanticipated
    safety concerns related to the use of our lead product candidate;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failures
    to meet external expectations or management guidance;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in our capital structure or dividend policy, future issuances of securities, sales of large blocks of common stock by our stockholders;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    cash position;</FONT></TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    and events surrounding financing efforts, including debt and equity securities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    inability to enter into new markets or develop new products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reputational
    issues;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">competition
    from existing technologies and products or new technologies and products that might emerge;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    of acquisitions, partnerships, collaborations, joint ventures, new products, capital commitments, or other events by us or our competitors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in general economic, political and market conditions in or any of the regions in which we conduct our business;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in industry conditions or perceptions;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in valuations of similar companies or groups of companies;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">analyst
    research reports, recommendations and changes in recommendations, price targets, and withdrawals of coverage;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">departures
    and additions of key personnel;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disputes
    and litigations related to intellectual properties, proprietary rights, and contractual obligations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in applicable laws, rules, regulations, or accounting practices and other dynamics; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    events or factors, many of which might be out of our control.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if the market for stocks in our industry or industries related to our industry, or the stock market in general, experiences
a loss of investor confidence, the trading price of our common stock could decline for reasons unrelated to our business, financial condition
and results of operations. If any of the foregoing occurs, it could cause our stock price to fall and might expose us to lawsuits that,
even if unsuccessful, could be costly to defend and a distraction to management.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.35pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.35pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Provisions
of the Warrants issued in the 2023 Financing and 2025 Financing could discourage an acquisition of us by a third party.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.35pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
provisions of the 2023 Warrants and 2025 Warrants could make it more difficult or expensive for a third party to acquire us. Such Warrants
prohibit us from engaging in certain transactions constituting &ldquo;fundamental transactions&rdquo; unless, among other things, the
surviving entity assumes our obligations under such Warrants. These could prevent or deter a third party from acquiring us even where
the acquisition could be beneficial to you. Also, we may be required to redeem these Warrants for a cash payment calculated pursuant
to the Black-Scholes option-pricing model.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>An
active, liquid and orderly trading market for our common stock may not develop, the price of our stock may be volatile, and you could
lose all or part of your investment.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 33.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
though our common stock is currently listed on the Nasdaq Capital Market, we cannot predict the extent to which investor interest in
our Company will lead to the development of an active trading market in our securities or how liquid that market might become. If such
a market does not develop or is not sustained, it may be difficult for you to sell your shares of common stock at the time that you wish
to sell them, at a price that is attractive to you, or at all. There could be extreme fluctuations in the price of our common stock if
there are a limited number of shares in our public float.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 33.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 33.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 33.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 33.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading price of our common stock may be highly volatile and could be subject to wide fluctuations in response to various factors, some
of which are beyond our control. Our stock price could be subject to wide fluctuations in response to a variety of factors, which include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    we achieve our anticipated corporate objectives;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
    or anticipated fluctuations in our quarterly or annual operating results;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in our financial or operational estimates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to implement our operational plans;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in the economic performance or market valuations of companies similar to ours; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
    economic or political conditions in the United States or elsewhere.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, broad market and industry factors may seriously affect the market price of companies&rsquo; stock, including ours, regardless
of actual operating performance. In the past, following periods of volatility in the overall market and the market price of a particular
company&rsquo;s securities, securities class action litigation has often been instituted against these companies. This litigation, if
instituted against us, could result in substantial costs and a diversion of our management&rsquo;s attention and resources.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 33.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <B><I>The common stock being issued
in this offering</I></B> <B><I> may cause the trading price of our common stock to decrease.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Depending on the
price of our common stock in this offering and the number of shares of common stock being issued, there could be
an immediate and sustained decrease in the trading price of our common stock. If the bid price of our common stock falls below
$1.00 per share for thirty (30) consecutive business days, we would no longer meet the Nasdaq Capital Market&rsquo;s minimum bid price
requirement and our common stock would be subject to delisting if, after notice from Nasdaq, we fail to satisfy the $1.00 per share
closing bid price requirement within the applicable cure periods. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
our shares of common stock become subject to the penny stock rules, it would become more difficult to trade our shares.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Securities and Exchange Commission has adopted rules that regulate broker-dealer practices in connection with transactions in penny stocks.
Penny stocks are generally equity securities with a price of less than $5.00, other than securities registered on certain national securities
exchanges or authorized for quotation on certain automated quotation systems, provided that current price and volume information with
respect to transactions in such securities is provided by the exchange or system. If we do not retain a listing on the Nasdaq Capital
Market and if the price of our common stock is less than $5.00, our common stock will be deemed a penny stock. The penny stock rules
require a broker-dealer, before a transaction in a penny stock not otherwise exempt from those rules, to deliver a standardized risk
disclosure document containing specified information. In addition, the penny stock rules require that before effecting any transaction
in a penny stock not otherwise exempt from those rules, a broker-dealer must make a special written determination that the penny stock
is a suitable investment for the purchaser and receive (i) the purchaser&rsquo;s written acknowledgment of the receipt of a risk disclosure
statement; (ii) a written agreement to transactions involving penny stocks; and (iii) a signed and dated copy of a written suitability
statement. These disclosure requirements may have the effect of reducing the trading activity in the secondary market for our common
stock, and therefore stockholders may have difficulty selling their shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 33.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we were to dissolve, the holders of our securities may lose all or substantial amounts of their investments.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we were to dissolve as a corporation, as part of ceasing to do business or otherwise, we will be required to pay all amounts owed to
any creditors before distributing any assets to holders of our capital stock. There is a risk that in the event of such a dissolution,
there will be insufficient funds to repay amounts owed to holders of any of our indebtedness and insufficient assets to distribute to
our capital stockholders, in which case investors could lose their entire investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 33.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
securities or industry analysts do not publish or cease publishing research or reports about us, our business or our market, or if they
change their recommendations regarding our securities adversely, our stock price and trading volume could decline.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for our common stock is influenced by the research and reports that industry or securities analysts may publish about
us, our business, our market or our competitors. If any of the analysts who may cover us change their recommendation regarding our common
stock adversely, or provide more favorable relative recommendations about our competitors, our stock price would likely decline. If any
of the analysts who may cover us were to cease coverage of our Company or fail to regularly publish reports on us, we could lose visibility
in the financial markets, which in turn could cause our stock price or trading volume to decline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>In
making your investment decision, you should understand that we have not authorized any other party to provide you with information concerning
us or this offering.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should carefully evaluate all of the information in this prospectus before investing in our company. We may receive media coverage regarding
our company, including coverage that is not directly attributable to statements made by our officers, that incorrectly reports on statements
made by our officers or employees, or that is misleading as a result of omitting information provided by us, our officers or employees.
We and the Placement Agent have not authorized any other party to provide you with information concerning us or this offering,
and you should not rely on unauthorized information in making an investment decision.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 33.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
common stock and Pre-Funded Warrants (which are exercisable for common stock) sold in this offering will increase the number of our shares
of common stock from 2,756,991 shares to 10,449,299 shares. The sales of these securities could depress the market price of our
shares of common stock and/or increase the volatility of our trading.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
substantial number of shares of common stock and Pre-Funded Warrants are being offered by this prospectus. Sales of a substantial number
of our shares of common stock in the public markets pursuant to the terms of this offering could depress the market price of our shares
of common stock and impair our ability to raise capital through the sale of additional equity securities. Additionally, such sales
could also greatly increase the volatility associated with the trading of our common stock. We cannot predict the number of shares that
might be sold, nor the effect future sales of shares would have on the market price of our shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>This
is a reasonable best efforts offering, with no minimum amount of securities required to be sold, and we may sell fewer than all of the
securities offered hereby.</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Placement Agent has agreed to use its reasonable best efforts to solicit offers to purchase the securities in this offering. The Placement
Agent has no obligation to buy any of the securities from us or to arrange for the purchase or sale of any specific number or dollar
amount of the Securities. There is no required minimum number of securities that must be sold as a condition to completion of this offering,
and there can be no assurance that the offering contemplated hereby will ultimately be consummated. Even if we sell the securities offered
hereby, because there is no minimum offering amount required as a condition to closing of this offering, the actual offering amount is
not presently determinable and may be substantially less than the maximum amount set forth on the cover page of this prospectus. We may
sell fewer than all of the securities offered hereby, which may significantly reduce the amount of proceeds received by us. Thus, we
may not raise the amount of capital we believe is required for our operations in the short-term and may need to raise additional funds,
which may not be available or available on terms acceptable to us.</FONT> </P>

<P STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0pt"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Because
there is no minimum required for the offering to close, investors in this offering will not receive a refund in the event that we do
not sell an amount of securities sufficient to pursue the business goals outlined in this prospectus.</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not specified a minimum offering amount. Because there is no minimum offering amount, investors could be in a position where they
have invested in our company, but we are unable to fulfill our objectives due to a lack of interest in this offering. Further, because
there is no minimum investment amount, any proceeds from the sale of securities offered by us will be available for our immediate use,
despite uncertainty about whether we would be able to use such funds to effectively implement our business plan. Investor funds will
not be returned under any circumstances whether during or after the offering.</FONT> </P>

<P STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Purchasers
who purchase our securities in this offering pursuant to a securities purchase agreement may have rights not available to purchasers
that purchase without the benefit of a securities purchase agreement.</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to rights and remedies available to all purchasers in this offering under federal securities and state law, the purchasers that
enter into a securities purchase agreement will also be able to bring claims of breach of contract against us. The ability to pursue
a claim for breach of contract provides those investors with the means to enforce the covenants uniquely available to them under the
securities purchase agreement, including: a covenant to not enter into any equity financings for thirty (30) days from closing of the
offering, subject to certain exceptions.</FONT> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
Pre-Funded Warrants are speculative in nature and there is not expected to be a trading market for the Pre-Funded Warrants.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no established trading market for the Pre-Funded Warrants and we do not expect a trading market to develop. Without a trading market,
the liquidity of the Pre-Funded Warrants will be limited.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Holders
of the Pre-Funded Warrants will have no rights as a common stockholder until they acquire our common stock.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Pre-Funded Warrants offered in this offering do not confer any rights of common stock ownership on their holders, such as voting rights
or the right to receive dividends, but rather merely represent the right to acquire shares of our common stock at a fixed price for a
limited period of time. In the case of Pre-Funded Warrants, holders may exercise their right to acquire the common stock and pay an exercise
price of $0.00001 per share. The Pre-Funded Warrants do not expire. Until holders of the Pre-Funded Warrants acquire shares of our common
stock upon exercise of the Pre-Funded Warrants, the holders will have no rights with respect to shares of our common stock issuable upon
exercise of the Pre-Funded Warrants. Upon exercise of the Pre-Funded Warrants, the holder will be entitled to exercise the rights of
a common stockholder as to the security exercised only as to matters for which the record date occurs after the exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Investors
in this offering will experience immediate and substantial dilution in the book value of their investment.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
public offering price will be substantially higher than the net tangible book value per share of our outstanding shares of common stock.
As a result, investors in this offering will incur immediate dilution of $0.17 per share based on the assumed public offering
price of $0.78 per share of common stock. Investors in this offering will pay a price per share of common stock that substantially
exceeds the book value of our assets after subtracting our liabilities. See &ldquo;Dilution&rdquo; for a more complete description of
how the value of your investment will be diluted upon the completion of this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>A
possible &ldquo;short squeeze&rdquo; due to a sudden increase in demand of our shares of common stock that largely exceeds supply may
lead to price volatility in our shares of common stock.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
this offering, investors may purchase our shares of common stock to hedge existing exposure in our shares of common stock or to speculate
on the price of our shares of common stock. Speculation on the price of our shares of common stock may involve long and short exposures.
To the extent aggregate short exposure exceeds the number of shares of our common stock available for purchase in the open market, investors
with short exposure may have to pay a premium to repurchase our shares of common stock for delivery to lenders of our shares of common
stock. Those repurchases may in turn, dramatically increase the price of our shares of common stock until investors with short exposure
are able to purchase additional shares of common stock to cover their short position. This is often referred to as a &ldquo;short squeeze&rdquo;.
A short squeeze could lead to volatile price movements in our shares of common stock that are not directly correlated to the performance
or prospects of our company and once investors purchase the shares of common stock necessary to cover their short position the price
of our common stock may decline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_005"></A>CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus, and the documents incorporated by reference herein may contain forward-looking statements within the meaning of Section 27A
of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), and Section 21E of the Securities Exchange Act of 1934,
as amended (the &ldquo;Exchange Act&rdquo;). All statements other than statements of historical facts contained in this prospectus, including
statements regarding our future results of operations and financial position, business strategy and plans and our objectives for future
operations, are forward-looking statements. The words &ldquo;anticipate&rdquo;, &ldquo;believe&rdquo;, &ldquo;could&rdquo;, &ldquo;estimate&rdquo;,
&ldquo;expect&rdquo;, &ldquo;forecast&rdquo;, &ldquo;intend&rdquo;, &ldquo;may&rdquo;, &ldquo;plan&rdquo;, &ldquo;potential&rdquo;, &ldquo;should&rdquo;,
&ldquo;will&rdquo;, &ldquo;would&rdquo;, &ldquo;might&rdquo;, and similar expressions are intended to identify forward-looking statements.
These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially
from historical results or anticipated results, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are engaged in early-stage research and as such might not be successful in our efforts to develop a portfolio of commercially viable
    products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have incurred substantial losses since our inception and anticipate that we will continue to incur substantial and increasing losses
    for the foreseeable future;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    need significant additional financing to fund our operations and complete the development and, if approved, the commercialization
    of our lead product candidate, LB-100. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate
    our product development programs or commercialization efforts;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    currently have no source of revenues. We might never generate revenues or achieve profitability;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    ability to use net operating losses to offset future taxable income might be subject to limitations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical-stage
    biopharmaceutical companies with product candidates in clinical development face a wide range of challenging activities which might
    entail substantial risk;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    might find it difficult to enroll patients in our clinical trials which could delay or prevent the start of clinical trials for our
    product candidate;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    results of preclinical studies or earlier clinical trials are not necessarily predictive of future results. Our lead product candidate
    in clinical trials, and any other product candidates that might advance into clinical trials, might not have favorable results in
    later clinical trials or receive regulatory approval;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
    drug development involves a lengthy and expensive process with an uncertain outcome;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
    is a risk that one or more of our clinical trials could be placed on hold by regulatory authorities due to serious adverse events
    (SAEs) related to our drug candidate or to another company&rsquo;s drug used in combination in one of our clinical trials. It is
    possible that the SAEs could be attributable to our drug candidate and could include, but not be limited to, unexpected severe side
    effects, treatment-related deaths, or long-term health complications. A dose given could result in non-tolerable adverse events defined
    as dose-limiting toxicity (DLT). When two DLTs occur at the same dose-level that dose-level is considered too high and unsafe. Further
    treatment is only allowed at lower dose-levels that have previously been found safe.</FONT></TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
    associated with operating in foreign countries could materially adversely affect our product development;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    current and future product candidates, the methods used to deliver them or their dosage levels may cause undesirable side effects
    or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label
    or result in significant negative consequences following any regulatory approval;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    product development program might not uncover all possible adverse events that patients who take our lead product candidate may experience.
    The number of subjects exposed to our lead product candidate and the average exposure time in the clinical development program might
    be inadequate to detect rare adverse events or chance findings that might only be detected once the product is administered to more
    patients and for greater periods of time;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    future success is dependent on the regulatory approval of our lead product candidate;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    lead product candidate and future product candidates could fail to receive regulatory approval from the FDA;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
    to obtain regulatory approval in international jurisdictions would prevent our lead product candidate from being marketed abroad;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
    if our current primary product candidate receives regulatory approval, it might still face future development and regulatory difficulties;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    depend on certain key scientific personnel for our success who do not work full time for us. The loss of any such personnel could
    adversely affect our business, financial condition and results of operations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    expect to rely heavily on third parties for the conduct of clinical trials of our product candidates. If these clinical trials are
    not successful, or if we or our collaborators are not able to obtain the necessary regulatory approvals, we will not be able to commercialize
    our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business
    interruptions could adversely affect future operations, revenues, and financial conditions, and might increase our costs and expenses;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    failure to find third party collaborators to assist or share in the costs of product development could materially harm our business,
    financial condition or results of operations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    might be subject to claims by third parties asserting that our employees, consultants, collaborators contractors or we have misappropriated
    their intellectual property, or claiming ownership of what we regard as our own intellectual property;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    cannot be certain we will be able to obtain patent protection to protect our product candidates and technology;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we do not obtain patent term extension in the United States under the Hatch-Waxman Act or in foreign countries under similar legislation,
    our business might be materially harmed;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we fail to comply with our obligations in agreements under which we have licensed or, might license, intellectual property rights
    from third parties, or if we otherwise experience disruptions to our business relationships with our licensors, we could lose rights
    that are important to our business;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    might infringe the intellectual property rights of others, which may prevent or delay our product development efforts and stop us
    from commercializing or increase the costs of commercializing our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    might be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed alleged trade
    secrets of one or more third parties;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    intellectual property might not be sufficient to protect our intended products from competition, which might negatively affect our
    business as well as limit our partnership or acquisition appeal;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we are not able to protect and control our unpatented trade secrets, know-how and other technological innovation, we might suffer
    competitive harm;</FONT></TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    might incur substantial costs prosecuting our patent applications, maintaining our patents and patent applications, enforcing our
    patents, defending against third party patent infringement suits, seeking invalidation of third party patents or in-licensing third
    party intellectual property, as a result of litigation or other proceedings relating to patent and other intellectual property rights;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we are unable to protect our intellectual property rights, our competitors might develop and market products with similar or identical
    features that might reduce demand for our potential products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    commercial success depends upon attaining significant market acceptance of our current product candidate and future product candidates,
    if approved, among physicians, patients, healthcare payors and cancer treatment centers;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
    if we are able to commercialize our lead product candidate or any future product candidates, the products might not receive coverage
    or adequate reimbursement from third party payors in the United States and in other countries in which we seek to commercialize our
    intended products, which could harm our business;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare
    legislative measures aimed at reducing healthcare costs might have a material adverse effect on our business and results of operations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Price
    controls might be imposed in foreign markets, which might adversely affect our future profitability;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    relationships with customers and third party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare
    laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished
    profits and future earnings. If we or they are unable to comply with these provisions, we might become subject to civil and criminal
    investigations and proceedings that could have a material adverse effect on our business, financial condition and prospects;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    employees might engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements,
    which could cause significant liability for us and harm our reputation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product
    liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that
    we might develop;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    face substantial competition, which might result in others discovering, developing or commercializing products before or more successfully
    than we do;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
    disruptions of information technology systems, computer system failures or breaches of information and cyber security could adversely
    affect our business;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    might need to grow the size of our organization in the future, and we might experience difficulties in managing this growth;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inadequate
    funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other
    personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those
    agencies from performing normal business functions on which the operation of our business might rely, which could negatively impact
    our business;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unstable
    market and economic conditions and adverse developments with respect to financial institutions and associated liquidity risk may
    have serious adverse consequences on our business, financial condition and stock price;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are a &ldquo;smaller reporting company&rdquo; and we have elected to comply with certain reduced reporting and disclosure requirements
    which could make its common stock less attractive to investors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    price of our common stock might fluctuate substantially;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    sale or perceived sale of a substantial number of shares of our common stock might cause the price of our common stock to decline;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market
    and economic conditions might negatively impact our business, financial condition and share price;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    securities or industry analysts do not publish research or reports, or publish unfavorable research or reports about our business,
    our stock price and trading volume might decline;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
    sales and issuances of our common stock could result in additional dilution of the percentage ownership of our stockholders and could
    cause our share price to fall;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    do not intend to pay cash dividends on our shares of common stock so any returns will be limited to the value of our shares;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    might be at risk of securities class action litigation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    Certificate of Incorporation and our Amended and Restated Bylaws, and Delaware law might have anti-takeover effects that could discourage,
    delay or prevent a change in control, which might cause our stock price to decline;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    reporting obligations of being a public company in the United States are expensive and time-consuming, and our management will be
    required to devote substantial time to compliance matters; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we fail to comply with the rules under Sarbanes-Oxley related to accounting controls and procedures in the future, or, if we discover
    material weaknesses and other deficiencies in our internal control and accounting procedures, our stock price could decline significantly
    and raising capital could be more difficult.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
caution you that the foregoing list may not contain all of the forward-looking statements made in this prospectus. We have based these
forward-looking statements largely on our current expectations about future events and financial trends that we believe may affect our
financial condition, results of operations, business strategy, short term and long-term business operations and objectives, and financial
needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in
&ldquo;Risk Factors&rdquo;. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to
time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the
extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking
statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed
in this prospectus may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking
statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected
in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events
and circumstances reflected in the forward-looking statements will be achieved or occur. We undertake no obligation to update publicly
any forward-looking statements for any reason after the date of this prospectus to conform these statements to actual results or to changes
in our expectations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should read this prospectus and the documents that we reference in this prospectus and have filed with the Securities and Exchange Commission
as exhibits to the registration statement of which this prospectus is a part with the understanding that our actual future results, levels
of activity, performance and events and circumstances may be materially different from what we expect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_006"></A>USE
OF PROCEEDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
estimate that the net proceeds from this offering will be approximately $5,180,000 after deducting the Placement Agent fees and
estimated offering expenses payable by us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will only receive additional proceeds from the exercise of the Placement Agent Warrants if such Warrants are exercised and the
holders of such Warrants pay the exercise price in cash.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently intend to use the net proceeds of this offering for working capital and for general corporate purposes, including funding our
research and development activities, consisting primarily of our ongoing clinical trials, and the legal, accounting and various other
costs of being a public company.&nbsp; Subject to the availability of adequate operating capital, from this offering or from other sources,
we also plan to expand our investor relations and public relations programs over the next twelve to eighteen months, at a cost of up
to approximately $2,000,000, to improve communications with the financial community, create targeted profiles, expand media distribution,
and build a digital community with an ongoing interest in our business prospects and activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
actual allocation of proceeds realized from this offering will depend upon our cash position and our working capital requirements. We
cannot currently allocate specific percentages of the net proceeds to us from this offering that we may use for these purposes. Therefore,
as of the date of this prospectus, we cannot specify with certainty all of the particular uses for the net proceeds to be received upon
the completion of this offering. Accordingly, we will have discretion in the application of the net proceeds, and investors will be relying
on our judgment regarding the application of the proceeds of this offering. Pending our use of the net proceeds from this offering, we
intend to invest the net proceeds in a variety of capital preservation investments, including short-term, investment-grade, interest-bearing
instruments and U.S. government securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_007"></A>CAPITALIZATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 33.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth our capitalization as of March 31, 2025 as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
    an actual basis; </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
    an as adjusted basis, to reflect the conversion of 350,000 shares of Series A Convertible Preferred Stock outstanding into 72,917
    shares of common stock pursuant to a notice of conversion dated May 16, 2025; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    an as further adjusted basis, to reflect the issuance and sale of 7,692,308 shares of common stock in the offering as described
    herein at the public offering price of $0.78 per share of common stock, assuming no sale of Pre-Funded Warrants and
    after deducting Placement Agent fees and estimated offering expenses and the receipt of the proceeds of such sale.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information below is illustrative only. Our capitalization following the closing of this common stock offering will change based on the
actual public offering price and other terms of this offering determined at pricing. You should read this table in conjunction with &ldquo;Item
7. Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo; and the unaudited consolidated
financial statements and related notes included in our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">As of March 31, 2025</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Actual</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>As</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Adjusted</B></FONT></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>As</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Further</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Adjusted</B></FONT></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">(unaudited)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">(unaudited)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">(unaudited)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 52%; padding-bottom: 2.5pt">Cash</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; border-bottom: Black 2.5pt double; text-align: right">1,384,697</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; border-bottom: Black 2.5pt double; text-align: right">1,384,697</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; border-bottom: Black 2.5pt double; text-align: right">6,564,697</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Stockholders&rsquo; equity:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Preferred stock, $0.0001 par value per share, 10,000,000 shares authorized; issued and outstanding &ndash; 350,000 shares</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,500,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Common stock, $0.0001 par value per share; 100,000,000 shares
    authorized; issued and outstanding &ndash; 2,684,074 shares actual, 2,756,991 shares on an as adjusted basis, and 10,449,299
    shares on an as further adjusted basis</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">268</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">275</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 1.045 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Additional paid-in capital</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">50,436,110</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">53,936,103</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 59,115,334 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Accumulated deficit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right">(52,777,248</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right">(52,777,248</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right">(52,777,248</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total stockholders&rsquo; equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right">1,159,130</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right">1,159,130</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right">6,339,130</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total capitalization</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">1,159,130</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">1,159,130</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">6,339,130</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of shares of our common stock outstanding as set forth above excludes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">662,078
    shares of common stock issuable upon the exercise of common stock options issued to members of management, consultants and directors
    at a weighted average exercise price of $11.526 per share; </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,275,758
    shares of common stock issuable upon exercise of outstanding common stock warrants at an average exercise price of $11.254 per share
    of common stock, including 434,784 shares of common stock issuable upon exercise of 434,784 common stock warrants exercisable at
    $2.29 per share issued in our February 13, 2025 offering, 32,609 shares of common stock issuable upon exercise of 32,609 common stock
    warrants exercisable at $3.1088 per share issued to the placement agent in our February 13, 2025 offering, and 149,700 shares of
    common stock issuable upon exercise of 149,700 publicly traded warrants at $57.00 per share of common stock through November 30,
    2025;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">133,339
    shares of common stock reserved for future grants pursuant to our 2020 Stock Incentive Plan, as amended (the &ldquo;2020 Plan&rdquo;);
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">384,615
    </FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock issuable upon exercise
    of the Placement Agent Warrants at an exercise price of $0.975 per share of common stock issuable to the Placement
    Agent in this offering.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 33.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Unless otherwise indicated, this prospectus also assumes
no sale of Pre-Funded Warrants and no exercise of any of the Placement Agent Warrants. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DILUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you invest in our common stock in this offering, your investment will be immediately and substantially diluted to the extent of the difference
between the public offering price per share of our common stock and the as adjusted net tangible book value per share of our common stock
after giving effect to the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
net tangible book value as of March 31, 2025 was $1,159,130, or $0.42 per share. Net tangible book value per share represents our total
tangible assets less total liabilities, divided by the number of shares of common stock outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
adjusted net tangible book value dilution per share of common stock to new investors represents the difference between the amount per
share of common stock that is paid by investors in the offering and the net tangible book value per share of common stock immediately
after completion of the offering. After giving effect to the offering and our sale of the common stock in the offering at an assumed
public offering price of $0.78 per share of common stock, and after deduction of Placement Agent fees from gross proceeds
raised in the offering and estimated offering expenses payable by us, our as adjusted net tangible book value as of March 31, 2025 would
have been $6,339,130 or $0.61 per share of common stock. This represents an immediate increase in net tangible book value of $0.19
per share of common stock to existing stockholders and an immediate dilution in net tangible book value of $0.17 per share
of common stock to investors in the offering, as illustrated in the following table, based on the shares of common stock outstanding
as of March 31, 2025, as adjusted to reflect the conversion of 350,000 shares of Series A Convertible Preferred Stock outstanding into
72,917 shares of common stock pursuant to a notice of conversion dated May 16, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information below is illustrative only and assumes the maximum offering amount of $6,000,000 is sold. The dilution caused by this offering
will change based on the actual public offering amount and price and other terms of this offering determined at pricing. You should read
this table in conjunction with &ldquo;Item 7. Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo;
and the unaudited consolidated financial statements and related notes included in our Quarterly Report on Form 10-Q for the quarterly
period ended March 31, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%">Assumed offering price per share of common stock</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"> 0.78 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actual net tangible book value
    per share of common stock before this offering<SUP>(1)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.42</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase
    in net tangible book value per share attributable to new investors<SUP>(2)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"> 0.19 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net tangible
    book value per share after this offering<SUP>(3)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"> 0.61 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Immediate dilution in net tangible book value per share to new investors</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"> 0.17 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determined
    by dividing (i) net tangible book value (total assets less intangible assets) less total liabilities by (ii) the total number of
    shares of common stock issued and outstanding prior to the offering.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    the difference between (i) as adjusted net tangible book value per share after this offering and (ii) net tangible book value per
    share as of March 31, 2025.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determined
    by dividing (i) as adjusted net tangible book value, which is our net tangible book value plus the cash proceeds of this offering,
    after deducting the estimated offering expenses payable by us, by (ii) the total number of shares of common stock to be outstanding
    following this offering.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">An
increase of $0.25 in the assumed public offering price of $0.78 per share of common stock would increase the net tangible book
value per share after this offering by $0.13 per share and increase the dilution to new investors purchasing common stock in this
offering by $0.12 per share, assuming the amount of the offering as set forth on the cover page of this prospectus remains the
same, and after deducting the Placement Agent fees and estimated offering expenses payable by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">A decrease
of $0.25 in the assumed public offering price of $0.78 per share of common stock would decrease the net tangible book value per
share after this offering by $0.16 per share and would decrease the dilution to new investors purchasing common stock in this
offering by $0.09 per share, assuming the amount of the offering as set forth on the cover page of this prospectus remains the
same, and after deducting the Placement Agent fees and estimated offering expenses payable by us.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">If
we only sell 75%, 50% or 25% of the maximum offering amount of $6,000,000, our net tangible book value per share after this offering
would be $0.58, $0.55 or $0.48, respectively, and the immediate dilution in net tangible book value per share to new investors
purchasing common stock in this offering would be $0.20, $0.23 or $0.30, respectively, assuming no Pre-Funded Warrants
are issued and after deducting the Placement Agent fees and estimated offering expenses payable by us.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information discussed above is illustrative only and will adjust based on the actual public offering price, the actual number of shares
of common stock that we offer in this offering, and other terms of this offering determined at the time of pricing. The foregoing discussion
and table assume no issuance of Pre-Funded Warrants, which if sold, would reduce the number of shares of common stock that we are offering
on a one-for-one basis. In addition, we may choose to raise additional capital due to market conditions or strategic considerations.
To the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance of these securities
could result in further dilution to our stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of shares of our common stock outstanding as set forth above excludes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">662,078
    shares of common stock issuable upon the exercise of common stock options issued to members of management, consultants and directors
    at a weighted average exercise price of $11.526 per share; </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,275,758
    shares of common stock issuable upon exercise of outstanding common stock warrants at an average exercise price of $11.254 per share
    of common stock, including 434,784 shares of common stock issuable upon exercise of 434,784 common stock warrants exercisable at
    $2.29 per share issued in our February 13, 2025 offering, 32,609 shares of common stock issuable upon exercise of 32,609 common stock
    warrants exercisable at $3.1088 per share issued to the placement agent in our February 13, 2025 offering, and 149,700 shares of
    common stock issuable upon exercise of 149,700 publicly traded warrants at $57.00 per share of common stock through November 30,
    2025;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">133,339
    shares of common stock reserved for future grants pursuant to our 2020 Stock Incentive Plan, as amended (the &ldquo;2020 Plan&rdquo;);
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">384,615
    </FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock issuable upon exercise
    of common stock warrants at an exercise price of $0.975 per share of common stock issuable to the Placement Agent in
    this offering.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Unless otherwise indicated, this prospectus also assumes
no sale of Pre-Funded Warrants and no exercise of any of the Placement Agent Warrants. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_008"></A>SELECTED
HISTORICAL FINANCIAL DATA</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consolidated
Statements of Operations Data</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Three Months Ended March 31,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2025</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2024</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Revenues</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Costs and expenses:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Research and development costs</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">91,457</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">119,064</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">General and administrative costs</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right">615,483</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right">847,815</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total costs and expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right">706,940</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right">966,879</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Loss from operations</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(706,940</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(966,879</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Interest income</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">441</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,859</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Interest expense</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(3,135</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(7,186</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Foreign currency gain (loss)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right">79</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right">(116</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">(709,555</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">(971,322</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net loss per share of common stock &ndash; basic and diluted</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">(0.29</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">(0.43</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Weighted average shares of common stock outstanding &ndash; basic and diluted</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">2,471,513</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">2,249,290</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Consolidated Balance Sheet Data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">March 31,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2025</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2024</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left; padding-bottom: 1pt">Total current assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; border-bottom: Black 1pt solid; text-align: right">1,514,228</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; border-bottom: Black 1pt solid; text-align: right">3,589,203</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">1,514,228</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">3,589,203</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total current liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right">355,098</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right">462,836</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">355,098</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">462,836</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Stockholders&rsquo; equity:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Preferred Stock, $0.0001 par value; authorized &ndash; 10,000,000 shares; issued and outstanding &ndash;
    350,000 shares of Series A Convertible Preferred Stock, $10.00 per share stated value, liquidation preference based on assumed conversion
    into common stock &ndash; 72,917 shares at March 31, 2025 and 2024</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,500,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,500,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Common stock, $0.0001 par value; authorized &ndash; 100,000,000 shares; issued and outstanding &ndash;
    2,684,074 shares and 2,249,290 shares at March 31, 2025 and 2024, respectively</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">268</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">225</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Additional paid-in capital</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">50,436,110</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">49,079,192</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Accumulated deficit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right">(52,777,248</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right">(49,453,050</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total stockholders&rsquo; equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">1,159,130</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">3,126,367</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consolidated
Statements of Operations Data</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Years Ended December 31,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2024</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2023</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Revenues</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Costs and expenses:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Research and development costs</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">726,232</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">898,100</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">General and administrative costs</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,846,557</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4,192,136</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total costs and expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right">3,572,789</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right">5,090,236</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Loss from operations</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(3,572,789</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(5,090,236</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Interest income</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">7,048</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">17,486</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Interest expense</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(16,821</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(16,233</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Foreign currency gain (loss)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right">(3,403</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right">1,954</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">(3,585,965</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">(5,087,029</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net loss per share of common stock &ndash; basic and diluted</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">(1.59</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">(2.66</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Weighted average shares of common stock outstanding &ndash; basic and diluted</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">2,249,290</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">1,915,838</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consolidated
Balance Sheet Data</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2024</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2023</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left; padding-bottom: 1pt">Total current assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; border-bottom: Black 1pt solid; text-align: right">1,145,503</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; border-bottom: Black 1pt solid; text-align: right">4,308,620</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">1,145,503</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">4,308,620</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total current liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right">318,824</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right">313,858</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">318,824</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">313,858</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Stockholders&rsquo; equity:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Preferred Stock, $0.0001 par value; authorized &ndash; 10,000,000 shares; issued and outstanding &ndash;
    350,000 shares of Series A Convertible Preferred Stock, $10.00 per share stated value, liquidation preference based on assumed conversion
    into common stock &ndash; 72,917 shares</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,500,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,500,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Common stock, $0.0001 par value; authorized &ndash; 100,000,000 shares; issued and outstanding &ndash;
    2,249,290 shares at December 31, 2024 and 2023, respectively</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">225</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">225</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Additional paid-in capital</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">49,394,687</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">48,976,265</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Accumulated deficit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right">(52,067,693</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right">(48,481,728</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total stockholders&rsquo; equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">827,219</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">3,994,762</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_009"></A>DESCRIPTION
OF SECURITIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
certificate of incorporation, as amended, authorizes the issuance of up to 100,000,000 shares of common stock, par value $0.0001 per
share, and up to 10,000,000 shares of preferred stock, par value $0.0001 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2025, there were 2,684,074 shares of common stock outstanding, which were held by 46 stockholders of record, and 350,000
shares of Series A Convertible Preferred Stock outstanding, which were subsequently converted into 72,917 shares of common stock pursuant
to a notice of conversion dated May 16, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 2, 2023, we effected a reverse stock split of our common stock at a ratio of 1-for-10. All share and per share information presented
in this prospectus reflects the effect of the reverse stock split.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
holder of common stock is entitled to one vote for each share of common stock held on all matters submitted to a vote of the stockholders,
including the election of directors. Our certificate of incorporation, as amended and bylaws do not provide for cumulative voting rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to preferences that may be applicable to any then outstanding preferred stock, the holders of our outstanding shares of common stock
are entitled to receive dividends, if any, as may be declared from time to time by our Board of Directors out of legally available funds.
In the event of our liquidation, dissolution or winding up, holders of common stock will be entitled to share ratably in the net assets
legally available for distribution to stockholders after the payment of all of our debts and other liabilities, subject to the satisfaction
of any liquidation preference granted to the holders of any outstanding shares of preferred stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of our common stock have no pre-emptive, conversion or subscription rights, and there are no redemption or sinking fund provisions applicable
to the common stock. The rights, preferences and privileges of the holders of common stock are subject to, and may be adversely affected
by, the rights of the holders of shares of any series of our preferred stock that are outstanding or that we may designate and issue
in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Preferred
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors is authorized, without vote or action by our stockholders, to issue from time to time up to an aggregate of 10,000,000
shares of preferred stock in one or more series and to fix or alter the designations, preferences, rights and any qualifications, limitations
or restrictions of the shares of each of these series, including, if applicable, the dividend rights and preferences, conversion rights,
voting rights, terms and rights of redemption, including without limitation sinking fund provisions, redemption price or prices, liquidation
rights and preferences, and the number of shares constituting any series. The issuance of preferred stock may have the effect of delaying,
deferring or preventing a change in control of us without further action by our stockholders and may adversely affect the dividend, liquidation
and voting and other rights of the holders of common stock. The issuance of preferred stock with voting and conversion rights may adversely
affect the voting power of the holders of common stock, including the loss of voting control to others. We currently have no plans to
issue any additional shares of preferred stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that the ability to issue preferred stock without the expense and delay of a special stockholders&rsquo; meeting provides us
with increased flexibility in structuring possible future financings and acquisitions, and in meeting other corporate needs that might
arise. This also permits the Board of Directors of the Company to issue preferred stock containing terms which could impede the completion
of a takeover attempt. This could discourage an acquisition attempt or other transaction which stockholders might believe to be in their
best interests or in which they might receive a premium for their stock over the then market price of the stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the 2023 Financing and 2025 Financing, we issued warrants to purchase a total of 1,085,727 shares to the investors and
placement agents, including Warrants to purchase 583,334 shares of common stock exercisable at $6.00 per share to the investor in the
2023 Financing and Warrants to purchase 434,784 shares of common stock exercisable at $2.29 per share to the investors in the 2025 Financing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise prices of the Warrants are subject to customary adjustments for stock splits, stock dividends, stock combinations, reclassifications,
reorganizations, or similar events affecting our common stock. In addition, the Warrants contain a &ldquo;fundamental transaction&rdquo;
provision which provides that if any defined fundamental transactions are within our control and are consummated, the holder of the unexercised
common stock Warrants would be entitled to receive, at its option, in exchange for extinguishment of such Warrants, cash consideration
equal to a Black-Scholes valuation amount, as defined in the Warrant agreement. The fundamental transaction provision includes (i) a
sale, lease, assignment, transfer, conveyance or other disposition of all or substantially all of assets in one or a series of related
transactions, or (ii) a change in control of the Company by which it, directly or indirectly, in one or more related transactions, consummates
a stock or share purchase agreement or other business combination with another person or group, whereby such other person or group acquires
more than 50% of the voting power of our common equity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
such fundamental transaction is not within our control, including not being approved by our Board of Directors, the Warrant holder would
only be entitled to receive the same type or form of consideration (and in the same proportion) equal to the Black-Scholes valuation
amount of the remaining unexercised portion of the Warrant on the date of consummation of such fundamental transaction as the holders
of our common stock receive. Accordingly, these Warrants are classified as a component of permanent stockholders&rsquo; equity. We will
account for any cash payment for a Warrant redemption as a distribution from stockholders&rsquo; equity, as and when a fundamental transaction
is consummated and such cash payment is made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Anti-Takeover
Effects of Certain Provisions in our Certificate and Bylaws</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Exclusive
Forum</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
certificate of incorporation provides that, unless we consent to the selection of an alternative forum, the Court of Chancery of the
State of Delaware shall be the sole and exclusive forum for (i) any derivative action or proceeding brought on our behalf, (ii) any action
asserting a claim of breach of fiduciary duty owed by any of our directors, officers, or other employee to us or to our stockholders,
(iii) any action asserting a claim against us arising pursuant to any provision of the Delaware General Corporation Law, the certificate
of incorporation or the bylaws or (iv) any action asserting a claim governed by the internal affairs doctrine. However, this provision
does not apply to suits brought to enforce a duty or liability created by the Exchange Act. In addition, the Court of Chancery of the
State of Delaware and the federal district courts will have concurrent jurisdiction for the resolution of any suit brought to enforce
any duty or liability created by the Securities Act. Notwithstanding the foregoing, the inclusion of such provisions in the certificate
of incorporation will not be deemed to be a waiver by us or our stockholders of the obligation to comply with federal securities laws,
rules and regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we believe these provisions benefit the Company by providing increased consistency in the application of Delaware law in the types of
lawsuits to which it applies, these provisions may have the effect of discouraging lawsuits against the Company&rsquo;s directors and
officers. Furthermore, the enforceability of choice of forum provisions in other companies&rsquo; certificates of incorporation has been
challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Advance
Notice of Stockholder Proposals and Nominations</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
bylaws include an advance notice procedure for stockholders to nominate candidates for election as directors or to bring other business
before any meeting of our stockholders. The stockholder notice procedure provides that only persons who are nominated by, or at the direction
of, the Board of Directors, or by a stockholder who has given timely written notice prior to the meeting at which directors are to be
elected, will be eligible for election as directors and that, at a stockholders&rsquo; meeting, only such business may be conducted as
has been brought before the meeting by, or at the direction of, the Board of Directors or by a stockholder who has given timely written
notice of such stockholder&rsquo;s intention to bring such business before such meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the stockholder notice procedure, for notice of stockholder nominations or other business to be made at a stockholders&rsquo; meeting
to be timely, such notice must be received by us not earlier than the close of business on the 120th calendar day and not later than
the close of business on the 90th calendar day prior to the one-year anniversary of the immediately preceding year&rsquo;s annual meeting
or as otherwise provided in the bylaws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
stockholder&rsquo;s notice to us proposing to nominate a person for election as a director or proposing other business must contain certain
information specified in the bylaws, including the identity and address of the nominating stockholder, a representation that the stockholder
is a record holder of our stock entitled to vote at the meeting and information regarding each proposed nominee or each proposed matter
of business that would be required under the federal securities laws to be included in a proxy statement soliciting proxies for the proposed
nominee or the proposed matter of business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
stockholder notice procedure may have the effect of precluding a contest for the election of directors or the consideration of stockholder
proposals if the proper procedures are not followed, and of discouraging or deterring a third party from conducting a solicitation of
proxies to elect its own slate of directors or to approve its own proposal, without regard to whether consideration of such nominees
or proposals might be harmful or beneficial to us and our stockholder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Restrictions
on Call of Special Meetings</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
bylaws provide that special meetings of stockholders can only be called by the Board of Directors, Chief Executive Officer or President
(in the absence of a Chief Executive Officer), but not by our stockholders or any other person or persons.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>No
Cumulative Voting</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
certificate of incorporation does not authorize cumulative voting for the election of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Preferred
Stock Authorization</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors, without stockholder approval, has the authority under our certificate of incorporation to issue preferred stock with
rights superior to the rights of the holders of common stock. As a result, preferred stock, while not intended as a defensive measure
against takeovers, could be issued quickly and easily, could adversely affect the rights of holders of common stock, and could be issued
with terms calculated to delay or prevent a change of control of the Company or make removal of management more difficult.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DESCRIPTION
OF SECURITIES WE ARE OFFERING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
material terms and provisions of our common stock are described under the caption &ldquo;Description of Securities&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pre-Funded
Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following description of the Pre-Funded Warrants we are offering is a summary and is qualified in its entirety by reference to the provisions
of the Pre-Funded Warrants, the form of which is filed as an exhibit to the registration statement of which this prospectus forms a part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Pre-Funded Warrant is exercisable for one share of our common stock, with an exercise price equal to $0.00001 per share, at any time
that the Pre-Funded Warrant is outstanding. There is no expiration date for the Pre-Funded Warrants. The holder of a Pre-Funded Warrant
will not be deemed a holder of our underlying common stock until the Pre-Funded Warrant is exercised.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise price and the number of shares of common stock issuable upon exercise of the Pre-Funded Warrants are subject to appropriate
adjustment in the event of recapitalization events, stock dividends, stock splits, stock combinations, reclassifications, reorganizations
or similar events affecting our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
term &ldquo;pre-funded&rdquo; refers to the fact that the purchase price of our common stock in this offering includes almost the entire
exercise price that will be paid under the Pre-Funded Warrants, except for a nominal remaining exercise price of $0.00001. The purpose
of the Pre-Funded Warrants is to enable investors that may have restrictions on their ability to beneficially own more than 4.99% (or,
upon election of the holder, 9.99%) of our outstanding common stock following the consummation of this offering the opportunity to make
an investment in us without triggering their ownership restrictions, by receiving Pre-Funded Warrants in lieu of our common stock which
would result in such ownership of more than 4.99% (or 9.99%), and receive the ability to exercise their option to purchase the shares
underlying the Pre-Funded Warrants at such nominal price at a later date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Pre-Funded Warrants are exercisable, at the option of the holder, in whole or in part, by delivering to us a duly executed exercise notice
accompanied by payment in full for the number of shares of common stock purchased upon such exercise (except in the case of a cashless
exercise, as discussed below). A holder (together with its affiliates) may not exercise any portion of the Pre-Funded Warrants to the
extent that the holder would own more than 4.99% (or, at the election of the holder, 9.99%) of the outstanding shares of common stock
immediately after exercise. However, upon notice from the holder to us, the holder may decrease or increase the holder&rsquo;s beneficial
ownership limitation, which may not exceed 9.99% of the number of outstanding shares of common stock immediately after giving effect
to the exercise, as such percentage ownership is determined in accordance with the terms of the Pre-Funded Warrants, provided that any
increase in the beneficial ownership limitation will not take effect until sixty-one (61) days following notice to us. Purchasers in
this offering may also elect, prior to the issuance of the Pre-Funded Warrants, to have the initial exercise limitation set at 9.99%
of our outstanding shares of common stock. No fractional shares will be issued in connection with the exercise of a Pre-Funded Warrant.
In lieu of fractional shares, we will either pay the holder an amount in cash equal to the fractional amount multiplied by the exercise
price or round up to the next whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
at the time a holder exercises its Pre-Funded Warrants, a registration statement registering the issuance of the shares of common stock
underlying the Pre-Funded Warrants under the Securities Act is not then effective or available and an exemption from registration under
the Securities Act is not available for the issuance of such shares, then in lieu of making the cash payment otherwise contemplated to
be made to us upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise
(either in whole or in part) the net number of shares of common stock determined according to a formula set forth in the Pre-Funded Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to applicable laws, a Pre-Funded Warrant may be transferred at the option of the holder upon surrender of the Pre-Funded Warrant to us
together with the appropriate instruments of transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Exchange
Listing</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no trading market available for the Pre-Funded Warrants on any securities exchange or nationally recognized trading system. Accordingly,
we do not intend to list the Pre-Funded Warrants on any securities exchange or nationally recognized trading system.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Right
as a Stockholder</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise provided in the Pre-Funded Warrants or by virtue of such holder&rsquo;s ownership of our shares of common stock, the holders
of the Pre-Funded Warrants do not have the rights or privileges of holders of our shares of common stock, including any voting rights,
until the holder exercises their Pre-Funded Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Fundamental
Transaction</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of a fundamental transaction, as described in the Pre-Funded Warrants and generally including any reorganization, recapitalization
or reclassification of our shares of common stock, the sale, transfer or other disposition of all or substantially all of our properties
or assets, our consolidation or merger with or into another person, the acquisition of more than 50% of our outstanding shares of common
stock, or any person or group becoming the beneficial owner of more than 50% of the voting power represented by our outstanding shares
of common stock, the holders of the Pre-Funded Warrants will be entitled to receive upon exercise of the Pre-Funded Warrants the kind
and amount of securities, cash or other property that the holders would have received had they exercised the Pre-Funded Warrants immediately
prior to such fundamental transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="vi_001"></A><B>PLAN
OF DISTRIBUTION</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 0.5in; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
engaged Spartan Capital Securities, LLC to act as our exclusive Placement Agent to solicit offers to purchase the securities offered
by this prospectus on a reasonable best-efforts basis, subject to the terms and conditions of a placement agent agreement between the
Company and the Placement Agent. The Placement Agent is not purchasing or selling any of the securities offered by this prospectus, nor
is it required to arrange the purchase or sale of any specific number or dollar amount of securities, but has agreed to use its reasonable
best efforts to arrange for the sale of the securities offered hereby. Therefore, we may not sell the entire amount of securities offered
pursuant to this prospectus. The Placement Agent may engage one or more sub-placement agents or selected dealers to assist with the offering.
We may enter into a securities purchase agreement directly with certain investors, at the investor&rsquo;s option, who purchase our securities
in this offering. Investors who do not enter into a securities purchase agreement shall rely solely on this prospectus and the documents
incorporated by reference herein in connection with the purchase of our securities in this offering.</FONT> </P>

<P STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 0.5in; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will deliver the securities being issued to the investors upon receipt of such investor&rsquo;s funds for the purchase of the securities
offered pursuant to this prospectus. We expect this offering to be completed not later than one (1) business day following the commencement
of this offering. We will deliver all securities to be issued in connection with this offering delivery versus payment (&ldquo;DVP&rdquo;)/receipt
versus payment (&ldquo;RVP&rdquo;) upon receipt of investor funds received by us.</FONT> </P>

<P STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-bottom: 0pt"> &nbsp; </P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-indent: 0.5in; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed to indemnify the Placement Agent and specified other persons against specified liabilities, including liabilities under the
Securities Act, and to contribute to payments the Placement Agent may be required to make in respect thereof.</FONT> </P>

<P STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fees
and Expenses</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows the per share, the per Pre-Funded Warrant and total of the public offering price, Placement Agent fees and proceeds
to us before expenses. These amounts are shown assuming the sale of all of the securities we are offering</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Per</B></FONT> </P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Share</B></FONT> </P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <B>Per
                                            Pre-Funded Warrant</B> </P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total</B></FONT> </P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> &nbsp; </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 46%"> Public offering price </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Placement Agent Fees (8.0%) </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> (&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> ) </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> (&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> ) </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> (&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> ) </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accountable
    expense allowance (1.0%)<SUP>(1)</SUP></FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> (&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> ) </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> (&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> ) </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> (&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> ) </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"> Proceeds to us (before expenses) </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
We have agreed to pay a non-accountable expense allowance to Spartan equal to 1.0% of the gross proceeds received in this offering. We
have also agreed to reimburse Spartan for up to $125,000 of out-of-pocket fees and expenses, including, but not limited to, legal fees
and disbursements for the Placement Agent counsel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, Spartan or its affiliates have in the past or may in the future engage in investment banking and/or other services with
us and our affiliates for which they have received or may in the future receive customary fees and expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lock-Up
Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
directors, executive officers and 10% stockholders have agreed that, for a period of sixty (60) days from the closing date of the offering,
subject to certain limited exceptions, they will not directly or indirectly, without the prior written consent of Spartan, (a) offer,
sell, or otherwise transfer or dispose of, directly or indirectly, any shares of capital stock of the Company or any securities convertible
into or exercisable or exchangeable for shares of capital stock of the Company; or (b) file or caused to be filed any registration statement
with the Commission relating to the offering of any shares of capital stock of the Company or any securities convertible into or exercisable
or exchangeable for shares of capital stock of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Spartan,
in its sole discretion, may release the common stock and other securities subject to the lock-up agreements described above in whole
or in part at any time. When determining whether or not to release common stock and other securities from lock-up agreements, Spartan
will consider, among other factors, the holder&rsquo;s reasons for requesting the release, the number of shares of common stock and other
securities for which the release is being requested and market conditions at the time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Company
Standstill</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed, for a period of sixty (60) days after the closing date of the offering (the &ldquo;Standstill Period&rdquo;), that without
the prior written consent of Spartan, we will not (a) offer, sell, issue, or otherwise transfer or dispose of, directly or indirectly,
any equity of our Company or any securities convertible into or exercisable or exchangeable for equity of our Company; (b) file or caused
to be filed any registration statement with the Commission relating to the offering of any equity of our Company or any securities convertible
into or exercisable or exchangeable for equity of our Company; or (c) enter into any agreement or announce the intention to effect any
of the actions described in subsections (a) or (b) hereof (all of such matters, the &ldquo;Standstill Restrictions&rdquo;). So long as
none of such equity securities shall be saleable in the public market until the expiration of the Standstill Period, the following matters
shall not be prohibited by the Standstill Restrictions: (i) the adoption of an equity incentive plan and the grant of awards or equity
pursuant to any equity incentive plan, and the filing of a registration statement on Form S-8; and (ii) securities issued pursuant to
acquisitions or strategic transactions approved by a majority of the disinterested directors of our Company, provided that such securities
are issued as &ldquo;restricted securities&rdquo; (as defined in Rule 144) and carry no registration rights that require or permit the
filing of any registration statement in connection therewith during the Standstill Period, and provided that any such issuance shall
only be to a person or entity (or to the equity holders of an entity) which is, itself or through its subsidiaries, an operating company
or an owner of an asset in a business synergistic with the business of our Company and shall provide to our Company additional benefits
in addition to the investment of funds, but shall not include a transaction in which our Company is issuing securities primarily for
the purpose of raising capital or to an entity whose primary business is investing in securities. In no event should any equity transaction
during the Standstill Period result in the sale of equity at an offering price to the public less than that of this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Placement
Agent</B></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B> Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">As
additional compensation to Spartan, upon consummation of the offering, we will issue to Spartan or its designees warrants to purchase
an aggregate number of shares of common stock equal to 5.0% of the number of shares of common stock issued in the offering, at an exercise
price per share equal to 125.0% of the public offering price (the &ldquo;Placement Agent Warrants&rdquo;). The Placement Agent
Warrants and the underlying shares of common stock will not be sold, transferred, assigned, pledged, or hypothecated, or be the subject
of any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the Placement
Agent Warrants by any person for a period of one hundred eighty (180) Calendar Days beginning on the date of commencement of sales
of the offering in compliance with FINRA Rule 5110(e)(1).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The
Placement Agent Warrants will be exercisable from the date that is six (6) months from the commencement of the sales of the offering,
and will expire five (5) years from the commencement of sales of the offering in compliance with FINRA Rule 5110(g)(8)(A). In addition,
such Placement Agent Warrants shall be exercisable on a cash basis, provided that if a registration statement registering the
common stock underlying the Placement Agent Warrants is not effective, the Placement Agent Warrants may be exercised on
a cashless basis. Furthermore, (i) the Placement Agent Warrants do not have more than one demand registration right at our Company&rsquo;s
expense in compliance with FINRA Rule 5110(g)(8)(B); (ii) the Placement Agent Warrants do not have a demand registration right
with a duration of more than five (5) years from the commencement of sales of the public offering in compliance with FINRA Rule 5110(g)(8)(C);
(iii) the Placement Agent Warrants do not have piggyback registration rights with a duration of more than seven (7) years from
the commencement of sales of the public offering in compliance with FINRA Rule 5110(g)(8)(D); and (iv) the Placement Agent Warrants
have anti-dilution terms that are consistent with FINRA Rule 5110(g)(8)(E) and (F).</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Right
of First Refusal</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the Right of First Refusal Period and subject to any Senior Right of First Refusal (as defined below), if we or any of our subsidiaries
(a) decides to dispose of or acquire business units or acquire any of its outstanding securities or make any exchange or tender offer
or enter into a merger, consolidation or other business combination or any recapitalization, reorganization, restructuring or other similar
transaction, including, without limitation, an extraordinary dividend or distributions or a spin-off or split-off, and the Company decides
to retain a financial advisor for such transaction, Spartan (or any affiliate designated by Spartan) shall have the right to act as the
Company&rsquo;s exclusive financial advisor for any such transaction; or (b) decides to finance or refinance any indebtedness, Spartan
(or any affiliate designated by Spartan) shall have the right to act as sole book-runner, sole manager, sole placement agent or sole
agent with respect to such financing or refinancing; or (c) decides to raise funds by means of a public offering (including an at-the-market
facility) or a private placement or any other capital raising financing of equity, equity-linked or debt securities, Spartan (or any
affiliate designated by Spartan) shall have the right to act as sole book-running manager, sole Placement Agent or sole placement
agent for such financing. The Company shall provide written notice to Spartan of any proposed transaction set forth in (a) &ndash; (c)
above, including a detailed term sheet. Spartan (including through its affiliates) shall have ten (10) business days following receipt
of such detailed term sheet to determine whether to waive its rights under the right of first refusal. If Spartan or one of its affiliates
decides to accept any such engagement, the agreement governing such engagement will contain, among other things, provisions for customary
fees and terms for transactions of similar size and nature, including indemnification, which are appropriate to such a transaction, provided,
however, that after Spartan delivers such engagement letter, the Company may notify Spartan that it wishes to terminate the right of
first refusal by paying a fee of $10,000, to be effective only upon receipt of such payment. The Right of First Refusal Period shall
be the period beginning on the date hereof and ending on the date that is the earlier of (i) six (6) months after the expiration or earlier
termination of any senior right of first refusal (&ldquo;Senior Right of First Refusal&rdquo;) existing on the date hereof with respect
to any transactions described in (a) &ndash; (c) above, or (ii) the date that is the three (3) year anniversary of the commencement of
sales in the Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the foregoing, the decision to accept our engagement shall be made by Spartan or one of its affiliates, by a written notice to us, within
ten (10) Business Days after the receipt of our notification of financing needs, including a detailed term sheet. Spartan&rsquo;s determination
of whether in any case to exercise its right of first refusal will be strictly limited to the terms on such term sheet, and any waiver
of such right of first refusal shall apply only to such specific terms. If Spartan waives its right of first refusal, any deviation from
such terms shall void the waiver and require us to seek a new waiver from the right of first refusal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tail
Financing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Spartan
shall be entitled to compensation with respect to any public or private offering or other financing or capital raising transaction of
any kind to the extent that such financing or capital is provided to us by funds whom Spartan had contacted during the engagement period
or introduced to us during the engagement period, if such tail financing is consummated at any time within the twelve (12) month period
following the closing of the offering or the expiration or termination of the letter of engagement, as amended between Spartan and us
dated April 23, 2025, as may be further amended from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Regulation
M</B></FONT></P>

<P STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 0.5in; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Placement Agent may be deemed to be an underwriter within the meaning of Section 2(a)(11) of the Securities Act, and any commissions
received by it and any profit realized on the resale of the securities sold by it while acting as principal might be deemed to be underwriting
discounts or commissions under the Securities Act. As an underwriter, the Placement Agent would be required to comply with the requirements
of the Securities Act and the Exchange Act, including, without limitation, Rule 10b-5 and Regulation M under the Exchange Act. These
rules and regulations may limit the timing of purchases and sales of our securities by the placement agent acting as principal. Under
these rules and regulations, the Placement Agent (i) may not engage in any stabilization activity in connection with our securities and
(ii) may not bid for or purchase any of our securities or attempt to induce any person to purchase any of our securities, other than
as permitted under the Exchange Act, until it has completed its participation in the distribution.</FONT> </P>

<P STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0pt"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Determination
of Offering Price</B></FONT> </P>

<P STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 35pt; margin-bottom: 0pt"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 35pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
public offering price of the securities were negotiated between us, the Placement Agent and the investors. The determination of the public
offering price considered, among other things, the following</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 35pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17.45pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            trading of our shares of common stock prior to the offering</FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17.45pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            information set forth in this prospectus and otherwise available to the Placement Agent;</FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17.45pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            prospectus for our Company and the industry in which we operate;</FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17.45pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
                                            assessment of our management;</FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17.45pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            past and present financial and operating performance;</FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17.45pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            prospectus for future earnings;</FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17.45pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial
                                            and operating information and market valuations of publicly traded companies engaged in activities
                                            similar to ours;</FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17.45pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            prevailing conditions of the United States securities markets at the time of this offering;
                                            and</FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17.45pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
                                            factors deemed relevant.</FONT> </TD></TR></TABLE>

<P STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Indemnification</B></FONT></P>

<P STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 0.5in; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed to indemnify the Placement Agent against certain liabilities, including liabilities under the Securities Act, and liabilities
arising from breaches of representations and warranties contained in the Placement Agent Agreement, or to contribute to payments that
the placement agent may be required to make in respect of those liabilities.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
Relationships</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Placement Agent is a full service financial institution engaged in various activities, which may include sales and trading, commercial
and investment banking, advisory, investment management, investment research, principal investment, hedging, market making, brokerage
and other financial and non-financial activities and services. The Placement Agent may in the future provide various investment
banking, commercial banking and other financial services for us and our affiliates for which they may in the future receive customary
fees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of its business activities, the Placement Agent and its affiliates, officers, directors and employees may
purchase, sell or hold a broad array of investments and actively traded securities, derivatives, loans, commodities, currencies, credit
default swaps and other financial instruments for their own account and for the accounts of their customers, and such investment and
trading activities may involve or relate to assets, securities and/or instruments of the issuer (directly, as collateral securing other
obligation or otherwise) publish or express independent research views in respect of such assets, securities or instruments and may at
any time hold, or recommend to clients that they should acquire, long and/or short positions in such assets, securities and instruments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Electronic
Offer, Sale and Distribution of Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">A prospectus
in electronic format may be made available on the websites maintained by the Placement Agent, if any, participating in this offering
and the Placement Agent participating in this offering may distribute prospectuses electronically. The Placement Agent
may agree to allocate a number of shares of common stock and Pre-Funded Warrants for sale to its online brokerage account holders. Internet
distributions will be allocated by the Placement Agent that will make internet distributions on the same basis as other allocations.
Other than the prospectus in electronic format, the information on these websites is not part of, nor incorporated by reference into,
this prospectus or the registration statement of which this prospectus forms a part, has not been approved or endorsed by us or the Placement
Agent in its capacity as Placement Agent, and should not be relied upon by investors.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Offer
Restrictions Outside the United States</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than in the United States, no action has been taken by us or the Placement Agent that would permit a public offering of the securities
offered by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may
not be offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection
with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will
result in compliance with the applicable rules and regulations of that jurisdiction. Persons who come into possession of this prospectus
are advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus.
This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in
any jurisdiction in which such an offer or a solicitation is unlawful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Listing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is currently listed on the Nasdaq Capital Market under the symbol &ldquo;LIXT&rdquo;. The warrants issued in our November
2020 public offering are currently listed on the Nasdaq Capital Market under the symbol &ldquo;LIXTW&rdquo;. We do not intend to apply
for listing of the Pre-funded Warrants on any securities exchange or other nationally recognized trading system. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Transfer
Agent and Registrar</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transfer agent and registrar for our common stock and the warrants issued in our November 2020 public offering is Computershare Trust
Company, N.A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_011"></A>LEGAL
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
validity of the securities offered by this prospectus will be passed upon by TroyGould PC, Los Angeles, California. Kaufman &amp; Canoles,
Richmond, Virginia is acting as counsel to the Placement Agent. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_012"></A>EXPERTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weinberg
&amp; Company, P.A., our independent, registered public accounting firm, has audited our consolidated financial statements as of December
31, 2024 and 2023 and for the years then ended included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024,
which is incorporated by reference into this prospectus and elsewhere in the registration statement of which this prospectus is a part.
Our consolidated financial statements are incorporated by reference in reliance on Weinberg &amp; Company P.A.&rsquo;s report, which
includes an explanatory paragraph regarding substantial doubt about the Company&rsquo;s ability to continue as a going concern, given
on their authority as experts in accounting and auditing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_013"></A>INCORPORATION
OF CERTAIN INFORMATION BY REFERENCE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC allows us to incorporate by reference into this prospectus certain information we file with it, which means that we can disclose
important information by referring you to those documents. The information incorporated by reference is considered to be part of this
prospectus. Because we are incorporating by reference future filings with the SEC, this prospectus is continually updated and those future
filings may modify or supersede some of the information included or incorporated in this prospectus. We incorporate by reference the
documents listed below and all documents subsequently filed with the SEC (excluding any portions of any Form 8-K that are not deemed
&ldquo;filed&rdquo; pursuant to the General Instructions of Form 8-K) pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act,
after the date of this prospectus and prior to the date this offering is terminated or we issue all of the securities under this prospectus:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    Annual Report on <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000164117225000208/form10-k.htm" STYLE="-sec-extract: exhibit">Form 10-K</A> for the fiscal year ended December 31, 2024, filed with the SEC on March 24, 2025;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    Quarterly Report on <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000164117225009575/form10-q.htm" STYLE="-sec-extract: exhibit">Form 10-Q</A> for the quarterly period ended March 31, 2025, filed with the SEC on May 12, 2025;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    Current Reports on Form 8-K, filed with the SEC on <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315225001069/form8-k.htm" STYLE="-sec-extract: exhibit">January
    6, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315225006285/form8-k.htm" STYLE="-sec-extract: exhibit">February
    13, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315225007865/form8-k.htm" STYLE="-sec-extract: exhibit">February
    21, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315225008203/form8-k.htm" STYLE="-sec-extract: exhibit">February
    25, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315225009782/form8-k.htm" STYLE="-sec-extract: exhibit">March
    11, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315225009786/form8-k.htm" STYLE="-sec-extract: exhibit">March
    11, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315225010282/form8-k.htm" STYLE="-sec-extract: exhibit">March
    14, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000164117225000971/form8-k.htm" STYLE="-sec-extract: exhibit">March
    27, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000164117225001763/form8-k.htm" STYLE="-sec-extract: exhibit">March
    31, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000164117225005466/form8-k.htm" STYLE="-sec-extract: exhibit">April
    18, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000164117225011701/form8-k.htm" STYLE="-sec-extract: exhibit">May
    20, 2025</A>, and <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000164117225015346/form8-k.htm" STYLE="-sec-extract: exhibit">June 17, 2025</A>; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    description of our common stock contained in the registration statement on <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315220021857/form8-a12b.htm" STYLE="-sec-extract: exhibit">Form 8-A</A>, filed with the SEC on November 17, 2020, and
    any amendment or report filed for the purpose of updating such description (including <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315220004697/ex4-1.htm" STYLE="-sec-extract: exhibit">Exhibit 4.1</A> to the Annual Report on Form 10-K
    for the fiscal year ended December 31, 2023).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
obtain copies of these filings, see &ldquo;Where You Can Find More Information&rdquo; in this prospectus. Nothing in this prospectus
shall be deemed to incorporate information furnished, but not filed, with the SEC, including pursuant to Item 2.02 or Item 7.01 of Form
8-K and any corresponding information or exhibit furnished under Item 9.01 of Form 8-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
in this prospectus supersedes related information in the documents listed above and information in subsequently filed documents supersedes
related information in both this prospectus and the incorporated documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_014"></A>WHERE
YOU CAN FIND MORE INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to the periodic reporting requirements of the Exchange Act, and we will file periodic reports, proxy statements and other
information with the SEC. These periodic reports, proxy statements and other information are available at www.sec.gov. We maintain a
website at https://lixte.com. We have not incorporated by reference into this prospectus the information contained in, or that can be
accessed through, our website, and you should not consider it to be a part of this prospectus. You may access our Annual Reports on Form
10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section
13(a) or 15(d) of the Exchange Act with the SEC free of charge at our website as soon as reasonably practicable after such material is
electronically filed with, or furnished to, the SEC. You may also request a copy of these filings (other than exhibits to these documents
unless the exhibits are specifically incorporated by reference into these documents or referred to in this prospectus), at no cost, by
writing us at 680 East Colorado Boulevard, Suite 180, Pasadena, California 91101 or contacting us at (631) 830-7092.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have filed with the SEC a registration statement under the Securities Act relating to the offering of these securities. The registration
statement, including the attached exhibits, contains additional relevant information about us and the securities. This prospectus does
not contain all of the information set forth in the registration statement. You may review a copy of the registration statement and the
documents incorporated by reference herein through the SEC&rsquo;s website at www.sec.gov.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LIXTE
BIOTECHNOLOGY HOLDINGS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
23, 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 0pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PART
II</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INFORMATION
NOT REQUIRED IN PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
13. Other Expenses of Issuance and Distribution</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the various expenses, all of which will be borne by the registrant, in connection with the sale and distribution
of the securities being registered, other than the Placement Agent fees. All amounts shown are estimates except for the SEC registration
fee and the FINRA filing fee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left">SEC registration fee</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">918.60</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">FINRA fees</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,000.00</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Transfer agent and registrar fees</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10,000.00</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Accounting fees and expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">40,000.00</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Legal fees and expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">75,000.00</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Placement Agent expense allowance</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">125,000.00</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Miscellaneous</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">27,081.40</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Total</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">280,000.00</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
14. Indemnification of Directors and Officers.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
102(b)(7) of the Delaware General Corporation Law (&ldquo;DGCL&rdquo;) provides that a Delaware corporation, in its certificate of incorporation,
may limit the personal liability of a director to the corporation or its stockholders for monetary damages for breach of fiduciary duties
as a director, except for liability for any:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">transaction
    from which the director derived an improper personal benefit;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">act
    or omission not in good faith or that involved intentional misconduct or a knowing violation of law;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unlawful
    payment of dividends or redemption of shares; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">breach
    of the director&rsquo;s duty of loyalty to the corporation or its stockholders.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Section 145 of the DGCL, we can indemnify our directors and officers against liabilities they may incur in such capacities, including
liabilities under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;). Our certificate of incorporation (Exhibit
3.1 to this registration statement) provides that we must indemnify our directors and officers to the fullest extent permitted by law
and requires us to pay expenses incurred in defending or other participating in any proceeding in advance of its final disposition upon
our receipt of an undertaking by the director or officer to repay such advances if it is ultimately determined that the director or officer
is not entitled to indemnification. Our certificate of incorporation further provides that rights conferred under such certificate of
incorporation do not exclude any other right such persons may have or acquire under the certificate of incorporation, the bylaws, any
statute, agreement, vote of stockholders or disinterested directors or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
certificate of incorporation also provides that, pursuant to Delaware law, our directors shall not be liable for monetary damages for
breach of the directors&rsquo; fiduciary duty of care to us and our stockholders. This provision in the certificate of incorporation
does not eliminate the duty of care, and in appropriate circumstances equitable remedies such as injunctive or other forms of non-monetary
relief will remain available under Delaware law. In addition, each director will continue to be subject to liability for breach of the
director&rsquo;s duty of loyalty to us for acts or omissions not in good faith or involving intentional misconduct, or knowing violations
of law, for actions leading to improper personal benefit to the director, and for payment of dividends or approval of stock repurchases
or redemptions that are unlawful under Delaware law. The provision also does not affect a director&rsquo;s responsibilities under any
other law, such as the federal securities laws or state or federal environmental laws. We also intend to obtain directors&rsquo; and
officers&rsquo; liability insurance pursuant to which our directors and officers are insured against liability for actions taken in their
capacities as directors and officers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we have entered into agreements to indemnify our directors and certain of our officers in addition to the indemnification provided
for in the certificate of incorporation. These agreements, among other things, indemnify our directors and some of our officers for certain
expenses (including attorney&rsquo;s fees), judgments, fines and settlement amounts incurred by such person in any action or proceeding,
including any action by or in our right, on account of services by that person as a director or officer of our company or as a director
or officer of our subsidiary, or as a director or officer of any other company or enterprise that the person provides services to at
our request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 44; Options: NewSection; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Value: 1; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 0pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
15. Recent Sales of Unregistered Securities.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information below lists all of the securities sold by us during the past three years which were not registered under the Securities Act:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 16, 2025, the Company received a notice of conversion with respect to its 350,000 shares of Series A Convertible Preferred Stock
outstanding, These shares of preferred stock were issued to an investor in 2015 and 2016 and were convertible into 72,917 shares of common
stock on such date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
16. Exhibits and Financial Statement Schedules.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
list of exhibits to this registration statement is set forth in the Index to Exhibits as presented below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INDEX
TO EXHIBITS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit<BR>
    Number</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.1in; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description
    of Document</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><A HREF="ex1-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Placement Agent Agreement*</FONT></A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000114420406027818/v047035_ex2-1.htm" STYLE="-sec-extract: exhibit">Share
    Exchange Agreement dated as of June 8, 2006 among the Company, John S. Kovach and Lixte Biotechnology, Inc., filed as Exhibit 2.1
    to the Company&rsquo;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on July 7, 2006 and incorporated
    herein by reference.</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000114420405023652/v022460_ex3-1.txt" STYLE="-sec-extract: exhibit">Certificate
    of Incorporation, as filed with the Delaware Secretary of State on May 24, 2005, filed as Exhibit 3.1 to the Company&rsquo;s Registration
    Statement on Form 10-SB, as filed with the Securities and Exchange Commission on August 3, 2005 and incorporated herein by reference.</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000114420406039012/v053105_pre14c.htm" STYLE="-sec-extract: exhibit">Certificate
    of Amendment of Certificate of Incorporation, filed as Appendix A to the Company&rsquo;s Information Statement, as filed with the
    Securities and Exchange Commission on September 19, 2006 and incorporated herein by reference.</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315215000869/ex4-01.htm" STYLE="-sec-extract: exhibit">Certificate
    of Designations for the Company&rsquo;s Series A Convertible Preferred Stock, filed as Exhibit 4.01 to the Company&rsquo;s Current
    Report on Form 8-K, as filed with the Securities and Exchange Commission on March 18, 2015 and incorporated herein by reference.</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315216008321/ex3-4.htm" STYLE="-sec-extract: exhibit">Certificate
    of Amendment of Certificate of Designations of the Series A Convertible Preferred Stock, filed as Exhibit 3.4 to the Company&rsquo;s
    Annual Report on Form 10-K for the fiscal year ended December 31, 2015, as filed with the Securities and Exchange Commission on March
    28, 2016 and incorporated herein by reference.</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315222031348/ex3-1.htm" STYLE="-sec-extract: exhibit">Amended
    and Restated Bylaws, filed as Exhibit 3.1 to the Company&rsquo;s Current Report on Form 8-K, as filed with the Securities and Exchange
    Commission on November 10, 2022 and incorporated herein by reference.</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315220022628/ex3-1.htm" STYLE="-sec-extract: exhibit">Certificate
    of Amendment of Certificate of Incorporation, filed as Exhibit 3.1 to the Company&rsquo;s Current Report on Form 8-K, as filed with
    the Securities and Exchange Commission on November 27, 2020 and incorporated herein by reference.</A></FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 0pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify; width: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315223020163/ex3-1.htm" STYLE="-sec-extract: exhibit">Certificate
    of Amendment to the Certificate of Incorporation of Lixte Biotechnology Holdings, Inc., filed as Exhibit 3.1 to the Company&rsquo;s
    Current Report on Form 8-K, as filed with the Securities and Exchange Commission on June 6, 2023 and incorporated herein by reference.</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315220004697/ex4-1.htm" STYLE="-sec-extract: exhibit">Description
    of Registrant&rsquo;s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended, filed as Exhibit
    4.1 to the Company&rsquo;s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, as filed with the Securities and
    Exchange Commission on March 25, 2020 and incorporated herein by reference.</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315220022628/ex4-2.htm" STYLE="-sec-extract: exhibit">Form
    of Public Common Stock Purchase Warrant included in Unit, filed as Exhibit 4.2 to the Company&rsquo;s Current Report on Form 8-K, as
    filed with the Securities and Exchange Commission on November 27, 2020 and incorporated herein by reference.</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315223025013/ex4-1.htm" STYLE="-sec-extract: exhibit">Form
    of Common Stock Purchase Warrant, filed as Exhibit 4.1 to the Company&rsquo;s Current Report on Form 8-K, as filed with the
    Securities and Exchange Commission on July 20, 2023 and incorporated herein by reference.</A></FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315223025013/ex4-3.htm" STYLE="-sec-extract: exhibit">Form
    of Placement Agent Common Stock Purchase Warrant, filed as Exhibit 4.3 to the Company&rsquo;s Current Report on Form 8-K, as filed
    with the Securities and Exchange Commission on July 20, 2023 and incorporated herein by reference.</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315225006285/ex4-1.htm" STYLE="-sec-extract: exhibit">Form
    of Common Stock Purchase Warrant, filed as Exhibit 4.1 to the Company&rsquo;s Current Report on Form 8-K, as filed with the Securities
    and Exchange Commission on February 13, 2025 and incorporated herein by reference.</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315225006285/ex4-2.htm" STYLE="-sec-extract: exhibit">Form
    of Placement Agent Common Stock Purchase Warrant, filed as Exhibit 4.2 to the Company&rsquo;s Current Report on Form 8-K, as filed
    with the Securities and Exchange Commission on February 13, 2025 and incorporated herein by reference.</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex5-1.htm">Opinion of TroyGould PC*</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000114420413015451/v336103_ex10-15.htm" STYLE="-sec-extract: exhibit">Master
    Agreement between Lixte Biotechnology Holdings, Inc. and Theradex Systems, Inc. dated January 12, 2010, filed as Exhibit 10.15 to
    the Company&rsquo;s Annual Report on Form 10-K for the fiscal year ended December 31, 2012, as filed with the Securities and Exchange
    Commission on March 15, 2013 and incorporated herein by reference.</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000114420414017092/v369493_ex10-16.htm" STYLE="-sec-extract: exhibit">Materials
    Cooperative Research and Development Agreement between Lixte Biotechnology Holdings, Inc. and the National Institute of Neurological
    Disorders and Stroke dated October 18, 2013, filed as Exhibit 10.16 to the Company&rsquo;s Annual Report on Form 10-K for the fiscal
    year ended December 31, 2013, as filed with the Securities and Exchange Commission on March 21, 2014 and incorporated herein by reference.</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315215004422/ex10-01.htm" STYLE="-sec-extract: exhibit">Collaboration
    Agreement between Lixte Biotechnology Holdings, Inc. and BioPharmaWorks LLC effective September 14, 2015, filed as Exhibit 10.01
    to the Company&rsquo;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on September 18, 2015 and
    incorporated herein by reference.</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315219011717/ex10-1.htm" STYLE="-sec-extract: exhibit">Collaboration
    Agreement for an Investigator-Initiated Clinical Trial between Lixte Biotechnology Holdings, Inc. and the Spanish Sarcoma Group as
    of July 31, 2019 (certain portions of this exhibit have been omitted based on a request for confidential treatment filed by the Company
    with the Securities and Exchange Commission that was granted on September 19, 2019), filed as Exhibit 10.1 to the Company&rsquo;s
    Current Report on Form 8-K, as filed with the Securities and Exchange Commission on August 6, 2019 and incorporated herein by reference.</A></FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 0pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify; width: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315220016207/ex10-02.htm" STYLE="-sec-extract: exhibit">Employment
    Agreement Between the Company and Robert N. Weingarten, filed as Exhibit 10.02 to the Company&rsquo;s Current Report on Form 8-K,
    as filed with the Securities and Exchange Commission on August 18, 2020 and incorporated herein by reference.+</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315220013560/ex10-2.htm" STYLE="-sec-extract: exhibit">Employment
    Agreement Between the Company and Eric Forman, filed as Exhibit 10.02 to the Company&rsquo;s Current Report on Form 8-K, as filed
    with the Securities and Exchange Commission on July 17, 2020 and incorporated herein by reference.+</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315221006882/ex10-21.htm" STYLE="-sec-extract: exhibit">Amendment
    to Employment Agreement between the Company and Eric Forman, filed as Exhibit 10.21 to the Company&rsquo;s Annual Report on Form
    10-K for the fiscal year ended December 31, 2020, as filed with the Securities and Exchange Commission on March 26, 2021.+</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315223009386/ex10-15.htm" STYLE="-sec-extract: exhibit">Second
    Amendment to Employment Agreement between the Company and Eric Forman, filed as Exhibit 10.15 to the Company&rsquo;s Annual Report
    on Form 10-K for the fiscal year ended December 31, 2022, as filed with the Securities and Exchange Commission on March 29, 2023
    and incorporated herein by reference.+</A></FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315220013545/ex10-1.htm" STYLE="-sec-extract: exhibit">Lixte
    Biotechnology Holdings, Inc. 2020 Stock Incentive Plan, filed as Exhibit 10.1 to the Company Current Report on Form 8-K, as filed
    with the Securities and Exchange Commission on July 17, 2020 and incorporated herein by reference.+</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315223042954/ex10-1.htm" STYLE="-sec-extract: exhibit">Lixte
    Biotechnology Holdings, Inc. 2020 Stock Incentive Plan (as amended), filed as Exhibit 10.1 to the Company&rsquo;s Current Report
    on Form 8-K, as filed with the Securities and Exchange Commission on November 28, 2023 and incorporated herein by reference.+</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315221027755/ex10-1.htm" STYLE="-sec-extract: exhibit">Development
    Collaboration Agreement by and between Lixte Biotechnology Holdings, Inc. and the Netherlands Cancer Institute, Amsterdam, and Oncode
    Institute, Utrecht, entered into on October 8, 2021 (certain portions of this Exhibit have been omitted), filed as Exhibit 10.1 to
    the Company&rsquo;s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021, as filed with the Securities
    and Exchange Commission on November 10, 2021 and incorporated herein by reference.</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315223009386/ex10-21.htm" STYLE="-sec-extract: exhibit">Insider
    Trading Policy, filed as Exhibit 10.21 to the Company&rsquo;s Annual Report on Form 10-K for the fiscal year ended December 31, 2022,
    as filed with the Securities and Exchange Commission on March 29, 2023 and incorporated herein by reference.</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315224010427/ex10-16.htm" STYLE="-sec-extract: exhibit">Compensation
    Clawback Policy, filed as Exhibit 10.16 to the Company&rsquo;s Annual Report on Form 10-K for the fiscal year ended December 31,
    2023, as filed with the Securities and Exchange Commission on March 19, 2024 and incorporated herein by reference.+</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315223016069/ex10-1.htm" STYLE="-sec-extract: exhibit">Amendment
    to Contract between Lixte Biotechnology Holdings, Inc. and MRI Global effective April 17, 2022, filed as Exhibit 10.1 to the Company&rsquo;s
    Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023, as filed with the Securities and Exchange Commission
    on May 10, 2023 and incorporated herein by reference.</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315223025013/ex10-1.htm" STYLE="-sec-extract: exhibit">Securities
    Purchase Agreement, filed as Exhibit 10.1 to the Company&rsquo;s Current Report on Form 8-K, as filed with the Securities and Exchange
    Commission on July 20, 2023 and incorporated herein by reference.</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315223033825/ex10-1.htm" STYLE="-sec-extract: exhibit">Employment
    Agreement between the Company and Bastiaan van der Baan effective September 26, 2023, filed as Exhibit 10.1 to the Company&rsquo;s
    Current Report on Form 8-K, as filed with the Securities and Exchange Commission on September 27, 2023 and incorporated herein by
    reference.</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315223040115/ex10-3.htm" STYLE="-sec-extract: exhibit">Amendment
    No. 1 to Development Collaboration Agreement by and between Lixte Biotechnology Holdings, Inc. and the Netherlands Cancer Institute,
    Amsterdam, and the Oncode Institute, Utrecht, entered into on October 8, 2021, filed as Exhibit 10.3 to the Company&rsquo;s Quarterly
    Report on Form 10-Q for the quarterly period ended September 30, 2023, as filed with the Securities and Exchange Commission on November
    9, 2023 and incorporated herein by reference.</A></FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 0pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify; width: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315223037533/ex10-1.htm" STYLE="-sec-extract: exhibit">Amendment
    No. 2 to Development Collaboration Agreement by and between Lixte Biotechnology Holdings, Inc. and the Netherlands Cancer Institute,
    Amsterdam, and the Oncode Institute, Utrecht, entered into on October 13, 2023 (certain portions of this Exhibit have been omitted),
    filed as Exhibit 10.1 to the Company&rsquo;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on
    October 17, 2023 and incorporated herein by reference.</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315223040115/ex10-5.htm" STYLE="-sec-extract: exhibit">Termination
    letter between H. Lee Moffitt Cancer Center and Research Institute, Inc. and the Company dated October 4, 2023 and effective as of
    September 30, 2023, filed as Exhibit 10.5 to the Company&rsquo;s Quarterly Report on Form 10-Q for the quarterly period ended September
    30, 2023, as filed with the Securities and Exchange Commission on November 9, 2023 and incorporated herein by reference.</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315224007784/ex10-1.htm" STYLE="-sec-extract: exhibit">Exclusive
    Patent License Agreement between Lixte Biotechnology, Inc. and the National Institute of Neurological Disorders and Stroke and the
    National Cancer Institute, each a component of the National Institute of Health, effective as of February 23, 2024, filed as Exhibit
    10.1 to the Company&rsquo;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on February 26, 2024
    and incorporated herein by reference.</A></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315224022709/ex10-1.htm" STYLE="-sec-extract: exhibit">Consulting
    Agreement between the Company and Dr. Jan Schellens dated as of May 31, 2024, filed as Exhibit 10.1 to the Company&rsquo;s Current
    Report on Form 8-K, as filed with the Securities and Exchange Commission on June 5, 2024 and incorporated herein by reference.+</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315224023798/ex10-1.htm" STYLE="-sec-extract: exhibit">Clinical
    Trial Agreement between the Company and the Netherlands Cancer Institute dated as of June 10, 2024, filed as Exhibit 10.1 to the
    Company&rsquo;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on June 14, 2024 and incorporated
    herein by reference.</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315225006285/ex10-1.htm" STYLE="-sec-extract: exhibit">Securities
    Purchase Agreement filed as Exhibit 10.1 to the Company&rsquo;s Current Report on Form 8-K, as filed with the Securities and Exchange
    Commission on February 13, 2025 and incorporated herein by reference.</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000164117225015346/ex10-1.htm" STYLE="-sec-extract: exhibit">Employment Agreement between the Company and Geordan Pursglove dated as of June 16, 2025, filed as Exhibit 10.1 to the Company&rsquo;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on June 17, 2025 and incorporated herein by reference.+</A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000164117225015346/ex10-2.htm" STYLE="-sec-extract: exhibit">Amendment to Employment Agreement between the Company and Bastiaan van der Baan dated as of June 16, 2025, filed as Exhibit 10.2 to the Company&rsquo;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on June 17, 2025 and incorporated herein by reference.+</A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.26</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000164117225015482/ex10-26.htm" STYLE="-sec-extract: exhibit">Form of Registered Pre-Funded Warrant to Purchase Common Stock** </A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.27</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000164117225015482/ex10-27.htm" STYLE="-sec-extract: exhibit">Form of Lock-Up Agreement** </A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.28</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000164117225015482/ex10-28.htm" STYLE="-sec-extract: exhibit">Form of Placement Agent Warrant to Purchase Common Stock** </A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315223009386/ex21-1.htm" STYLE="-sec-extract: exhibit">Subsidiaries
    of the Registrant, filed as Exhibit 21.1 to the Company&rsquo;s Annual Report on Form 10-K for the fiscal year ended December 31,
    2022, as filed with the Securities and Exchange Commission on March 29, 2023 and incorporated herein by reference.</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex23-1.htm">Consent of Weinberg &amp; Company, P.A., Independent Registered Public Accounting Firm*</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex5-1.htm">Consent of TroyGould PC (included in Exhibit 5.1)</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#sss_001">Power of Attorney (included on the signature line)*</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000164117225015482/ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Director Nominee &ndash; Peter Stazzone** </FONT></A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">107</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000164117225015482/ex107.htm" STYLE="-sec-extract: exhibit">Filing Fee Table** </A></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
    herewith.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> ** </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> Previously filed. </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">+</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicates
    a management contract or any compensatory plan, contract or arrangement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 0pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
17. Undertakings.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned registrant hereby undertakes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    include any prospectus required by section 10(a)(3) of the Securities Act of 1933;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent
    post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set
    forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if
    the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end
    of the estimated maximum offering amount may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if,
    in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth
    in the &ldquo;Calculation of Registration Fee&rdquo; table in the effective registration statement; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    include any material information with respect to the plan of distribution not previously disclosed in the registration statement
    or any material change to such information in the registration statement;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provided,
however, that the undertakings set forth in paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) above do not apply if the information required
to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the registrant
pursuant to section 13 or section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in this registration
statement or are contained in a form of prospectus filed pursuant to Rule 424(b) that is part of this registration statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That,
    for the purposes of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form
    of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of
    such securities at that time shall be deemed to be the initial bona fide offering thereof.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the
    termination of the offering.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That
    in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting
    method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the
    following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such
    securities to such purchaser:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule
    424;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 0pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by
    the undersigned registrant;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant
    or its securities provided by or on behalf of the undersigned registrant; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    other communication that is an offer in the offering made by the undersigned registrant to the purchaser.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    undersigned registrant hereby undertakes that, for the purposes of determining any liability under the Securities Act of 1933, each
    filing of the registrant&rsquo;s annual report pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (and, where
    applicable, each filing of an employee benefit plan&rsquo;s annual report pursuant to Section 15(d) of the Securities Exchange Act
    of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating
    to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering
    thereof.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insofar
    as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling
    persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion
    of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore,
    unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of
    expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action,
    suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered,
    the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court
    of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and
    will be governed by the final adjudication of such issue.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That,</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed
    as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant
    to Rule 424(b)(1) or (4) or 497(h) under the Securities Act of 1933 shall be deemed to be part of this registration statement as
    of the time it was declared effective.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of
    prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such
    securities at that time shall be deemed to be the initial bona fide offering thereof.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 0pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf
by the undersigned, thereunto duly authorized, in the city of Pasadena, State of California, on June 23, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lixte
    Biotechnology Holdings, Inc.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Geordan Pursglove</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Geordan
    Pursglove</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="sss_001"></A>POWER
OF ATTORNEY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
person whose signature appears below appoints Geordan Pursglove and Robert Weingarten, and each of them, each of whom may act without
the joinder of the other, as their true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution for
them and in their name, place and stead, in any and all capacities to sign any and all amendments (including post-effective amendments)
to this registration statement (and to any registration statement filed pursuant to Rule 462 under the Securities Act of 1933, as amended),
and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission,
granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and
necessary to be done, as fully to all intents and purposes as they might or would do in person, hereby ratifying and confirming all that
said attorneys-in-fact and agents or any of them or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities
and on the dates indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 28%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signature</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 54%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title(s)</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Geordan Pursglove</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and Chairman of the Board of Directors</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    23, 2025</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Geordan
    Pursglove</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Bastiaan van der Baan</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President,
    Chief Scientific Officer and Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    23, 2025</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bastiaan
    van der Baan</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Robert Weingarten</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice
    President and Chief Financial Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    23, 2025</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    Weingarten</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial and Accounting Officer)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>*</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    23, 2025</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stephen
    Forman</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>*</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    23, 2025</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yun
    Yen</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>*</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    23, 2025</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rene
    Bernards</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>*</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    23, 2025</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regina
    Brown</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*By:
<I>/s/ Robert Weingarten,</I> Attorney-in-Fact</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 51; Options: Last -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>ex1-1.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
1.1</B></FONT></P>

<P STYLE="margin-right: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="ex1-1_001.jpg" ALT=""></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
[&#9679;], 2025</FONT></P>

<P STYLE="margin-right: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>PERSONAL
AND CONFIDENTIAL</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Geordan Pursglove, Chief Executive Officer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lixte
Biotechnology Holdings, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">680
East Colorado Boulevard, Suite 180<BR>
Pasadena, CA 91101</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Re:</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>LIXT
                                            | Best Efforts Secondary Offering | Placement Agent Agreement</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear
Mr. Pursglove:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
purpose of this placement agent agreement (the &ldquo;<B><U>Agreement</U></B>&rdquo;) is to outline our agreement pursuant to which Spartan
Capital Securities, LLC (&ldquo;<B><U>Spartan</U></B>&rdquo;) will act as the placement agent on a &ldquo;best efforts&rdquo; basis in
connection with the proposed Best Efforts Secondary Offering (the &ldquo;<B><U>Placement</U></B>&rdquo;) by Lixte Biotechnology Holdings,
Inc. (collectively, with its subsidiaries and affiliates, the &ldquo;<B><U>Company</U></B>&rdquo;) of its shares of Common Stock or Pre-funded
Warrants to purchase shares of Common Stock in lieu of shares of Common Stock (the &ldquo;<B><U>Securities</U></B>&rdquo;). This Agreement
sets forth certain conditions and assumptions upon which the Placement is premised. The Company expressly acknowledges and agrees that
Spartan&rsquo;s obligations hereunder are on a reasonable &ldquo;best efforts&rdquo; basis only and that the execution of this Agreement
does not constitute a commitment by Spartan to purchase the Securities and does not ensure the successful placement of the Securities
or any portion thereof or the success of Spartan with respect to securing any other financing on behalf of the Company. The Company confirms
that entry into this Agreement and completion of the Placement with Spartan will not breach or otherwise violate the Company&rsquo;s
obligations to any other party or require any payments to such other party. For the sake of clarity, such obligations may include but
not be limited to obligations under an engagement letter, placement agency agreement, underwriting agreement, advisory agreement, right
of first refusal, tail fee obligation or other agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
terms of our agreement are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Engagement</U></B>.
                                            The Company hereby engages Spartan, for the period beginning on the date hereof and July
                                            1, 2025 or upon the completion of the Placement, whichever is sooner (the &ldquo;<B><U>Engagement
                                            Period</U></B>&rdquo;), to act as the Company&rsquo;s exclusive investment bank in connection
                                            with the proposed Placement. During the Engagement Period or until the consummation of the
                                            Placement, and as long as Spartan is proceeding in good faith with preparations for the Placement,
                                            the Company agrees not to solicit, negotiate with or enter into any agreement with any other
                                            source of financing (whether equity, debt or otherwise), any underwriter, potential underwriter,
                                            placement agent, financial advisor, investment banking firm or any other person or entity
                                            in connection with an offering of the Company&rsquo;s debt or equity securities or any other
                                            financing by the Company. Spartan will use its reasonable &ldquo;best efforts&rdquo; to solicit
                                            offers to purchase the Securities from the Company on the terms, and subject to the conditions,
                                            set forth in the Prospectus (as defined below). Spartan shall use commercially reasonable
                                            efforts to assist the Company in obtaining performance by each Purchaser (as defined below)
                                            whose offer to purchase Securities has been solicited by Spartan, but Spartan shall not,
                                            except as otherwise provided in this Agreement, be obligated to disclose the identity of
                                            any potential purchaser or have any liability to the Company in the event any such purchase
                                            is not consummated for any reason. The Company acknowledges that under no circumstances will
                                            Spartan be obligated to underwrite or purchase any Securities for its own account and, in
                                            soliciting purchases of the Securities, Spartan shall act solely as an agent of the Company.
                                            The services provided pursuant to this Agreement shall be on an &ldquo;agency&rdquo; basis
                                            and not on a &ldquo;principal&rdquo; basis.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>The
                                            Placement</U></B>. The Placement is expected to consist of a sale of approximately $6.0 million
                                            of the Company&rsquo;s Securities. Spartan will act as placement agent for the Placement
                                            subject to, among other matters referred to herein and additional customary conditions, completion
                                            of Spartan&rsquo;s due diligence examination of the Company and its affiliates, listing approval
                                            by the Nasdaq Capital Market (&ldquo;<B><U>Exchange</U></B>&rdquo;) of the Securities to
                                            be issued, and the execution of a definitive Securities Purchase Agreement in connection
                                            with the Placement (the &ldquo;<B><U>Securities Purchase Agreement</U></B>&rdquo;). The actual
                                            size of the Placement, the precise number of Securities to be offered by the Company and
                                            the offering price will be the subject of continuing negotiations between the Company and
                                            the investors thereto. In connection with entry into the Securities Purchase Agreement, the
                                            Company (i) will meet with Spartan and its representatives to discuss such due diligence
                                            matters and to provide such documents as Spartan may require; (ii) will not file with the
                                            Commission any document regarding the Placement without the prior approval of Spartan and
                                            its counsel; (iii) will deliver to Spartan and the investors in the Placement such legal
                                            and accounting opinions and letters (including, without limitation, accounting comfort letters,
                                            legal opinions, negative assurance letters, good standing certificates and officers&rsquo;
                                            and secretary certificates) as Spartan may require, all in form and substance acceptable
                                            to Spartan and (iv) will ensure that Spartan is a third party beneficiary of all representations,
                                            warranties, covenants, closing conditions and deliverables in connection with the Placement.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Placement
                                            Compensation</U></B>. The placement commission will be 8.0% for the Placement and a non-accountable
                                            expense allowance equal to 1.0% of the Placement. As additional compensation for Spartan&rsquo;s
                                            services, the Company shall issue to Spartan or its designees at each Closing, warrants (the
                                            &ldquo;<B><U>Placement Agent Warrants</U></B>&rdquo;) to purchase that number of shares of
                                            common stock of the Company equal to 5.0% of the aggregate number of shares of common stock
                                            (or common stock equivalent, if applicable) or units, as applicable, placed in the Placement
                                            (and if a Placement includes a &ldquo;greenshoe&rdquo; or &ldquo;additional investment&rdquo;
                                            component, such number of shares of common stock underlying such &ldquo;greenshoe&rdquo;
                                            or &ldquo;additional investment&rdquo; component, with the Placement Agent Warrants issuable
                                            upon the exercise of such component). If the Securities included in the Placement are convertible
                                            (other than warrants that may be included in a unit), the number of shares of common stock
                                            underlying the Placement Agent Warrants shall be determined by multiplying the number of
                                            shares of common stock issuable upon conversion of the convertible securities by 110%. The
                                            Placement Agent Warrants shall have a term of five (5) years from the commencement of the
                                            offering, contain cashless exercise provisions and piggyback registration rights, and have
                                            an exercise price equal to 125% of the offering price per share (or unit, if applicable)
                                            in the applicable Placement and if such offering price is not available, the market price
                                            of the common stock on the date the Placement is commenced (such price, the &ldquo;<B><U>Offering
                                            Price</U></B>&rdquo;). The Placement Agent Warrants may not be exercised, sold, transferred,
                                            assigned, pledged or hypothecated, or be the subject of any hedging, short sale, derivative,
                                            put, or call transaction that would result in the effective economic disposition of such
                                            securities for a period of one hundred eighty (180) days beginning on the commencement of
                                            sales of the offering in accordance with FINRA Rule 5110(e)(1), except as provided for in
                                            FINRA Rule 5110(e)(e). If warrants are issued to investors in the Placement, the Placement
                                            Agent Warrants shall have the same terms as the warrants issued to investors in the Placement,
                                            except that (i) such Placement Agent Warrants shall have an exercise price equal to 125%
                                            of the Offering Price and (ii) the Placement Agent Warrants shall comply in all regards with
                                            the requirements of FINRA Rules 5110(c)(1) and 5110(g)(8).</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Registration
                                            Statement</U></B>. To the extent the Company decides to proceed with the Placement, the Company
                                            will, as soon as practicable, prepare and file with the Securities and Exchange Commission
                                            (the &ldquo;<B><U>Commission</U></B>&rdquo;) a Registration Statement on Form S-1 (the &ldquo;<B><U>Registration
                                            Statement</U></B>&rdquo;) under the Securities Act of 1933, as amended (the &ldquo;<B><U>Securities
                                            Act</U></B>&rdquo;) and a prospectus included therein (the &ldquo;<B><U>Prospectus</U></B>&rdquo;)
                                            covering the Securities to be offered and sold in the Placement. The Registration Statement
                                            (including the Prospectus therein), and all amendments and supplements thereto, will be in
                                            form reasonably satisfactory to Spartan and counsel to Spartan. Other than any information
                                            provided by Spartan in writing specifically for inclusion in the Registration Statement or
                                            the Prospectus, the Company will be solely responsible for the contents of its Registration
                                            Statement and Prospectus and any and all other written or oral communications provided by
                                            or on behalf of the Company to any actual or prospective investor of the Securities, and
                                            the Company represents and warrants that such materials and such other communications will
                                            not, as of the date of the offer or sale of the Securities, contain any untrue statement
                                            of a material fact or omit to state a material fact required to be stated therein or necessary
                                            in order to make the statements therein, in light of the circumstances under which they were
                                            made, not misleading. If at any time prior to the completion of the offer and sale of the
                                            Securities an event occurs that would cause the Registration Statement or Prospectus (as
                                            supplemented or amended) to contain an untrue statement of a material fact or to omit to
                                            state a material fact necessary in order to make the statements therein, in light of the
                                            circumstances under which they were made, not misleading, the Company will notify Spartan
                                            immediately of such event and Spartan will suspend solicitations of the prospective purchasers
                                            of the Securities until such time as the Company shall prepare a supplement or amendment
                                            to the Registration Statement or Prospectus that corrects such statement or omission.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Lock-Ups</U></B>.
                                            In connection with the Placement, the Company&rsquo;s directors, executive officers, employees
                                            and shareholders holding at least ten percent (10%) of the outstanding common stock will
                                            enter into customary &ldquo;lock-up&rdquo; agreements in favor of the Placement Agent for
                                            a period of sixty (60) days after the Closing of the Placement (the &ldquo;<B><U>Lock-Up
                                            Period</U></B>&rdquo;); provided, however, that any sales by parties to the lock-ups shall
                                            be subject to the lock-up agreements and provided further, that none of such common stock
                                            shall be saleable in the public market until the expiration of the Lock-Up Period.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Company
                                            Standstill</U></B>. In connection with the Placement, without the prior written consent of
                                            the investors, the Company will not, for a period of sixty (60) days after the Closing of
                                            the Placement (the &ldquo;<B><U>Standstill Period</U></B>&rdquo;), (a) offer, pledge, sell,
                                            contract to sell, sell any option or contract to purchase, purchase any option or contract
                                            to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose
                                            of, directly or indirectly, any shares of capital stock of the Company or any securities
                                            convertible into or exercisable or exchangeable for shares of capital stock of the Company;
                                            (b) file or caused to be filed any registration statement with the Commission relating to
                                            the offering of any shares of capital stock of the Company or any securities convertible
                                            into or exercisable or exchangeable for shares of capital stock of the Company; (c) complete
                                            any offering of debt securities of the Company, other than entering into a line of credit
                                            with a traditional bank or (d) enter into any swap or other arrangement that transfers to
                                            another, in whole or in part, any of the economic consequences of ownership of capital stock
                                            of the Company, whether any such transaction described in clause (a), (b), (c) or (d) above
                                            is to be settled by delivery of shares of capital stock of the Company or such other securities,
                                            in cash or otherwise (all of such matters, the &ldquo;<B><U>Standstill Restrictions</U></B>&rdquo;).
                                            So long as none of such equity securities shall be saleable in the public market until the
                                            expiration of the Standstill Period, the following matters shall not be prohibited by the
                                            Standstill Restrictions: (i) the adoption of an equity incentive plan and the grant of awards
                                            or equity pursuant to any equity incentive plan, and the filing of a registration statement
                                            on Form S-8; (ii) securities issued pursuant to agreements, options, restricted share units
                                            or convertible securities existing as of the date hereof provided the terms are not modified;
                                            and (iii) securities issued pursuant to acquisitions or strategic transactions (whether by
                                            merger, consolidation, purchase of equity, purchase of assets, reorganization or otherwise)
                                            approved by a majority of the disinterested directors of the Company, provided that such
                                            securities are issued as &ldquo;restricted securities&rdquo; (as defined in Rule 144) and
                                            carry no registration rights that require or permit the filing of any registration statement
                                            in connection therewith during the Standstill Period, and provided that any such issuance
                                            shall only be to a person or entity (or to the equityholders of an entity) which is, itself
                                            or through its subsidiaries, an operating company or an owner of an asset in a business synergistic
                                            with the business of the Company and shall provide to the Company additional benefits in
                                            addition to the investment of funds, but shall not include a transaction in which the Company
                                            is issuing securities primarily for the purpose of raising capital or to an entity whose
                                            primary business is investing in securities. In no event should any equity transaction during
                                            the Standstill Period result in the sale of equity at an offering price to the public less
                                            than that of the Placement referred herein.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Expenses</U></B>.
                                            Out of the proceeds of the Closing, the Company shall pay Spartan up to $125,000 for fees
                                            and expenses of legal counsel and other expenses, including but not limited to, roadshow
                                            expenses and cost of background checks; plus the additional amount payable by the Company
                                            pursuant to the following sentence and, if applicable, the costs associated with the use
                                            of a third-party electronic road show service (such as Net Roadshow); provided, however,
                                            that such amount in no way limits or impairs the indemnification and contribution provisions
                                            of this Agreement. The Company will bear all fees, disbursements and expenses in connection
                                            with the Placement, including, without limitation, the Company&rsquo;s legal and accounting
                                            fees and disbursements; the costs of preparing, printing, mailing and delivering the Registration
                                            Statement, the preliminary and final prospectus contained therein and amendments thereto,
                                            post-effective amendments and supplements thereto, any other offering materials, this Agreement
                                            and related documents (all in such quantities as Spartan may reasonably require); preparing
                                            and printing stock certificates and warrant certificates; the costs of any &ldquo;due diligence&rdquo;
                                            meetings or background checks for members of management; filing fees (including SEC filing
                                            fees), costs and expenses (including third party expenses and disbursements) incurred in
                                            registering the Placement, FINRA filing fees; costs and expenses of qualifying the offering
                                            under the &ldquo;blue sky&rdquo; laws of the states specified by Spartan; preparation of
                                            leather bound volumes and Lucite cube mementos in such quantities as Spartan may reasonably
                                            request in connection with an underwritten offering; transfer taxes; and transfer and warrant
                                            agent and registrar fees, but excluding those costs and expenses that FINRA regulations require
                                            to be borne by a selling agent, placement agent or underwriter.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Right
                                            of First Refusal</U></B>. During the Right of First Refusal Period (as defined below)and
                                            subject to any Senior Right of First Refusal (as defined below), if the Company or any of
                                            its subsidiaries (a) decides to dispose of or acquire business units or acquire any of its
                                            outstanding securities or make any exchange or tender offer or enter into a merger, consolidation
                                            or other business combination or any recapitalization, reorganization, restructuring or other
                                            similar transaction, including, without limitation, an extraordinary dividend or distributions
                                            or a spin-off or split-off, and the Company decides to retain a financial advisor for such
                                            transaction, Spartan (or any affiliate designated by Spartan) shall have the right to act
                                            as the Company&rsquo;s exclusive financial advisor for any such transaction; or (b) decides
                                            to finance or refinance any indebtedness using a manager or agent, Spartan (or any affiliate
                                            designated by Spartan) shall have the right to act as sole book-runner, sole manager, sole
                                            placement agent or sole agent with respect to such financing or refinancing; or (c) decides
                                            to raise funds by means of a public offering (including through an at-the-market facility)
                                            or a private placement or any other capital-raising financing of equity, equity-linked or
                                            debt securities using an underwriter or placement agent, Spartan (or any affiliate designated
                                            by Spartan) shall have the right to act as sole book-running manager, sole underwriter or
                                            sole placement agent for such financing. The Company shall provide written notice to Spartan
                                            of any proposed transaction set forth in (a) - (c) above, including a detailed term sheet.
                                            Spartan (including through its affiliates) shall have ten (10) Business Days following receipt
                                            of such detailed term sheet to determine whether to waive its rights under this Section 8.
                                            If Spartan or one of its affiliates decides to accept any such engagement, the agreement
                                            governing such engagement will contain, among other things, provisions for customary fees
                                            for transactions of similar size and nature and the provisions of this Agreement, including
                                            indemnification, which are appropriate to such a transaction; provided, however, that after
                                            Spartan delivers such engagement letter, the Company may notify Spartan that it wishes to
                                            terminate the Right of First Refusal by paying a fee of $10,000, to be effective only upon
                                            receipt of such payment. The &ldquo;<B><U>Right of First Refusal Period</U></B>&rdquo; shall
                                            be the period beginning on the date hereof and ending on the date that is the earlier of
                                            (i) six (6) months after the expiration or earlier termination of any senior right of first
                                            refusal (&ldquo;<B><U>Senior Right of First Refusal</U></B>&rdquo;) existing on the date
                                            hereof with respect to transactions described in (a) &ndash; (c) above, or (ii) the date
                                            that is the three (3) year anniversary of the commencement of sales in the Placement. Notwithstanding
                                            the foregoing, the decision to accept the Company&rsquo;s engagement under this Section 8
                                            shall be made by Spartan or one of its affiliates, by a written notice to the Company, within
                                            ten (10) Calendar Days after the receipt of the Company&rsquo;s notification of its financing
                                            needs, including a detailed term sheet. Spartan&rsquo;s determination of whether in any case
                                            to exercise its right of first refusal hereunder will be strictly limited to the terms on
                                            such term sheet, and any waiver of such right of first refusal shall apply only to such specific
                                            terms. If Spartan waives its right of first refusal, any deviation from such terms (including
                                            without limitation after the launch of a subsequent transaction) shall void the waiver and
                                            require the Company to seek a new waiver from the right of first refusal on the terms set
                                            forth in this Section 8.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Tail
                                            Financing</U></B>. Spartan shall be entitled to compensation under Section 3 herein, calculated
                                            in the manner set forth therein, with respect to any public or private offering or other
                                            financing or capital raising transaction of any kind (&ldquo;<B><U>Tail Financing</U></B>&rdquo;)
                                            to the extent that such financing or capital is provided to the Company by investors Spartan
                                            has introduced to and/or contacted on behalf of the Company through an in-person, electronic
                                            or telephonic communication or investors that Spartan had &ldquo;wall-crossed&rdquo; in connection
                                            with this Placement (or any entity under common management or having a common investment
                                            advisor), if such Tail Financing is consummated at any time within twelve (12) months after
                                            the Closing, expiration or termination of this Agreement. Notwithstanding anything to the
                                            contrary contained herein, the Company has the right to terminate this Agreement for cause
                                            in compliance with FINRA Rule 5110(g)(5)(B)(i). The exercise of such right of termination
                                            for cause eliminates the Company&rsquo;s obligations with respect to the provisions relating
                                            to Right of First Refusal and Tail Financing.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Closing;
                                            Closing Deliverables</U></B>. Unless otherwise directed by the Placement Agent, settlement
                                            of the Securities shall occur via &ldquo;Delivery Versus Payment&rdquo; (&ldquo;<B><U>DVP</U></B>&rdquo;)
                                            (i.e., on the Closing Date, the Company shall cause the Depositary to issue the Securities
                                            directly to the clearing firm designated by the Placement Agent; upon receipt of such Securities,
                                            the Placement Agent shall promptly electronically deliver such Securities to the applicable
                                            Purchaser, and payment therefor shall be made by the Placement Agent (or its clearing firm)
                                            by wire transfer to the Company).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1. <B><U>Company
Deliveries</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 121.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1.1. On
the date hereof, the Company shall deliver each of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1.1.1 This
Agreement duly executed by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1.1.2 A
cold comfort letter from the Company&rsquo;s auditor, addressed to the Placement Agent in form and substance reasonably satisfactory
in all material respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1.1.3 A
certificate executed by the Chief Financial Officer of the Company in customary form reasonably satisfactory to the Placement Agent and
its counsel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1.1.4 The
Lock-Up Agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1.2. On
or prior to the Closing Date, the Company shall deliver each the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1.2.1 A
legal opinion of TroyGould PC, addressed to the Placement Agent and the Purchasers, in form and substance reasonably acceptable to the
Placement Agent and Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1.2.2 A
negative assurance letter from TroyGould PC, addressed to the Placement Agent and dated the Closing Date, in a form reasonably satisfactory
to the Placement Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1.2.3 A
copy of the irrevocable instructions to the Transfer Agent instructing the Transfer Agent to deliver, on an expedited basis, a certificate
(or at the request of the Purchaser, book entry statement) evidencing a number of shares of common stock equal to such Purchaser&rsquo;s
Subscription Amount divided by the Per Share Purchase Price, registered in the name of such Purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1.2.4 For
each Purchaser of Pre-Funded Warrants pursuant to Section 10, a Pre-Funded Warrant registered in the name of such Purchaser to purchase
up to a number of shares of Common Stock equal to the portion of such Purchaser&rsquo;s Subscription Amount applicable to Pre-Funded
Warrants divided by the Per Share Purchase Price, with an exercise price equal to $0.00001, subject to adjustment as provided therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1.2.5 The
Placement Agent Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1.2.6 The
Company shall have provided each Purchaser with the Company&rsquo;s wire instructions, on Company letterhead and executed by the Chief
Executive Officer or Chief Financial Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1.2.7 A
duly executed and delivered Officers&rsquo; Certificate, in customary form reasonably satisfactory to the Placement Agent and its counsel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1.2.8 A
cold comfort letter from the Company&rsquo;s auditor, addressed to the Placement Agent in form and substance reasonably satisfactory
in all material respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1.2.9 The
Prospectus and Prospectus Supplement (which may be delivered in accordance with Rule 172 under the Securities Act).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Representations
                                            and Warranties of the Company</U></B>. The representations and warranties of the Company
                                            contained herein shall be true and correct on the date hereof and on and as of the Closing
                                            Date, as the case may be, and the statements of the Company and its officers made in any
                                            certificates delivered pursuant to this Agreement shall be true and correct on and as of
                                            the Closing Date, as the case may be.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.1.
<B><U>Registration Statement</U>. </B>The Company has prepared and filed the Registration Statement with the Commission under the Securities
Act. The Commission has declared the Registration Statement effective under the Securities Act and the Company has not as of the date
of this Agreement filed a post-effective amendment to the Registration Statement. The Commission has not issued any order suspending
the effectiveness of the Registration Statement or any order preventing or suspending the use of the Registration Statement, the Final
Prospectus, any Preliminary Prospectus, any Issuer Free Writing Prospectus or any Testing-the-Waters Communication, and no proceedings
for such purpose or pursuant to Section 8A of the Securities Act have been initiated, are pending before or, to the Company&rsquo;s knowledge,
threatened by the Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.1.1. &nbsp;
The Registration Statement, at the time it became effective, did not contain, and any post-effective amendment thereto, as of the effective
date of such amendment, will not contain, any untrue statement of a material fact or omit to state a material fact required to be stated
therein or necessary to make the statements therein not misleading; <U>provided</U> that the Company makes no representation or warranty
with respect to any statements or omissions made in reliance upon and in conformity with information relating to the Placement Agent
furnished to the Company in writing by the Placement Agent expressly for use in the Registration Statement (including any post-effective
amendment thereto), the Pricing Disclosure Package, the Final Prospectus (including any amendments or supplements thereto), any Preliminary
Prospectus, any Issuer Free Writing Prospectus or any Testing-the-Waters Communication, it being understood and agreed that the only
such information furnished by the Placement Agent consists of the information described herein (collectively, the &ldquo;<B><U>Placement
Agent Information</U></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.1.2. &nbsp;
Each of the Registration Statement and any post-effective amendment thereto, at the time it became effective and at the date hereof,
complied and will comply in all material respects with the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.2.
<B><U>Pricing Disclosure Package</U></B>. The Pricing Disclosure Package did not, and as of the Closing Date (as defined below), as the
case may be, will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the
statements therein, in the light of the circumstances under which they were made, not misleading; <U>provided</U> that the Company makes
no representation or warranty with respect to any statements or omissions made in reliance upon and in conformity with the Placement
Agent Information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.3.
<B><U>Final Prospectus</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.3.1. &nbsp;
Each of the Final Prospectus and any amendments or supplements thereto, as of its date, as of the time it is filed with the Commission
pursuant to Rule 424(b) under the Securities Act, as of the Closing Date will not contain any untrue statement of a material fact or
omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were
made, not misleading; <U>provided</U> that the Company makes no representation or warranty with respect to any statements or omissions
made in reliance upon and in conformity with the Placement Agent Information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.3.2. &nbsp;
Each of the Final Prospectus and any amendments or supplements thereto, at the time it is filed with the Commission pursuant to Rule
424(b) under the Securities Act, as of the Closing Date, will comply in all material respects with the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.4.
<B><U>Preliminary Prospectuses</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.4.1. &nbsp;
Each Preliminary Prospectus, when considered together with any amendments or supplements thereto, as of the time it was filed with the
Commission pursuant to Rule 424(a) under the Securities Act, if any, did not contain any untrue statement of a material fact or omit
to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made,
not misleading; <U>provided</U> that the Company makes no representation or warranty with respect to any statements or omissions made
in reliance upon and in conformity with the Placement Agent Information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.4.2. &nbsp;
Each Preliminary Prospectus, when considered together with any amendments or supplements thereto, at the time it was filed with the Commission
pursuant to Rule 424(a) under the Securities Act, if any, complied in all material respects with the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.5.
<B><U>Issuer Free Writing Prospectuses</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.5.1. &nbsp;
Each Issuer Free Writing Prospectus, when considered together with the Preliminary Prospectus accompanying, or delivered prior to the
delivery of, such Issuer Free Writing Prospectus, did not, as of the date of such Issuer Free Writing Prospectus, and will not, as of
the Closing Date, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading; <U>provided</U> that the Company makes no representation
or warranty with respect to any statements or omissions made in reliance upon and in conformity with the Placement Agent Information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.5.2. &nbsp;
Each Issuer Free Writing Prospectus, at the time of filing with the Commission, complied or will comply in all material respects with
the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.5.3. &nbsp;
The Company has filed, or will file, with the Commission, within the time period specified in Rule 433(d) under the Securities Act, any
Free Writing Prospectus it is required to file pursuant to Rule 433(d) under the Securities Act. The Company has made available any Bona
Fide Electronic Road Show used by it in compliance with Rule 433(d)(8)(ii) under the Securities Act such that no filing of any &ldquo;road
show&rdquo; (as defined in Rule 433(h) under the Securities Act) (&ldquo;<B><U>Road Show</U></B>&rdquo;) is required in connection with
the offering of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.5.4. &nbsp;
Except for the Issuer Free Writing Prospectuses, if any, set forth in Schedule 11.5.4 hereto and electronic road shows, if any, each
furnished to the Placement Agent before first use, the Company has not used, authorized the use of, referred to or participated in the
planning for use of, and will not, without the prior consent of the Placement Agent, use, authorize the use of, refer to or participate
in the planning for use of, any Free Writing Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.6.
<B><U>Testing-the-Waters Communications</U></B>. The Company has not (x) alone engaged in any Testing-the-Waters Communication other
than Testing-the-Waters Communications with the consent of the Placement Agent or any underwriter that the Company has previously identified
to the Placement Agent with entities that are qualified institutional buyers within the meaning of Rule 144A under the Act or institutions
that are accredited investors within the meaning of Rule 501 under the Act, and (y) authorized anyone other than the Placement Agent,
or any underwriter that the Company has previously identified to the Placement Agent, to engage in Testing-the-Waters Communications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.7.
<B><U>No Other Disclosure Materials</U></B>. Other than the Registration Statement, the Pricing Disclosure Package, the Final Prospectus
and the Road Show, the Company (including its agents and representatives, other than the Placement Agent or any underwriter that the
Company has previously identified to the Placement Agent, as to which no representation or warranty is given) has not, directly or indirectly,
distributed, prepared, used, authorized, approved or referred to, and will not distribute, prepare, use, authorize, approve or refer
to, any offering material in connection with the offering and sale of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.8.
<B><U>Ineligible Issuer</U></B>. At the time of filing of the registration statement on Form S-1 (File No. 333-288120) registering the
offer and sale of the Securities submitted to the Commission on and any amendment thereto and at the date hereof, the Company was not
and is not an &ldquo;ineligible issuer&rdquo; (as defined in Rule 405 under the Securities Act).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.9.
<B><U>Smaller Reporting Company</U></B>. From the time of initial filing of the Registration Statement with the Commission (or, if earlier,
the first date on which the Company engaged directly or through any person authorized to act on its behalf in any Testing-the-Waters
Communication) through the date hereof, the Company has been and is a &ldquo;smaller reporting company,&rdquo; as defined in Rule 12b-2
under the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.10.
<B><U>Due Authorization</U></B>. The Company has full right, power and authority to execute and deliver this Agreement and to perform
its obligations hereunder; and all action required to be taken for the due and proper authorization, execution and delivery by it of
this Agreement and the Placement Agent Warrant and the consummation by it of the transactions contemplated hereby and thereby has been
duly and validly taken.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.11.
<B><U>Placement Agent Agreement</U></B>. Each of this Agreement and the Placement Agent Warrant has been duly authorized, executed and
delivered by the Company and each, assuming the due authorization, execution and delivery by the other parties hereto and thereto, constitutes
the legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except as (i) the
enforcement may be limited by bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium or other similar laws relating
to or affecting the rights and remedies of creditors generally or by general equitable principles (whether considered in a proceeding
at law or in equity) relating to enforceability and (ii) rights to indemnification and contribution hereunder may be limited by applicable
law and public policy considerations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.12.
<B><U>No Material Adverse Change</U></B>. Except as otherwise disclosed in the Registration Statement, the Pricing Disclosure Package
and the Final Prospectus (in each case exclusive of any amendment or supplement thereto), since the date of the most recent financial
statements included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus:
(i) there has been no material adverse change, or any development that could result in a material adverse change, in or affecting the
condition (financial or otherwise), earnings, business, properties, management, financial position, stockholders&rsquo; equity, or results
of operations, whether or not arising from transactions in the ordinary course of business, of the Company and its subsidiaries, considered
as a whole; (ii) there has been no change in the share capital (other than (A) the issuance of shares upon the exercise or settlement
(including any &ldquo;net&rdquo; or &ldquo;cashless&rdquo; exercises or settlements) of stock options, restricted stock units or warrants
described as outstanding, (B) the grant of options and awards under existing equity incentive plans, or (C) the repurchase of shares
of Common Stock by the Company, which were issued pursuant to the early exercise of stock options by option holders and are subject to
repurchase by the Company, in each case, as described in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus),
or material change in the short-term debt or long-term debt of the Company or any of its subsidiaries, considered as a whole; and (iii)
the Company and its subsidiaries, considered as a whole, have not incurred any material liability or obligation, indirect, direct or
contingent (whether or not in the ordinary course of business); nor entered into any transaction or agreement (whether or not in the
ordinary course of business) that is material to the Company and its subsidiaries, considered as a whole; and (iv) there has been no
dividend or distribution of any kind declared, set aside for payment, paid or made by the Company or, except for dividends paid to the
Company or other subsidiaries of the Company, any of its subsidiaries on any class of capital stock or repurchase or redemption by the
Company or any of its subsidiaries of any class of capital stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.13.
<B><U>Organization and Good Standing of the Company and its Subsidiaries</U></B>. The Company and each of its subsidiaries have been
duly incorporated and are validly existing and in good standing under the laws of their respective jurisdictions of organization, are
duly qualified to do business and are in good standing in each jurisdiction in which their respective ownership or lease of property
or the conduct of their respective businesses requires such qualification, and have all power and authority (corporate and other) necessary
to own, lease or hold their respective properties and to conduct the businesses in which they are engaged as described in the Registration
Statement, the Pricing Disclosure Package and the Final Prospectus, except where the failure to be in good standing, to be so qualified
or to have such power or authority could not, individually or in the aggregate, have a material adverse effect on the condition (financial
or otherwise), earnings, business, properties, management, financial position, stockholders&rsquo; equity, or results of operations of
the Company and its subsidiaries, considered as a whole, or adversely affect the performance by the Company of its obligations under
this Agreement (a &ldquo;<B><U>Material Adverse Effect</U></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.14.
<B><U>Capitalization</U></B>. The capitalization of the Company is as set forth in the Registration Statement, the Pricing Disclosure
Package and the Final Prospectus under the heading &ldquo;Capitalization&rdquo;. All of the outstanding capital stock of the Company
has been duly authorized and validly issued and is fully paid and non-assessable. The Securities, the Placement Agent Warrants and the
securities underlying the Placement Agent Warrants have been duly authorized and, when issued and paid for as contemplated herein, will
be validly issued, fully paid and non-assessable; the holders thereof are not and will not be subject to personal liability by reason
of being such holders; the Securities, the Placement Agent Warrants and the securities underlying the Placement Agent Warrants are not
and will not be subject to the preemptive rights of any holders of any security of the Company or similar contractual rights granted
by the Company; and all corporate action required to be taken for the authorization, issuance and sale of the Securities and the Placement
Agent Warrants has been duly and validly taken. When paid for and issued in accordance with the Placement Agent Warrant , the securities
underlying the Placement Agent Warrants will be validly issued, fully paid and non-assessable; the holders thereof are not and will not
be subject to personal liability by reason of being such holders; the securities underlying the Placement Agent Warrants are not and
will not be subject to the preemptive rights of any holders of any security of the Company or similar contractual rights granted by the
Company; and all corporate action required to be taken for the authorization, issuance and sale of the Placement Agent Warrants has been
duly and validly taken. None of the outstanding shares of Common Stock of the Company were issued in violation of any preemptive rights,
rights of first refusal or other similar rights to subscribe for or purchase securities of the Company. Except as disclosed in the Registration
Statement, the Pricing Disclosure Package and the Final Prospectus, there are no authorized or outstanding options, warrants, preemptive
rights, rights of first refusal or other rights to acquire, or instruments convertible into or exchangeable or exercisable for, any shares
of, or other equity interest in, the Company or any of its subsidiaries. All of the outstanding shares of, or other equity interest in,
each of the Company&rsquo;s subsidiaries (i) have been duly authorized and validly issued, (ii) are fully paid and non-assessable and
(iii) are owned by the Company, directly or through the Company&rsquo;s subsidiaries, free and clear of any security interest, mortgage,
pledge, lien, encumbrance, charge, claim or restriction on voting or transfer (collectively, &ldquo;<B><U>Liens</U></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.15.
<B><U>Common Stock Incentive Plans</U></B>. With respect to the Common Stock options (the &ldquo;<B><U>Stock Options</U></B>&rdquo;)
granted pursuant to the Common Stock-based compensation plans of the Company and its subsidiaries (the &ldquo;<B><U>Company Common Stock
Incentive Plans</U></B>&rdquo;), (i) each Stock Option intended to qualify as an &ldquo;incentive stock option&rdquo; under Section 422
of the Internal Revenue Code of 1986, as amended (the &ldquo;<B><U>Code</U></B>&rdquo;), so qualifies, (ii) each grant of a Stock Option
was duly authorized by all necessary corporate action, including, as applicable, approval by the Board of Directors of the Company (or
a duly constituted and authorized committee thereof) and any required stockholders approval by the necessary number of votes or written
consents, and the award agreement governing such grant (if any), to the Company&rsquo;s knowledge, was duly executed and delivered by
each party thereto, (iii) each such grant was made in all material respects in accordance with the terms of the Company Common Stock
Incentive Plans, and (iv) each such grant was properly accounted for in accordance with United States generally accepted accounting principles
applied on a consistent basis during the periods involved (&ldquo;<B><U>GAAP</U></B>&rdquo;) in the financial statements (including the
related notes) of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.16.
<B><U>No Violation or Default</U></B>. Neither the Company nor any of its subsidiaries is: (i) in violation of its charter, by-laws or
similar organizational documents; (ii) in default, and no event has occurred that, with notice or lapse of time or both, would constitute
such a default, in the due performance or observance of any term, covenant, condition or other obligation contained in any indenture,
mortgage, deed of trust, loan agreement, contract, undertaking or other agreement or instrument to which the Company or any of its subsidiaries
is a party or by which the Company or any of its subsidiaries is bound or to which any property, right or asset of the Company or any
of its subsidiaries is subject; or (iii) in violation of any law or statute applicable to the Company or any of its subsidiaries or any
judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority having jurisdiction over the Company
or any of its subsidiaries, or any of their respective properties or assets, except, in the case of clauses (ii) and (iii) above, for
any such default or violation that would not, individually or in the aggregate, have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.17.
<B><U>No Conflicts</U></B>. None of (i) the execution, delivery and performance of this Agreement by the Company, (ii) the issuance,
sale and delivery of the Securities , (iii) the application of the proceeds of the offering as described under &ldquo;Use of Proceeds&rdquo;
in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus, or (iv) the consummation of the transactions
contemplated herein will: (x) result in any violation of the terms or provisions of the charter, by-laws or similar organizational documents
of the Company or any of its subsidiaries; (y) conflict with, result in a breach or violation of, or require the approval of stockholders,
members or partners or any approval or consent of any persons under, any of the terms or provisions of, constitute a default under, result
in the termination, modification, or acceleration of, or result in the creation or imposition of any lien, charge or encumbrance upon
any property, right or asset of the Company or any of its subsidiaries pursuant to, any indenture, mortgage, deed of trust, loan agreement,
note agreement, contract, undertaking or other agreement, obligation, condition, covenant or instrument to which the Company or any of
its subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any property, right or asset of the
Company or any of its subsidiaries is subject; or (z) result in the violation of any law, statute, judgment, order, rule, decree or regulation
applicable to the Company or any of its subsidiaries of any court, arbitrator, governmental or regulatory authority, agency or body having
jurisdiction over the Company or any of its subsidiaries or any of their respective properties or assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.18.
<B><U>No Consents Required</U></B>. No consent, approval, authorization, order, filing, registration, license or qualification of or
with any court, arbitrator, or governmental or regulatory authority, agency, or body is required for (i) the execution, delivery and
performance by the Company of this Agreement; (ii) the issuance, sale and delivery of the Securities; or (iii) the consummation of the
transactions contemplated herein, except for such consents, approvals, authorizations, orders, filings, registrations or qualifications
as (x) have already been obtained or made and are still in full force and effect, (y) may be required by FINRA and the Nasdaq Capital
Market, and (z) may be required under applicable state securities laws in connection with the placement of the Securities by the Placement
Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.19.
<B><U>Independent Accountants</U></B>. Weinberg &amp; Company, P.A., with offices at 1925 Century Park East, Suite 1120, Los Angeles,
CA 90067, which expressed its opinion with respect to the financial statements (which term as used in this Agreement includes the related
notes thereto) and supporting schedules included in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus,
is an independent registered public accounting firm with respect to the Company and its subsidiaries within the meaning of the rules
and regulations of the Commission and the Public Company Accounting Oversight Board and as required by the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.20.
<B><U>Financial Statements and Other Financial Data</U></B>. The financial statements (including the related notes thereto), together
with the supporting schedules, included in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus comply
in all material respects with the applicable requirements of the Securities Act and present fairly the consolidated financial position
of the entities to which they relate as of and at the dates indicated and the results of their operations and cash flows for the periods
specified. Such financial statements, notes and schedules have been prepared in conformity with GAAP applied on a consistent basis throughout
the periods involved, except as may be expressly stated in the notes thereto and except, in the case of unaudited interim financial statements,
subject to normal year end audit adjustments and the exclusion of certain footnotes as permitted by the applicable rules of the Commission.
The financial data set forth in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus under the captions
&ldquo;Capitalization&rdquo; present fairly the information set forth therein on a basis consistent with that of the audited financial
statements included in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.21.
<B><U>Statistical and Market-Related Data</U></B>. The statistical and market-related data included in the Registration Statement, the
Pricing Disclosure Package and the Final Prospectus are based on or derived from sources that the Company reasonably and in good faith
believes to be accurate and reliable in all material respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.22.
<B><U>Forward-Looking Statements</U></B>. No forward-looking statement (within the meaning of Section 27A of the Securities Act and Section
21E of the Exchange Act) included in the Registration Statement, the Pricing Disclosure Package or the Final Prospectus has been made
or reaffirmed without a reasonable basis or has been disclosed other than in good faith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.23.
<B><U>Legal Proceedings</U></B>. Except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus,
(i) there are no legal, governmental or regulatory investigations, actions, demands, claims, suits, arbitrations, inquiries or proceedings
(collectively, &ldquo;<B><U>Actions</U></B>&rdquo;) pending to which the Company or any of its subsidiaries is or may be a party or to
which any property, right or asset of the Company or any of its subsidiaries is or may be the subject that, individually or in the aggregate,
if determined adversely to the Company or any of its subsidiaries, could have a Material Adverse Effect; and (ii) to the knowledge of
the Company, no such Actions are threatened or contemplated by any governmental or regulatory authority or by others.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.24.
<B><U>Labor Disputes</U></B>. No labor disturbance by or dispute with the employees of the Company or any of its subsidiaries exists
or, to the knowledge of the Company, is threatened or contemplated that could, individually or in the aggregate, have a Material Adverse
Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.25.
<B><U>Intellectual Property Rights</U></B>. (i) The Company and its subsidiaries own or have the right to use all patents, patent applications,
trademarks, service marks, trade names, and other source indicators and registrations and applications for registration thereof, domain
name registrations, copyrights and registrations and applications for registration thereof, technology and know-how, trade secrets, and
all other intellectual property and related proprietary rights (collectively, &ldquo;<B><U>Intellectual Property Rights</U></B>&rdquo;)
necessary to conduct their respective businesses; (ii) other than as disclosed in the Prospectus, neither the Company nor any of its
subsidiaries has received any notice of infringement, misappropriation or other conflict with (and neither the Company nor any of its
subsidiaries is otherwise aware of any infringement, misappropriation or other conflict with) the Intellectual Property Rights of any
other person, except for such infringement, misappropriation or other conflict as could not have a Material Adverse Effect; and (iii)
to the knowledge of the Company, the Intellectual Property Rights of the Company and its subsidiaries are not being infringed, misappropriated
or otherwise violated by any person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.26.
<B><U>Licenses and Permits</U></B>. (i) The Company and its subsidiaries possess such valid and current certificates, authorizations,
approvals, licenses and permits (collectively, &ldquo;<B><U>Authorizations</U></B>&rdquo;) issued by, and have made all declarations,
amendments, supplements and filings with, the appropriate state, federal or foreign regulatory agencies or bodies necessary to own, lease
and operate their respective properties and to conduct their respective businesses as set forth in the Registration Statement, the Pricing
Disclosure Package and the Final Prospectus; (ii) all such Authorizations are valid and in full force and effect and the Company and
its subsidiaries are in compliance with the terms and conditions of all such Authorizations; and (iii) neither the Company nor any of
its subsidiaries has received notice of any revocation, termination or modification of, or non-compliance with, any such Authorization
or has any reason to believe that any such Authorization will not be renewed in the ordinary course, except where, in the case of clauses
(i), (ii) and (iii), the failure to possess, make or obtain such Authorizations (by possession, declaration or filing) could not, individually
or in the aggregate, have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.27.
<B><U>Title to Property</U></B>. The Company and its subsidiaries have good and marketable title to, or have valid and enforceable rights
to lease or otherwise use, all items of real property and personal property (other than with respect to Intellectual Property Rights,
which is addressed exclusively in Section 11.25) that are material to the respective businesses of the Company and its subsidiaries,
in each case, free and clear of all liens, encumbrances, claims, and defects and imperfections of title, except such liens, encumbrances,
claims, defects and imperfections as (i) are disclosed in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus,
or (ii) do not materially affect the value of such property and do not materially interfere with the use made or proposed to be made
of such property by the Company and its subsidiaries. The Company and its subsidiaries have good and marketable title to, or have valid
and enforceable rights to lease or otherwise use, all items of real and personal property that are material to the respective businesses
of the Company and its subsidiaries, in each case, free and clear of all liens, encumbrances, claims and defects and imperfections of
title, except such liens, encumbrances, claims, defects and imperfections as (i) are disclosed in the Registration Statement, the Pricing
Disclosure Package and the Final Prospectus, or (ii) do not materially affect the value of such property and do not materially interfere
with the use made or proposed to be made of such property by the Company and its subsidiaries. All items of real and personal property
held under lease by the Company and its subsidiaries are held under valid, subsisting and enforceable leases, with such exceptions as
do not materially interfere with the use made or proposed to be made of such property by the Company and its subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.28.
<B><U>Taxes</U></B>. The Company and each of its subsidiaries have filed all federal, state, local and foreign tax returns required to
be filed through the date hereof or have timely requested extensions thereof and have paid all taxes required to be paid thereon (except
as currently being contested in good faith and for which reserves required by GAAP have been created in the financial statements of the
Company). The charges, accruals and reserves in respect of any income and other tax liability in the financial statements of the Company
referred to in Section 11.20 are adequate, in accordance with GAAP principles, to meet any assessments for any taxes of the Company accruing
through the end of the last period specified in such financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.29.
<B><U>Solvency</U></B>. Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the
receipt by the Company of the proceeds from the sale of the Securities hereunder, (i) the fair saleable value of the Company&rsquo;s
assets exceeds the amount that will be required to be paid on or in respect of the Company&rsquo;s existing debts and other liabilities
(including known contingent liabilities) as they mature, (ii) the Company&rsquo;s assets do not constitute unreasonably small capital
to carry on its business as now conducted and as proposed to be conducted including its capital needs taking into account the particular
capital requirements of the business conducted by the Company, consolidated and projected capital requirements and capital availability
thereof, and (iii) the current cash flow of the Company, together with the proceeds the Company would receive, were it to liquidate all
of its assets, after taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of
its liabilities when such amounts are required to be paid. The Company does not intend to incur debts beyond its ability to pay such
debts as they mature (taking into account the timing and amounts of cash to be payable on or in respect of its debt). The Company has
no knowledge of any facts or circumstances which lead it to believe that it will file for reorganization or liquidation under the bankruptcy
or reorganization laws of any jurisdiction within one year after the Closing Date. The Registration Statement sets forth as of the date
hereof all outstanding secured and unsecured Indebtedness of the Company or any Subsidiary, or for which the Company or any Subsidiary
has commitments. Neither the Company nor any Subsidiary is in default with respect to any Indebtedness.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.30.
<B><U>Investment Company Act</U></B>. Neither the Company nor any of its subsidiaries is or, after giving effect to the offer and sale
of the Securities and the application of the proceeds therefrom as described under &ldquo;Use of Proceeds&rdquo; in the Registration
Statement, the Pricing Disclosure Package and the Final Prospectus, will be required to register as an &ldquo;investment company&rdquo;
(as defined in the Investment Company Act).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.31.
<B><U>Insurance</U></B>. The Company and its subsidiaries are insured by recognized, financially sound institutions in such amounts,
with such amounts, with such deductibles and covering such losses and risks as the Company reasonably believes to be adequate for the
conduct of their respective businesses and the value of their respective properties and as is prudent and customary for companies engaged
in similar businesses in similar industries. All insurance policies and fidelity or surety bonds insuring the Company and its subsidiaries
or their respective businesses, assets, employees, officers and directors are in full force and effect; the Company and its subsidiaries
are in compliance with the terms of such policies in all material respects; neither the Company nor any of its subsidiaries has received
notice from any insurer or agent of such insurer that capital improvements or other expenditures are required to be made in order to
continue such insurance; and neither the Company nor any of its subsidiaries has been refused any insurance coverage sought or applied
for. There are no claims by the Company or any of its subsidiaries under any such policy as to which any insurer is denying liability
or defending under a reservation of rights clause; and neither the Company nor any of its subsidiaries has any reason to believe that
it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar
insurers as may be necessary to continue its business at a cost that could not have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.32.
<B><U>No Stabilization or Manipulation</U></B>. None of the Company, nor its Affiliates, or, to the knowledge of the Company, any person
acting on its or any of their behalf (other than the Placement Agent, as to which no representation or warranty is given) has taken,
directly or indirectly, any action designed to or that has constituted or that could reasonably be expected to cause or result in the
stabilization or manipulation of the price of any securities of the Company. The Company acknowledges that the Placement Agent may engage
in passive market making transactions in the Common Stock on the Nasdaq Capital Market (the &ldquo;<B><U>Exchange</U></B>&rdquo;) in
accordance with Regulation M under the Exchange Act (&ldquo;<B><U>Regulation M</U></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.33.
<B><U>Compliance with the Sarbanes-Oxley Act</U></B>. The Company and, to the knowledge of the Company, its officers and directors, in
their capacities as such, are and have been in compliance with all applicable provisions of the Sarbanes-Oxley Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.34.
<B><U>Accounting Controls</U></B>. The Company and its subsidiaries maintain systems of &ldquo;internal control over financial reporting&rdquo;
(as defined in Rule 13a-15(f) of the Exchange Act) that comply with the requirements of the Exchange Act and have been designed by, or
under the supervision of, their principal executive and principal financial officers, or persons performing similar functions, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes
in accordance with GAAP. The Company and its subsidiaries maintain internal accounting controls sufficient to provide reasonable assurance
that (i) transactions are executed in accordance with management&rsquo;s general or specific authorizations; (ii) transactions are recorded
as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability; (iii) access
to assets is permitted only in accordance with management&rsquo;s general or specific authorization; and (iv) the recorded accountability
for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences.
Other than as disclosed in the Registration Statement, the Company maintains a system of internal control over financial reporting and
the Company is not aware of any other material weaknesses in its internal control over financial reporting (whether or not remediated).
Other than as disclosed in the Registration Statement, since the date of the most recent balance sheet included in the Registration Statement,
the Pricing Disclosure Package and the Final Prospectus, (x) the Company&rsquo;s auditors and the Board of Directors of the Company have
not been advised of (A) any new significant deficiencies or material weaknesses in the design or operation of the internal control over
financial reporting of the Company and its subsidiaries which could adversely affect the Company&rsquo;s ability to record, process,
summarize, and report financial data; or (B) any fraud, whether or not material, that involves management or other employees who have
a role in the internal control over financial reporting of the Company or its subsidiaries; and (y) there have been no significant changes
in the internal control over financial reporting of the Company or its subsidiaries or in other factors that could significantly affect,
such internal control over financial reporting, including any corrective actions with regard to significant deficiencies or material
weaknesses, since the respective dates as of which information is given in the Registration Statement, the Pricing Disclosure Package
and the Final Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.35.
<B><U>Disclosure Controls and Procedures</U></B>. The Company and its subsidiaries have established and maintain disclosure controls
and procedures (as such term is defined in Rule 13a-15(e) under the Exchange Act) that are designed to comply with the requirements of
the Exchange Act; such disclosure controls and procedures are designed to ensure that information required to be disclosed by the Company
and its subsidiaries in the reports they file or submit under the Exchange Act is recorded, processed, summarized and reported within
the time periods specified in the Commission&rsquo;s rules and forms, including controls and procedures designed to ensure that such
information is accumulated and communicated to the Company&rsquo;s management as appropriate to allow timely decisions regarding required
disclosure; and such disclosure controls and procedures are effective to perform the functions for which they were established.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.36.
<B><U>Compliance with Environmental Laws</U></B>. The Company and each of its subsidiaries (i) are, and at all times prior hereto were,
in compliance with all Environmental Laws (as defined below) applicable to such entity, which compliance includes, without limitation,
obtaining, maintaining and complying with all permits and authorizations and approvals required by Environmental Laws to conduct their
respective businesses; and (ii) have not received notice or otherwise have knowledge of any actual or alleged violation of Environmental
Laws, or of any actual or potential liability for or other obligation concerning the presence, disposal or release of hazardous or toxic
substances or wastes, pollutants or contaminants, and, except as described in the Registration Statement, the Pricing Disclosure Package
and the Final Prospectus, (x) there are no proceedings that are pending, or known to be contemplated, against the Company or any of its
subsidiaries under Environmental Laws, other than such proceedings regarding which would not, individually or in the aggregate, have
a Material Adverse Effect; (y) to the knowledge of the Company, none of the Company or any of its subsidiaries is aware of any issues
regarding compliance with Environmental Laws, including any pending or proposed Environmental Laws, or liabilities or other obligations
under Environmental Laws or concerning hazardous or toxic substances or wastes, pollutants or contaminants, that could reasonably be
expected to have a material effect on the capital expenditures, earnings or competitive position of the Company and its subsidiaries;
and (z) none of the Company or any of its subsidiaries anticipates material capital expenditures relating to Environmental Laws. As used
herein, the term &ldquo;<B><U>Environmental Laws</U></B>&rdquo; means any laws, regulations, ordinances, rules, orders, judgments, decrees,
permits or other legal requirements of any governmental authority, including, without limitation, any international, foreign, national,
state, provincial, regional, or local authority, relating to pollution, the protection of human health or safety, the environment, or
natural resources, or to the use, handling, storage, manufacturing, transportation, treatment, discharge, disposal or release of hazardous
or toxic substances or wastes, pollutants or contaminants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.37.
<B><U>ERISA</U></B>. Each &ldquo;employee benefit plan&rdquo; (within the meaning of Section 3(3) of the Employee Retirement Security
Act of 1974, as amended (&ldquo;<B><U>ERISA</U></B>&rdquo;)) for which the Company or any member of its &ldquo;Controlled Group&rdquo;
(defined as any organization which is a member of a controlled group of corporations within the meaning of Section 414 of the Code) would
have any liability (each, a &ldquo;<B><U>Plan</U></B>&rdquo;) complies in form with the requirements of all applicable statutes, rules
and regulations including ERISA and the Code, and has been maintained and administered in substantial compliance with its terms and with
the requirements of all applicable statutes, rules and regulations including ERISA and the Code; (ii) with respect to each Plan subject
to Title IV of ERISA or Section 302 of ERISA or Section 412 and 430 of the Code (A) no &ldquo;reportable event&rdquo; (within the meaning
of Section 4043(c) of ERISA) has occurred or is reasonably expected to occur, (B) no failure to satisfy the minimum funding standard
(within the meaning of Section 302 of ERISA or Section 412 and 430 of the Code), whether or not waived, has occurred or is reasonably
expected to occur, (C) the fair market value of the assets under each Plan (excluding for these purposes accrued but unpaid contributions)
exceeds the present value of all benefits accrued under such Plan (determined based on those assumptions used to fund such Plan) and
(D) neither the Company or any member of its Controlled Group has incurred, or reasonably expects to incur, any liability under Title
IV of ERISA (other than contributions to the Plan or premiums to the Pension Benefit Guaranty Corporation in the ordinary course and
without default) in respect of a Plan (including a &ldquo;multiemployer plan&rdquo;, within the meaning of Section 4001(a)(3) of ERISA);
(iii) each Plan that is intended to be qualified under Section 401(a) of the Code is so qualified and nothing has occurred, whether by
action or by failure to act, which would cause the loss of such qualification; and (iv) no prohibited transaction, within the meaning
of Section 406 of ERISA or Section 4975 of the Code, has occurred with respect to any Plan excluding transactions to which a statutory
or administrative prohibited transaction exemption applies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.38. &nbsp;
<B><U>FDA</U></B>. As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (&ldquo;<B><U>FDA</U></B>&rdquo;)
under the Federal Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (&ldquo;<B><U>FDCA</U></B>&rdquo;) that is
manufactured, packaged, labeled, tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product,
a &ldquo;<B><U>Pharmaceutical Product</U></B>&rdquo;), such Pharmaceutical Product is being manufactured, packaged, labeled, tested,
distributed, sold and/or marketed by the Company in compliance with all applicable requirements under FDCA and similar laws, rules and
regulations relating to registration, investigational use, premarket clearance, licensure, or application approval, good manufacturing
practices, good laboratory practices, good clinical practices, product listing, quotas, labeling, advertising, record keeping and filing
of reports, except where the failure to be in compliance would not have a Material Adverse Effect. There is no pending, completed or,
to the Company's knowledge, threatened, action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding,
charge, complaint, or investigation) against the Company or any of its Subsidiaries, and none of the Company or any of its Subsidiaries
has received any notice, warning letter or other communication from the FDA or any other governmental entity, which (i) contests the
premarket clearance, licensure, registration, or approval of, the uses of, the distribution of, the manufacturing or packaging of, the
testing of, the sale of, or the labeling and promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall,
suspension, or seizure of, or withdraws or orders the withdrawal of advertising or sales promotional materials relating to, any Pharmaceutical
Product, (iii) imposes a clinical hold on any clinical investigation by the Company or any of its Subsidiaries, (iv) enjoins production
at any facility of the Company or any of its Subsidiaries, (v) enters or proposes to enter into a consent decree of permanent injunction
with the Company or any of its Subsidiaries, or (vi) otherwise alleges any violation of any laws, rules or regulations by the Company
or any of its Subsidiaries, and which, either individually or in the aggregate, would have a Material Adverse Effect. The properties,
business and operations of the Company have been and are being conducted in all material respects in accordance with all applicable laws,
rules and regulations of the FDA. The Company has not been informed by the FDA that the FDA will prohibit the marketing, sale, license
or use in the United States of any product proposed to be developed, produced or marketed by the Company nor has the FDA expressed any
concern as to approving or clearing for marketing any product being developed or proposed to be developed by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.39.
<B><U>Related Party Transactions</U></B>. Except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Final
Prospectus, no relationship, direct or indirect, exists between or among the Company or any of its subsidiaries, on the one hand, and
the directors, officers, stockholders, other Affiliates, customers or suppliers of the Company or any of its subsidiaries, on the other
hand, that would be required by the Securities Act to be described in the Registration Statement, the Pricing Disclosure Package and
the Final Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.40.
<B><U>No Unlawful Contributions or Other Payments</U></B>. Neither the Company nor any of its subsidiaries, nor any director, officer
of the Company, nor, to the knowledge of the Company, any agent, employee, Affiliate or other person associated with or acting on behalf
of the Company or any of its subsidiaries has (i) used any corporate funds for any unlawful contribution, gift, entertainment or other
unlawful expense relating to political activity; (ii) made any direct or indirect unlawful payment to any foreign or domestic government
or regulatory official or employee; (iii) made any bribe, rebate, payoff, influence payment, kickback or other unlawful payment; or (iv)
violated or is in violation of any provision of (y) the Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations
thereunder (the &ldquo;<B><U>FCPA</U></B>&rdquo;), or (z) any non-U.S. anti-bribery or anti-corruption statute or regulation. The Company
and its subsidiaries have instituted and maintain and enforce policies and procedures designed to promote and ensure compliance with
all applicable anti-bribery and anti-corruption laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.41.
<B><U>Compliance with Anti-Money Laundering Laws</U></B>. The operations of the Company and its subsidiaries are and have been conducted
at all times in compliance with all applicable financial recordkeeping and reporting requirements, including those of the Currency and
Foreign Transactions Reporting Act of 1970, as amended, the applicable anti-money laundering statutes of all jurisdictions where the
Company or any of its subsidiaries conduct business, the rules and regulations thereunder and any related or similar rules, regulations
or guidelines issued, administered or enforced by any governmental agency (collectively, the &ldquo;<B><U>Anti-Money Laundering Laws</U></B>&rdquo;);
and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company
or any of its subsidiaries with respect to the Anti-Money Laundering Laws is pending or, to the knowledge of the Company, threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.42.
<B><U>Compliance with OFAC</U></B>. Neither the Company nor any of its subsidiaries nor any director, officer of the Company, nor, to
the knowledge of the Company, any agent, employee or Affiliate of the Company or any of its subsidiaries is an individual or entity (an
&ldquo;<B><U>OFAC Person</U></B>&rdquo;), or is owned or controlled by an OFAC Person, that is currently the subject or target of any
sanctions administered or enforced by the U.S. government (including, without limitation, the Office of Foreign Assets Control of the
U.S. Treasury Department (&ldquo;<B><U>OFAC</U></B>&rdquo;) or the U.S. Department of State and including, without limitation, the designation
as a &ldquo;specially designated national&rdquo; or &ldquo;blocked person&rdquo;), the United Nations Security Council, the European
Union, His Majesty&rsquo;s Treasury, or other relevant sanctions authority (collectively, &ldquo;<B><U>Sanctions</U></B>&rdquo;), nor
is the Company or any of its subsidiaries located, organized or resident in a country or territory that is the subject or the target
of Sanctions, including, without limitation, Crimea, Cuba, Iran, North Korea, Sudan and Syria (each, a &ldquo;<B><U>Sanctioned Country</U></B>&rdquo;);
and the Company will not directly or indirectly use the proceeds of the offering, or lend, contribute or otherwise make available such
proceeds to any subsidiary, joint venture partner or other OFAC Person (i) to fund or facilitate any activities of or business with any
OFAC Person that, at the time of such funding or facilitation, is the subject or the target of Sanctions, (ii) to fund or facilitate
any activities or business in any Sanctioned Country or (iii) in any other manner that will result in a violation by any OFAC Person
(including any OFAC Person participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions. Since
the Company&rsquo;s inception, the Company and its subsidiaries have not knowingly engaged in and are not now knowingly engaged in any
dealings or transactions with any OFAC Person that at the time of the dealing or transaction is or was the subject or the target of Sanctions
or with any Sanctioned Country.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.43.
<B><U>No Registration Rights</U></B>. Except as described in the Registration Statement, the Pricing Disclosure Package and the Final
Prospectus, there are no contracts, agreements or understandings between the Company or any of its subsidiaries, on the one hand, and
any person, on the other hand, granting such person any rights to require the Company or any of its subsidiaries to file a registration
statement under the Securities Act with respect to any securities of the Company or any of its subsidiaries owned or to be owned by such
person or to require the Company or any of its subsidiaries to include such securities in any securities to be registered pursuant to
any registration statement to be filed by the Company or any of its subsidiaries under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.44.
<B><U>Subsidiaries</U></B>. The subsidiaries of the Company shall be referred to hereinafter each as a &ldquo;<B><U>Subsidiary</U></B>&rdquo;
and collectively as &ldquo;<B><U>Subsidiaries</U></B>.&rdquo; The description of the corporate structure of the Company and each of the
agreements among the Subsidiaries as set forth in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus
under the caption &ldquo;Corporate History and Structure&rdquo; filed as Exhibit 21.1 to the Registration Statement is true and accurate
in all material respects and nothing has been omitted from such description which would make it misleading. The Subsidiaries of the Company
listed in Schedule 11.44 hereto are the only &ldquo;significant subsidiaries&rdquo; (as defined under Rule 1.02(w) of Regulation S-X
under the Securities Act) of the Company (the &ldquo;<B><U>Significant Subsidiaries</U></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.45.
<B><U>No Restrictions on Subsidiaries</U></B>. Except as disclosed in the Registration Statement, the Pricing Disclosure Package and
the Final Prospectus, no Subsidiary of the Company is currently prohibited, directly or indirectly, from paying any dividends to the
Company, from making any other distribution on such Subsidiary&rsquo;s share capital or similar ownership interest, from repaying to
the Company any loans or advances to such Subsidiary from the Company or from transferring any of such Subsidiary&rsquo;s properties
or assets to the Company or any other Subsidiary of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.46.
<B><U>Exchange Listing</U></B>. The Common Stock is listed on the Exchange, and the Company has taken no action designed to, or likely
to have the effect of, delisting the Common Stock from the Exchange, nor has the Company received any notification that the Exchange
is contemplating terminating such listing, except as described in the Registration Statement, the Pricing Disclosure Package and the
Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.47.
<B><U>Exchange Act Registration</U></B>. The Common Stock is registered pursuant to Section 12(b) under the Exchange Act. The Company
has taken no action designed to, or likely to have the effect of, terminating the registration of the Common Stock under the Exchange
Act, nor has the Company received any notification that the Commission is contemplating terminating such registration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.48.
<B><U>Prior Securities Transactions</U></B>. No securities of the Company have been sold by the Company or by or on behalf of, or for
the benefit of, any person or persons controlling, controlled by or under common control with the Company, except as disclosed in the
Registration Statement, the Pricing Disclosure Package and the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.49.
<B><U>Application of Takeover Protections</U></B>. The Company and the Board of Directors have taken all necessary action, if any, in
order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights
agreement) or other similar anti-takeover provision under the Company&rsquo;s certificate of incorporation (or similar charter documents)
or the laws of its state of incorporation that is or could become applicable as a result of the Placement Agent and the Company fulfilling
their obligations or exercising their rights hereunder (including documents incorporated herein by reference or attached hereto).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.50. <B><U>D&amp;O
Questionnaires</U></B>. To the Company&rsquo;s knowledge, all information contained in the questionnaires (the
&ldquo;<B><U>Questionnaires</U></B>&rdquo;) completed by each of the Company&rsquo;s directors, officers and beneficial holders of
5% or more of the Company&rsquo;s Common Stock immediately prior to the Placement as supplemented by all information concerning the
Company&rsquo;s directors, officers and principal stockholders as described in the Registration Statement, the Pricing Disclosure
Package and the Prospectus, provided to the Placement Agent is true and correct in all material respects and the Company has not
become aware of any information which would cause the information disclosed in the Questionnaires to become inaccurate and incorrect
in any material respect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.51. <B><U>No
Integrated Offering</U></B>. Neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has,
directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances
that would cause this offering of the Securities to be integrated with prior offerings by the Company for purposes of any applicable
stockholder approval provisions of any Trading Market on which any of the securities of the Company are listed or
designated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.52. <B><U>Litigation;
Governmental Proceedings</U></B>. There is no material action, suit, proceeding, inquiry, arbitration, investigation, litigation or
governmental proceeding pending or, to the Company&rsquo;s knowledge, threatened against, or involving the Company, any of its
Subsidiaries or, to the Company&rsquo;s knowledge, any executive officer or director which has not been disclosed in the
Registration Statement, the Pricing Disclosure Package and the Prospectus which is required to be disclosed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.53. <B><U>FINRA
Matters</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.53.1.
<B><U>No Broker&rsquo;s Fees</U></B>. Except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Final
Prospectus, neither the Company nor any of its subsidiaries is a party to any contract, agreement or understanding with any person (other
than this Agreement) that would give rise to a valid claim against any of them or the Placement Agent for a brokerage commission, finder&rsquo;s
fee or like payment in connection with the offering and sale of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.53.2.
<B><U>Payments Within Six (6) Months</U></B>. Except as described in the Registration Statement, the Pricing Disclosure Package and the
Prospectus, the Company has not made any direct or indirect payments (in cash, securities or otherwise) to: (i) any person, as a finder&rsquo;s
fee, consulting fee or otherwise, in consideration of such person raising capital for the Company or introducing to the Company persons
who raised or provided capital to the Company; (ii) any FINRA member; or (iii) any person or entity that has any direct or indirect affiliation
or association with any FINRA member, within the six (6) months prior to the initial filing of the Registration Statement, other than
the payment to the Placement Agent as provided hereunder in connection with the Placement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.53.3.&nbsp;<B><U>Use of Proceeds</U></B>. None of the net proceeds of the Placement will be paid by the Company to any participating FINRA member
or its affiliates, except as specifically authorized herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.53.4.
<B><U>FINRA Affiliation</U></B>. There is no (i) officer or director of the Company, (ii) to the Company&rsquo;s knowledge, any beneficial
owner of 10% or more of any class of the Company&rsquo;s securities or (iii) to the Company&rsquo;s knowledge, any beneficial owner of
the Company&rsquo;s unregistered equity securities which were acquired during the 180-Calendar Day period immediately preceding the filing
of the Registration Statement that is an affiliate or associated person of a FINRA member participating in the Placement (as determined
in accordance with the rules and regulations of FINRA).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.53.5.
<B><U>Information</U></B>. All information provided by the Company in its FINRA questionnaire to Placement Agent Counsel specifically
for use by Placement Agent Counsel in connection with its Public Offering System filings (and related disclosure) with FINRA is true,
correct and complete in all material respects.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Conditions
                                            of the Obligations of the Placement Agent</U></B>. The obligations of the Placement Agent
                                            hereunder shall be subject to the accuracy of the representations and warranties on the part
                                            of the Company set forth in Section 11 hereof, in each case as of the date hereof
                                            and as of the Closing Date as though then made, to the timely performance by each of the
                                            Company of its covenants and other obligations hereunder on and as of such dates, and to
                                            each of the following additional conditions:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.1.</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
<B><U>Regulatory Matters</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 121.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.1.1.</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
<B><U>Effectiveness of Registration Statement; Rule 424 Information</U></B>. The Registration Statement is effective on the date of this
Agreement, and, on the Closing Date no stop order suspending the effectiveness of the Registration Statement or any post-effective amendment
thereto has been issued under the Securities Act, no order preventing or suspending the use of any Preliminary Prospectus or the Prospectus
has been issued and no proceedings for any of those purposes have been instituted or are pending or, to the Company&rsquo;s knowledge,
contemplated by the Commission. The Company has complied with each request (if any) from the Commission for additional information. All
filings with the Commission required by Rule 424 under the Securities Act to have been filed by the Closing Date shall have been made
within the applicable time period prescribed for such filing by Rule 424.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.1.2.</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
<B><U>FINRA Clearance</U></B>. On or before the Closing Date, the Placement Agent shall have received clearance from FINRA as to the
amount of compensation allowable or payable to the Placement Agent as described in the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.1.3.</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
<B><U>Listing of Additional Shares</U></B>. On or before the Closing Date, the Company shall have filed a notice with the Exchange with
respect to the Company&rsquo;s additional listing of the securities sold in the Placement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.2.</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
<B><U>Closing Deliverables</U></B>. The Company shall have delivered all closing deliverables to the Placement Agent as set forth in
Section 10.1 as of the time required and in form reasonably satisfactory to the Placement Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 121.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.2.1.</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
<B><U>No Material Changes</U></B>. Prior to and on the Closing Date: (i) there shall have been no Material Adverse Effect or development
involving a prospective Material Adverse Effect in the condition or prospects or the business activities, financial or otherwise, of
the Company from the latest dates as of which such condition is set forth in the Registration Statement, the Pricing Disclosure Package
and the Prospectus; (ii) no action, suit or proceeding, at law or in equity, shall have been pending or threatened against the Company
or any affiliates of the Company before or by any court or federal or state commission, board or other administrative agency wherein
an unfavorable decision, ruling or finding may materially adversely affect the business, operations, prospects or financial condition
or income of the Company, except as set forth in the Registration Statement and the Prospectus; (iii) no stop order shall have been issued
under the Securities Act and no proceedings therefor shall have been initiated or threatened by the Commission; and (iv) the Registration
Statement and the Prospectus and any amendments or supplements thereto shall contain all material statements which are required to be
stated therein in accordance with the Securities Act and the Securities Act Regulations and shall conform in all material respects to
the requirements of the Securities Act and the Securities Act Regulations, and neither the Registration Statement nor the Prospectus
nor any amendment or supplement thereto shall contain any untrue statement of a material fact or omit to state any material fact required
to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.2.2.</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
<B><U>Additional Documents</U></B>. At the Closing Date, Placement Agent&rsquo;s counsel shall have been furnished with such documents
and opinions as they may require in order to evidence the accuracy of any of the representations or warranties, or the fulfillment of
any of the conditions, herein contained; and all proceedings taken by the Company in connection with the issuance and sale of the Securities
as herein contemplated shall be satisfactory in form and substance to the Placement Agent and Placement Agent&rsquo;s counsel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Prior
                                            Agreement</U></B>. By entering into this Agreement, the parties agree that that certain letter
                                            of engagement, dated June 17, 2025, entered into between the same parties hereof, shall automatically
                                            terminate and cease to have any effect whatsoever and shall be superseded in its entirety
                                            by this Agreement.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Definitions</U></B>.
                                            In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement,
                                            the following terms have the meanings:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">14.1. &ldquo;<B><U>Affiliate</U></B>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">14.2. &ldquo;<B><U>Board of Directors</U></B>&rdquo;
means the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">14.3. &ldquo;<B><U>Business Day</U></B>&rdquo;
means a Calendar Day other than a Saturday, Sunday or any other Calendar Day which is a federal legal holiday in the United States or
any Calendar Day on which the commercial banks in the City of New York are required by law or other governmental action to close, provided
that the commercial banks in the City of New York shall not be deemed to be required to be closed due to a &ldquo;stay at home,&rdquo;
&ldquo;shelter in place,&rdquo; &ldquo;non-essential employee&rdquo; or similar orders or restrictions or the closure of any physical
branch locations at the direction of any governmental authority so long as the electronic funds transfer systems (including for wire transfers)
of commercial banks in the City of New York generally are open for use by customers on such Calendar Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">14.4. &ldquo;<B><U>Calendar Day</U></B>&rdquo;
means each and every day of the week (Sunday, Monday, Tuesday, Wednesday, Thursday, Friday and Saturday).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">14.5. &ldquo;<B><U>Closing Date</U></B>&rdquo;
means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties thereto, and
all conditions precedent to (i) the Purchasers&rsquo; obligations to pay the Subscription Amount and (ii) the Company&rsquo;s obligations
to deliver the Securities, in each case, have been satisfied or waived, but in no event later than the second (2nd) Trading Day following
the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">14.6. &ldquo;<B><U>Common Stock</U></B>&rdquo;
means the common stock of the Company, $0.0001 par value per share, and any other class of securities into which such securities may hereafter
be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">14.7. &ldquo;<B><U>Common Stock Equivalents</U></B>&rdquo;
means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including,
without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable
or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">14.8. &ldquo;<B><U>Disclosure Schedules</U></B>&rdquo;
means the Disclosure Schedules of the Company delivered concurrently herewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">14.9. &ldquo;<B><U>Exchange Act</U></B>&rdquo;
means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">14.10. &ldquo;<B><U>Final Prospectus</U></B>&rdquo;
means the prospectus in the form first filed with the Commission pursuant to and within the time limits described in Rule 424(b) under
the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">14.11. &ldquo;<B><U>Issuer Free Writing
Prospectus</U></B>&rdquo; means an &ldquo;issuer free writing prospectus&rdquo; (as defined in Rule 433(h)(1) under the Securities Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">14.12. &ldquo;<B><U>Liens</U></B>&rdquo;
means a lien, charge pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">14.13. &ldquo;<B><U>Per Share Purchase
Price</U></B>&rdquo; equals $[&#9679;] (less $0.00001 exercise price for each Pre-Funded Warrant), subject to adjustment for reverse and
forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date
of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">14.14. &ldquo;<B><U>Person</U></B>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">14.15. &ldquo;<B><U>Placement Agent</U></B>&rdquo;
means Spartan Capital Securities, LLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">14.16. &ldquo;<B><U>Placement Agent Counsel</U></B>&rdquo;
means Kaufman &amp; Canoles, P.C., with office at Two James Center, 14th Floor, 1021 E. Cary St., Richmond, VA 23219.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">14.17. &ldquo;<B><U>Pre-Funded Warrants</U></B>&rdquo;
means the pre-funded Common Stock purchase warrants, in the form of <B><U>Exhibit 14.17.1</U></B> attached hereto delivered to the Purchasers
at the Closing in accordance with Section 10.1.2.4 hereof, which Pre-Funded Warrants shall be exercisable immediately and shall expire
when exercised in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">14.18. &ldquo;<B><U>Preliminary Prospectus</U></B>&rdquo;
means any preliminary prospectus included in the Registration Statement prior to the time at which the Commission declared the Registration
Statement effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">14.19. &ldquo;<B><U>Pricing Disclosure
Package</U></B>&rdquo; means the Preliminary Prospectus collectively with this Agreement (including documents attached hereto or incorporated
by reference herein).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">14.20. &ldquo;<B><U>Proceeding</U></B>&rdquo;
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding,
such as a deposition), whether commenced or threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">14.21. &ldquo;<B><U>Purchaser</U></B>&rdquo;
means each purchaser of Securities in the Placement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">14.22. &ldquo;<B><U>Subscription Amount</U></B>&rdquo;
means, as to each Purchaser, the aggregate amount to be paid for Shares and Warrants purchased hereunder in United States dollars and
in immediately available funds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">14.23. &ldquo;<B><U>Subsidiary</U></B>&rdquo;
means any subsidiary of the Company as set forth in the SEC Reports and shall, where applicable, also include any direct or indirect subsidiary
of the Company formed or acquired after the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">14.24. &ldquo;<B><U>Testing-the-Waters
Communication</U></B>&rdquo; means any oral or Written Communication with potential investors undertaken in reliance on Section 5(d) of
the Securities Act and Rule 163B thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">14.25. &ldquo;<B><U>Trading Day</U></B>&rdquo;
means a Calendar Day on which the principal Trading Market is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">14.26. &ldquo;<B><U>Trading Market</U></B>&rdquo;
means any of the following markets or exchanges on which the Common Shares are listed or quoted for trading on the date in question: the
NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange, the
OTCQB, OTCQX, Pink Open Market (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">14.27. &ldquo;<B><U>Transaction Documents</U></B>&rdquo;
means this Agreement, the Securities, the Securities Purchase Agreement, the Lock-Up Agreement and all exhibits and schedules thereto
and hereto and any other documents or agreements executed in connection with the transactions contemplated hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">14.28. &ldquo;<B><U>Transfer Agent</U></B>&rdquo;
means Computershare Trust Company, N.A., the current transfer agent of the Company, with a mailing address of 150 Royall Street, Suite
101 Canton, MA 02021 and an email address of [&#9679;], and any successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">14.29. &ldquo;<B><U>Warrants</U></B>&rdquo;
means, collectively, the Pre-Funded Warrants and the Placement Agent Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">14.30. &ldquo;<B><U>Warrant Shares</U></B>&rdquo;
means the shares of Common Stock issuable upon exercise of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">14.31. &ldquo;<B><U>Written Communication</U></B>&rdquo;
has the meaning set forth in Rule 405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">

    <TD STYLE="font: 12pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-size: 10pt">15.</FONT></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt"><B><U>Termination</U></B>. Notwithstanding anything to the contrary contained herein, the Company agrees that the provisions relating to the payment of fees, reimbursement of expenses, right of first refusal, tail fee, indemnification and contribution, equitable remedies, confidentiality, conflicts, independent contractor and waiver of the right to trial by jury will survive any termination or expiration of this Agreement. Notwithstanding anything to the contrary contained herein, the Company has the right to terminate the placement agent agreement for cause in compliance with FINRA Rule 5110(g)(5)(B)(i). The exercise of such right of termination for cause eliminates the Company&rsquo;s obligations with respect to the provisions relating to the tail fees and right of first refusal. Notwithstanding anything to the contrary contained in this Agreement, in the event that no Placement is completed for any reason whatsoever during the Engagement Period, the Company shall be obligated to pay to Spartan its actual and accountable out-of-pocket expenses related to the Placement (including the fees and disbursements of Placement Agent&rsquo;s Counsel) and if applicable, for electronic road show service used in connection with the Placement. During the engagement hereunder: (i) the Company will not, and will not permit its representatives to, other than in coordination with Spartan, contact or solicit institutions, corporations or other entities or individuals as potential purchasers of the Securities and (ii) the Company will not pursue any financing transaction which would be in lieu of the Placement. Furthermore, the Company agrees that during Spartan&rsquo;s engagement hereunder, all inquiries from prospective investors will be referred to Spartan. Regardless of termination and except as stated in this Section 15, Section 9 of this Agreement will still remain in full effect if an offering is consummated.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">

    <TD STYLE="font: 12pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-size: 10pt">16.</FONT></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt"><B><U>Publicity</U></B>. The Company agrees that it will not issue press releases or engage in any other publicity, without Spartan&rsquo;s prior written consent, commencing on the date hereof and continuing until the final Closing of the Placement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">

    <TD STYLE="font: 12pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-size: 10pt">17.</FONT></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt"><B><U>Information</U></B>. During the Engagement Period or until the Closing, the Company agrees to cooperate with Spartan and to furnish, or cause to be furnished, to Spartan, any and all information and data concerning the Company, and the Placement that Spartan deems appropriate (the &ldquo;<B><U>Information</U></B>&rdquo;). The Company will provide Spartan reasonable access during normal business hours from and after the date of execution of this Agreement until the Closing to all of the Company&rsquo;s assets, properties, books, contracts, commitments and records and to the Company&rsquo;s officers, directors, employees, appraisers, independent accountants, legal counsel and other consultants and advisors. Except as contemplated by the terms hereof or as required by applicable law, Spartan will keep strictly confidential all non-public Information concerning the Company provided to Spartan. No obligation of confidentiality will apply to Information that: (a) is in the public domain as of the date hereof or hereafter enters the public domain without a breach by Spartan, (b) was known or became known by Spartan prior to the Company&rsquo;s disclosure thereof to Spartan as demonstrated by the existence of its written records, (c) becomes known to Spartan from a source other than the Company which information is not provided by the breach of an obligation of confidentiality owed to the Company, (d) is disclosed by the Company to a third party without restrictions on its disclosure or (e) is independently developed by Spartan as demonstrated by its written records. For the avoidance of doubt, except as otherwise provided herein, all information which is not publicly available relating to the Company&rsquo;s proprietary technology is proprietary and confidential.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">

    <TD STYLE="font: 12pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-size: 10pt">18.</FONT></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt"><B><U>No Third Party Beneficiaries; No Fiduciary Obligations</U></B>. This Agreement does not create, and shall not be construed as creating, rights enforceable by any person or entity not a party hereto, except those entitled hereto by virtue of the indemnification provisions hereof. The Company acknowledges and agrees that: (i) Spartan is not and shall not be construed as a fiduciary of the Company and shall have no duties or liabilities to the equity holders or the creditors of the Company or any other person or entity by virtue of this Agreement or the retention of Spartan hereunder, all of which are hereby expressly waived; and (ii) Spartan is a full service securities firm engaged in a wide range of businesses and from time to time, in the ordinary course of its business, Spartan or its affiliates may hold long or short positions and trade or otherwise effect transactions for its own account or the account of its customers in debt or equity securities or loans of the companies which may be the subject of the transactions contemplated by this Agreement. During the course of Spartan&rsquo;s engagement with the Company, Spartan may have in its possession material, non-public information regarding other companies that could potentially be relevant to the Company or the transactions contemplated herein but which cannot be shared due to an obligation of confidence to such other companies.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">

    <TD STYLE="font: 12pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-size: 10pt">19.</FONT></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt"><B><U>Indemnification, Advancement &amp; Contribution</U></B>.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">19.1. The Company hereby agrees to indemnify
and hold harmless Spartan and its affiliates, and the respective controlling persons, directors, officers, managers, members, shareholders,
agents and employees of any of the foregoing (collectively the &ldquo;<B><U>Indemnified Persons</U></B>&rdquo;), from and against any
and all claims, actions, suits, proceedings (including those of shareholders), damages, liabilities and expenses incurred by any of them
(including the reasonable fees and expenses of counsel), as incurred, whether or not the Company is a party thereto (collectively a &ldquo;<B><U>Claim</U></B>&rdquo;),
that are (A) related to or arise out of (i) any actions taken or omitted to be taken (including any untrue statements made or any statements
omitted to be made) by the Company, or (ii) any actions taken or omitted to be taken by any Indemnified Person in connection with the
Company&rsquo;s engagement of Spartan, or (B) otherwise relate to or arise out of Spartan&rsquo;s activities on the Company&rsquo;s behalf
under Spartan&rsquo;s engagement, and the Company shall reimburse any Indemnified Person for all expenses (including the reasonable fees
and expenses of counsel) and shall advance payment for such expenses as incurred by such Indemnified Person in connection with investigating,
preparing or defending any such claim, action, suit or proceeding, whether or not in connection with pending or threatened litigation
in which any Indemnified Person is a party. The Company will not, however, be responsible for any Claim that is finally judicially determined
to have resulted from the gross negligence or willful misconduct of any such Indemnified Person for such Claim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">19.2. The Company further agrees that it
will not, without the prior written consent of Spartan, settle, compromise or consent to the entry of any judgment in any pending or threatened
Claim in respect of which indemnification may be sought hereunder (whether or not any Indemnified Person is an actual or potential party
to such Claim), unless such settlement, compromise or consent includes an unconditional, irrevocable release of each Indemnified Person
from any and all liability arising out of such Claim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">19.3. Promptly upon receipt by an Indemnified
Person of notice of any complaint or the assertion or institution of any Claim with respect to which indemnification is being sought hereunder,
such Indemnified Person shall notify the Company in writing of such complaint or of such assertion or institution but failure to so notify
the Company shall not relieve the Company from any obligation it may have hereunder, except and only to the extent such failure results
in the forfeiture by the Company of substantial rights and defenses. If the Company so elects, or is requested by such Indemnified Person,
the Company will assume the defense of such Claim, including the employment of counsel for such Indemnified Person and the payment of
the fees and expenses of such counsel, provided, however, that such counsel shall be reasonably satisfactory to the Indemnified Person
and provided further that if the legal counsel to such Indemnified Person reasonably determines that having common counsel would present
such counsel with a conflict of interest or if the defendant in, or target of, any such Claim, includes an Indemnified Person and the
Company, and legal counsel to such Indemnified Person reasonably concludes that there may be legal defenses available to it or other Indemnified
Persons different from or in addition to those available to the Company, such Indemnified Person will employ its own separate counsel
(limited to one law firm and local counsel, if necessary) to represent or defend him, her or it in any such Claim and the Company shall
pay the reasonable fees and expenses of such counsel. If the Company does not assume the defense of such Claim, such Indemnified Person
will employ its own separate counsel (limited to one law firm and local counsel, if necessary) to represent or defend him, her, or it
in any such Claim and the Company shall pay the reasonable fees and expenses of such counsel. Notwithstanding anything herein to the contrary,
if the Company fails timely or diligently to defend, contest, or otherwise protect against any Claim, the relevant Indemnified Person
shall have the right, but not the obligation, to defend, contest, compromise, settle, assert crossclaims, or counterclaims or otherwise
protect against the same, and shall be fully indemnified by the Company therefor, including without limitation, for the reasonable fees
and expenses of its counsel (limited to one law firm and local counsel, if necessary) and all amounts paid as a result of such Claim or
the compromise or settlement thereof. In addition, with respect to any Claim in which the Company assumes the defense, the Indemnified
Person shall have the right to participate in such Claim and to retain his, her or its own counsel therefor at his, her or its own expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">19.4. The Company agrees that if any indemnity
sought by an Indemnified Person hereunder is held by a court to be unavailable for any reason then (whether or not Spartan is the Indemnified
Person), the Company and Spartan shall contribute to the Claim for which such indemnity is held unavailable in such proportion as is appropriate
to reflect the relative benefits to the Company, on the one hand, and Spartan on the other, in connection with Spartan&rsquo;s engagement
referred to above, subject to the limitation that in no event shall the amount of Spartan&rsquo;s contribution to such Claim exceed the
amount of fees actually received by Spartan from the Company pursuant to Spartan&rsquo;s engagement. The Company hereby agrees that the
relative benefits to the Company, on the one hand, and Spartan on the other, with respect to Spartan&rsquo;s engagement shall be deemed
to be in the same proportion as (a) the total value paid or proposed to be paid or received by the Company pursuant to the Placement (whether
or not consummated) for which Spartan is engaged to render services bears to (b) the fee paid or proposed to be paid to Spartan in connection
with such engagement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">19.5. The Company&rsquo;s indemnity, reimbursement
and contribution obligations under this Agreement (a) shall be in addition to and shall in no way limit or otherwise adversely affect
any rights that any Indemnified Person may have at law or at equity and (b) shall be effective whether or not the Company is at fault
in any way.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">19.6. Spartan and the Company further agree
that neither Spartan nor any of its affiliates or any of its or their respective officers, directors, controlling persons (within the
meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act), employees or agents shall have any liability to the Company,
its security holders or creditors, or any person asserting claims on behalf of or in the right of the Company (whether direct or indirect,
in contract, tort, for an act of negligence or otherwise) for any losses, fees, damages, liabilities, costs, expenses or equitable relief
arising out of or relating to this Agreement or the services rendered hereunder, except for losses, fees, damages, liabilities, costs
or expenses that arise out of or are based on any action of or failure to act by Spartan and that are finally judicially determined to
have resulted solely from the gross negligence or willful misconduct of Spartan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">

    <TD STYLE="font: 12pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-size: 10pt">20.</FONT></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt"><B><U>Equitable Remedies</U></B>. Each party to this Agreement acknowledges and agrees that (a) a breach or threatened breach by the Company of any of its obligations under Section 8 or Section 9 or the exclusivity provisions of Section 1 would give rise to irreparable harm to Spartan for which monetary damages would not be an adequate remedy and (b) if a breach or a threatened breach by the Company of any such obligations occurs, Spartan will, in addition to any and all other rights and remedies that may be available to such party at law, at equity, or otherwise in respect of such breach, be entitled to equitable relief, including a temporary restraining order, an injunction, specific performance of the terms of Section 8 or Section 9 or the exclusivity provisions of Section 1, as applicable, and any other relief that may be available from a court of competent jurisdiction, without any requirement to (i) post a bond or other security, or (ii) prove actual damages or that monetary damages will not afford an adequate remedy. Each party to this Agreement agrees that such party shall not oppose or otherwise challenge the existence of irreparable harm, the appropriateness of equitable relief or the entry by a court of competent jurisdiction of an order granting equitable relief, in either case, consistent with the terms of this Section 20.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">

    <TD STYLE="font: 12pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-size: 10pt">21.</FONT></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt"><B><U>Governing Law; Jurisdiction and Venue Arbitration</U></B>. This Agreement will be governed by and construed in accordance with the laws of the State of New York, without regard to principles of conflicts of law. Any controversy between the parties to this Agreement, or arising out of the Agreement, shall be resolved by arbitration before the American Arbitration Association (&ldquo;<B><U>AAA</U></B>&rdquo;) in New York, New York. The following arbitration agreement should be read in conjunction with these disclosures:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">21.1. ARBITRATION IS FINAL AND BINDING
ON THE PARTIES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">21.2. THE PARTIES ARE WAIVING THEIR RIGHT
TO SEEK REMEDIES IN COURT, INCLUDING THE RIGHT TO JURY TRIAL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">21.3. PRE-ARBITRATION DISCOVERY IS GENERALLY
MORE LIMITED THAN AND DIFFERENT FROM COURT PROCEEDING; AND</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">21.4. THE ARBITRATORS&rsquo; AWARD IS
NOT REQUIRED TO INCLUDE FACTUAL FINDING OR LEGAL REASONING AND ANY PARTY&rsquo;S RIGHT TO APPEAL OR TO SEEK MODIFICATION OF RULINGS BY
THE ARBITRATORS IS STRICTLY LIMITED.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">21.5. <U>ARBITRATION AGREEMENT</U>. ANY
AND ALL CONTROVERSIES, DISPUTES OR CLAIMS BETWEEN SPARTAN AND YOU OR YOUR AGENTS, REPRESENTATIVES, EMPLOYEES, DIRECTORS, OFFICERS OR CONTROL
PERSONS, ARISING OUT OF, IN CONNECTION WITH, OR WITH RESPECT TO (i) ANY PROVISIONS OF OR THE VALIDITY OF THIS AGREEMENT OR ANY RELATED
AGREEMENTS, (ii) THE RELATIONSHIP OF THE PARTIES HERETO, OR (iii) ANY CONTROVERSY ARISING OUT OF YOUR BUSINESS SHALL BE CONDUCTED BY THE
AMERICAN ARBITRATION ASSOCIATION UNDER ITS COMMERCIAL ARBITRATION RULES. ARBITRATION MUST BE COMMENCED BY SERVICE OF A WRITTEN DEMAND
FOR ARBITRATION OR A WRITTEN NOTICE OF INTENTION TO ARBITRATE. IF YOU ARE A PARTY TO SUCH ARBITRATION, TO THE EXTENT PERMITTED BY THE
RULES OF THE APPLICABLE ARBITRATION TRIBUNAL, THE ARBITRATION SHALL BE CONDUCTED IN NEW YORK, NEW YORK. THE DECISION AND AWARD OF THE
ARBITRATORS(S) SHALL BE CONCLUSIVE AND BINDING UPON ALL PARTIES, AND ANY JUDGMENT UPON ANY AWARD RENDERED MAY BE ENTERED IN THE STATE
OR FEDERAL COURTS LOCATED IN NEW YORK, NEW YORK, OR ANY OTHER COURT HAVING JURISDICTION THEREOF, AND NEITHER PARTY SHALL OPPOSE SUCH ENTRY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 121.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">

    <TD STYLE="font: 12pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-size: 10pt">22.</FONT></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt"><B><U>Miscellaneous</U></B>. The Company represents and warrants that it has all required power and authority to enter into and carry out the terms and provisions of this Agreement and the execution, delivery and performance of this Agreement does not breach or conflict with any agreement, document or instrument to which it is a party or bound. The binding provisions of this Agreement are legally binding upon and inure to the benefit of both the Company and Spartan and their respective assigns, successors, and legal representatives. If any provision of this Agreement is determined to be invalid or unenforceable in any respect, such determination will not affect such provision in any other respect, and the remainder of the placement agent agreement shall remain in full force and effect. This Agreement may be executed in counterparts (including electronic counterparts), each of which shall be deemed an original but all of which together shall constitute one and the same instrument. The undersigned hereby consents to receipt of this Agreement in electronic form and understands and agrees that this Agreement may be signed electronically. Signatures to this Agreement transmitted in electronic form will have the same effect as physical delivery of a paper document bearing the original signature, and if any signature is delivered electronically evidencing an intent to sign this Agreement, such electronic mail or other electronic transmission shall create a valid and binding obligation of the undersigned with the same force and effect as if such signature were an original. Execution and delivery of this Agreement by electronic mail or other electronic transmission is legal, valid and binding for all purposes.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">

    <TD STYLE="font: 12pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-size: 10pt">23.</FONT></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt"><B><U>Notices</U></B>. All notices, consents, claims, demands, waivers, and other communications hereunder (&ldquo;<B><U>Notices</U></B>&rdquo;) shall be in writing and sent by certified mail, hand delivery, overnight delivery or e-mail, if sent to Spartan, at the address set forth on the first page hereof, e-mail: kmonchik@spartancapital.com, attention: Kim Monchik, and if sent to the Company, to the address set forth on the first page hereof, e-mail: rweingarten@lixte.com, attention: Robert Weingarten, Chief Financial Officer. All Notices shall be deemed to have been effectively given (a) when delivered by hand (with written confirmation of receipt); (b) when received by the addressee if sent by FedEx or another nationally recognized overnight courier (receipt requested); (c) on the date sent by email (with confirmation of receipt from the intended recipient by return email or other written acknowledgment other than an automatic &ldquo;read receipt&rdquo;) if sent during normal business hours of the recipient, and on the next Business Day if sent after normal business hours of the recipient; or (d) if certified or registered mail is required by applicable law, the fifth day after the date mailed by certified or registered mail (in each case, return receipt requested, postage pre-paid).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If you are in agreement with the
foregoing, please sign and return to us one copy of this Agreement. This Agreement may be executed in counterparts (including facsimile
or .pdf counterparts), each of which shall be deemed an original but all of which together shall constitute one and the same instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>[Signature Page of LIXT Best Efforts Secondary Offering
Placement Agent Agreement Follows]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[Signature
Page of LIXT Best Efforts Secondary Offering Placement Agent Agreement]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
    truly yours,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Spartan
    Capital Securities, LLC</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kim
    Monchik</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AGREED
AND ACCEPTED</B>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing accurately sets forth our understanding and agreement with respect to the matters set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lixte
Biotechnology Holdings, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 45%"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Geordan
    Pursglove</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex1-1_002.jpg" ALT="">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>ex5-1.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 5.1</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 65%; font-size: 10pt"><IMG SRC="ex5-1_001.jpg" style="width:300px"></TD>
    <TD STYLE="width: 35%">
    <P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0">TroyGould pc</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">1801 Century Park East, 16th Floor</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Los Angeles, California 90067-2367</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Tel</B> (310) 553-4441 | <B>Fax</B> (310) 201-4746</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>www.troygould.com</U></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 2.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>David
    L. Ficksman</B> &#9679; (310) 789-1290 &#9679; dficksman@troygould.com</FONT></TD>
    <TD STYLE="padding-top: 2.9pt; font-size: 10pt">File No.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2.9pt; padding-left: 0.25in; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-top: 2.9pt; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0pt; font-size: 10pt"></TD>
    <TD STYLE="padding-top: 0pt; font-size: 10pt">June 23, 2025</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; font-size: 10pt">Lixte Biotechnology Holdings, Inc.<BR>
680 East Colorado Boulevard, Suite 180<BR>
Pasadena, CA 91101</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Dear Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have acted as counsel to Lixte
Biotechnology Holdings, Inc., a Delaware corporation (the &ldquo;Company&rdquo;), in connection with the Registration Statement on Form
S-1 (as amended, the &ldquo;Registration Statement&rdquo;) filed by the Company on June 17, 2025 with the Securities and Exchange Commission
(the &ldquo;Commission&rdquo;) under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), and the related prospectus
contained therein (the &ldquo;Prospectus&rdquo;). The Registration Statement relates to the offering by the Company of up to a maximum
aggregate offering of $6,000,000: of shares (the &ldquo;Shares&rdquo;) of common stock, par value $0.0001 per share, of the Company (the
&ldquo;Common Stock&rdquo;) (or, to each purchaser whose purchase of shares of Common Stock in such offering would otherwise result in
the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of
the purchaser, 9.99%) of the Company&rsquo;s outstanding Common Stock immediately following the consummation of such offering, one pre-funded
warrant (the &ldquo;Pre-Funded Warrant&rdquo;) and the shares of Common Stock issuable from time to time upon exercise of the Pre-Funded
Warrant (the &ldquo;Pre-Funded Warrant Shares&rdquo;), in lieu of a share of Common Stock. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The terms &ldquo;Shares,&rdquo;
&ldquo;Pre-Funded Warrants,&rdquo; &ldquo;Pre-Funded Warrant Shares,&rdquo; and &ldquo;Securities&rdquo; shall include any additional
securities registered by the Company pursuant to Rule 462(b) under the Act in connection with the offering contemplated by the Registration
Statement. This opinion is being furnished in connection with the requirements of Item 601(b)(5) of Regulation S-K under the Act, and
no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement or related prospectus, other
than as expressly stated herein with respect to the issue of the Shares, Pre-Funded Warrants and Pre-Funded Warrant Shares. The Securities
are being sold pursuant to a Placement Agent Agreement to be entered into between the Company and the Spartan Capital Securities,
LLC as placement agent in the form most recently filed as an exhibit to the Registration Statement .</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; height: 73px; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; font-size: 10pt"><IMG SRC="ex5-1_002.jpg" ALT=""></TD></TR>
  </TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Lixte Biotechnology Holdings, Inc.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">June 23, 2025</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Page 2</P></TD>
    <TD STYLE="width: 50%; font-size: 10pt; text-align: right">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with our opinion, we have examined the Registration Statement, including the exhibits thereto and the form of Pre-Funded Warrant,
and such other documents, corporate records and instruments, and have examined such laws and regulations, as we have deemed necessary
for the purposes of this opinion. In making our examination, we have assumed the genuineness of all signatures, the authenticity of all
documents submitted to us as originals, the conformity with the originals of all documents submitted to us as copies and the legal capacity
of all natural persons. As to matters of fact material to our opinions in this letter, we have relied on certificates and statements
from officers and other employees of the Company, public officials and other appropriate persons.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the foregoing and subject to the qualifications set forth below, we are of the opinion that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Shares, when issued by the Company against payment therefor in the circumstances contemplated
                                            by the Prospectus, will have been duly authorized for issuance by all necessary corporate
                                            action of the Company, and will be validly issued, fully paid and non-assessable.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Pre-Funded Warrants when issued by the Company against payment therefor in the circumstances
                                            contemplated by the Prospectus, will have been duly authorized by all necessary corporate
                                            action of the Company and will constitute a valid and binding agreement of the Company enforceable
                                            against the Company in accordance with its terms.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Pre-Funded Warrant Shares initially issuable upon exercise of the Pre-Funded Warrants, when
                                            issued by the Company against payment therefor (not less than par value) in the circumstances
                                            contemplated by the Pre-Funded Warrants will have been duly authorized by all necessary corporate
                                            action of the Company, and will be validly issued, fully paid and non-assessable.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
opinions set forth above are subject to the following qualifications:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            opinion expressed herein with respect to the legality, validity, binding nature and enforceability
                                            of the Pre-Funded Warrants is subject to (i) applicable laws relating to bankruptcy, insolvency,
                                            reorganization, moratorium, fraudulent transfer or other similar laws affecting creditors&rsquo;
                                            rights generally, whether now or hereafter in effect and (ii) general principles of equity,
                                            including, without limitation, concepts of materiality, laches, reasonableness, good faith
                                            and fair dealing and the principles regarding when injunctive relief or other equitable remedies
                                            will be available (regardless of whether considered in a proceeding at law or in equity).</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            foregoing opinions are limited to the General Corporation Law of Delaware (which includes
                                            those statutory provisions and all applicable provisions of the Delaware Constitution and
                                            the reported judicial decisions interpreting such laws) and the federal laws of the United
                                            States of America, and we express no opinion as to the laws of any other jurisdiction.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
opinions expressed in this opinion letter are as of the date of this opinion letter only and as to laws covered hereby only as they are
in effect on that date, and we assume no obligation to update or supplement such opinion to reflect any facts or circumstances that may
come to our attention after that date or any changes in law that may occur or become effective after that date. The opinions herein are
limited to the matters expressly set forth in this opinion letter, and no opinion or representation is given or may be inferred beyond
the opinions expressly set forth in this opinion letter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hereby consent to the filing of this opinion with the Commission as an exhibit to the Registration Statement and to the use of this firm&rsquo;s
name under the caption &ldquo;Legal Matters&rdquo; in the Registration Statement. In giving this consent, we do not thereby admit that
we are within the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of
the Commission promulgated thereunder.</FONT></P>


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 50%; font-size: 10pt">Very truly yours,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt"><I>/s/ TroyGould PC</I></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">TroyGould PC</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>ex23-1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consent to the incorporation by reference in this Amendment No. 1 to the Registration Statement on Form S-1 (File No. 333-288120)
of our report dated March 24, 2025, relating to the consolidated financial statements of Lixte Biotechnology Holdings, Inc., as of
and for the years ended December 31, 2024 and 2023 (which report includes an explanatory paragraph regarding substantial doubt about
the Company&rsquo;s ability to continue as a going concern) included in Lixte Biotechnology Holdings, Inc.&rsquo;s Annual Report on Form
10-K for the fiscal year ended December 31, 2024, filed with the Securities and Exchange Commission. We also consent to the reference
to our firm under the caption &ldquo;Experts&rdquo; in the Prospectus, which is part of this Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Weinberg &amp; Company, P.A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Los
Angeles, California</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
23, 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>ex5-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" != 2P# 2(  A$! Q$!_\0
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M;]IG_HYC]H__ ,/U\6?_ )KZ\6HH ]I_X:6_:9_Z.8_:/_\ #]?%G_YKZ/\
MAI;]IG_HYC]H_P#\/U\6?_FOKQ:B@#VG_AI;]IG_ *.8_:/_ /#]?%G_ .:^
MOZ)_^"//Q@^,?B?]G/XF7WB;XR?%WQ+?6_[0'B&R@O?$7Q.\<:]>P62?"[X1
M7"6<-WJVNWES%:)<7-S.EM'*L"3W-Q,L8DGE9_Y;Z_I-_P""+O\ R;3\4?\
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MT^+7C#XB^,?CA\5O 'PSUK5KIOAW\ O 'Q#\5>#OAK\/_!4-[+-X9T>X\/\
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M)56+;5I:>7_!/R#_ #!]""#^1HK[>_X*/_L\_"K]EC]M'XP_!7X$>)=7\:?
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M#9+'6/#6I,(;_0?A5X0OA;:O?Z7J%O<RQ2WMV#<DK;N[4=.C>US^3JOZ3?\
M@B[_ ,FT_%'_ +.)\1_^JH^#=?S95_2;_P $7?\ DVGXH_\ 9Q/B/_U5'P;H
M)GLO7]&?SY_%[_DL/QB_[*[\4/\ U.]?KSZO0?B]_P EA^,7_97?BA_ZG>OU
MY]06%?;7_!,S_E)-_P $^_\ L];]ES_U<_A&OB6OMK_@F9_RDF_X)]_]GK?L
MN?\ JY_"- /9^C_)G^PZW0_0_P J_P H[_@X$_Y3-?MY_P#8[?!S_P!9>^!=
M?ZN+=#]#_*O\H[_@X$_Y3,_MY_\ 8[?!S_UE[X%T'+0^-_X7^:/S]_9-_9>^
M*O[:G[2'PD_9<^"]E!/X^^+GBF#0K74[^.5]%\(^'[2"76/&'C_Q'Y)64>'/
M GA>PU3Q-JT4#?;M1BTY-&TF.ZUK4]-LKK_3.\9V'[-W_! #_@E+XYU?X5>%
M=/U'2/@CX/%SID>MO!9^)/V@?VB_'5SIGA?0]=\?ZE:B"]U'6O'/C2_TH:]+
M9-*/"O@2QET?P]:6WASPQI>G6?X@_P#!H%^R5HZ>$?VG/VYM?TZ.X\0ZWXGM
MOV9?A??W,;";2/#'AJQ\/?$'XL76FL\826W\5>(=:\!:-/>02-Y<W@&]L R/
M]MC/>_\ !X=\6-1TCX!?L9? JUN)(M-^(GQH^(GQ1UNWCF:-;J+X0>"].\.:
M-;W4*,!/;?VA\7Y+^)9%>-+W3;:7*3QQT#J>]445TM?7=Z;6[+3U/X?/C3\:
MOBO^T?\ %CQY\=OCGXVU;XB?%OXFZ[<>(?&?B[696>>[NY?W5KI>EVK.\&A>
M%_#]BL.B^%/"^EB#1O#.@6=CHND6UO8VD,8\QH_^N?Q/)_6B@Z$DE9!7T9^R
M7^UA\:?V(/V@/ /[2_P"\1W&@>/_  #?H\^GM<7">'O'WA*YGMW\2?#7QS8P
M2(-8\%>+[6W2TU.SD#3Z?>1Z=XDT22R\3:'HNIV7SG2'GMD=Q^!_D<'\* :N
MFGLU9^C/]"3_ (+@_'CX1?M2?\&]GA_]I'X':)IWAOX>_'3XF? /XH0:#IUC
MIVGR:-XO\6_%R?4_B7I>NQZ5:V=G=^,-.^)$OBRP\;:LD3R:UXLMM8U6>YNY
M[R2YE_SVUZ#Z#^5?KWX/_;[\!1?\$0/C%_P3C\8:IXLF^++?M>^#/C!\%[)=
M%O[_ ,)P?"Z?4O"'B?QII+>(4/\ 9V@3V'C#3?&6OQZ5<!)=4U#Q2\MHLKW%
MPT/Y" $  ]0 #]<4$4HN$9)]977I86N@U+Q?XPUGPYX1\':SXL\3:QX0\ ?\
M)+_P@GA75=<U*_\ #7@H>,]4@USQ>/"6AW5S+IWAT>*-:M;;5_$ T>VLQK&I
M6\%[J'VBXB21>?I"0/\ /^?4?G0:']I'_!F]_P E"_X*$^WA#]E_'_ M:^/&
M?SVC\N.]?Q^_&E0WQG^-BD9#?&7XNJ0>GS?$/Q(.1W&,C'O7]@'_  9ML'^(
M7_!0O9\P3PA^RZ'*_,$8ZS\>F5'*Y"NRAF5202JLP! S7\@/QIS'\;?C?#(I
M2:#XU?%Z*>)\"2&:+XC^)XY894SE)(G1DD0_,CJZ, RD4&4/CJ^J/V;_ ."/
M/_!.'X%?\%;OBY?^%/VB_P!N[XE>&/BKX&\-:8EE\!='\"^(/$OQ-\3?L_?"
MK1? O@O1M6\-?'KX@/K_ ,-_#'AGP=9:IX?^'V@>"(_#?B;6?"NCZ78+::);
M:#]@6+U7QY_P2W_X)2_!WX8?MA>%/C7_ ,%+-5^'_P"VS^SSK?QO\6^'_@+I
M<_@CQ)8VWP\\(7OB6\^$/P<U%M1\*:'IOQ8_:)\9>$=-\-7?CVR^''Q(TB3P
M!XP\32^$M5\!6,OAO4;J^W_^#3^.1_\ @JWK3I&[I!^QS\;GF9%9EA23XC?
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MPY9:KXBU2#XK?#'5FU*)'L1I7Q0\*:YXBD\-7Z3F._D\*SV[^4]SIRW7#_\
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M@'[IYX(95/RU^E?[+O\ P5$_X*)_LB?#.?X&?#7XV^ /&G[/]U87FD2_L_\
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M$>SNX=3TOXG_  7_ &5_V=;3QYX?U2+>4U/PGJ/Q%\=?$?1O"5[$Y\T2^&]
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ML%%%% !1110 4444 %>B?!SQ=X0\ ?&'X3>/OB#X'D^)G@7P'\2_ OCCQ?\
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M,+<__/MH_P"'(FJ_]'3Z?_X86Y_^?;0!^%=%?NI_PY$U7_HZ?3__  PMS_\
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M/_\ #"W/_P ^V@#\*Z*_=3_AR)JO_1T^G_\ AA;G_P"?;1_PY$U7_HZ?3_\
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@;XD:T93&=%-Q]I^U1!_M7D_9U\CS9@SJ-*-WW7ZG_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ex5-1_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-1_002.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  X +0# 2(  A$! Q$!_\0
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M;R33D>WM(9Y;J2,[9)&:16&-P8 * , =<T&G4^5/[/\ B_\ \^'C[_P%O_\
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M^ $O_P 3110 ?\*_\4_]"SK/_@!+_P#$T?\ "O\ Q3_T+.L_^ $O_P 3110
M?\*_\4_]"SK/_@!+_P#$T?\ "O\ Q3_T+.L_^ $O_P 3110 ?\*_\4_]"SK/
M_@!+_P#$T?\ "O\ Q3_T+.L_^ $O_P 3110 ?\*_\4_]"SK/_@!+_P#$T?\
M"O\ Q3_T+.L_^ $O_P 3110 ?\*_\4_]"SK/_@!+_P#$T?\ "O\ Q3_T+.L_
L^ $O_P 3110!]*?LS^$=>L_ NH)<:'J4#G4Y"%DM)%)'E1<\BBBB@BY__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>forms-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 forms-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "W NX# 2(  A$! Q$!_\0
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M<HK>45ZRBOSDCZ'C(+_\!/'<<KU'45/5"V!$C,Y"R2@[XR0Q5TVC$4APS1$
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MI/=7>ZVMX6*R3W*F")7D!6K]Q+!$%\V6&'<X \V2.+<Q#!5&]ERQ.0%')((
MR#3@FEJK:O?3MWL!H9!Z$'\:6N:N]<T339$BO]:TC3I9462.*]U*RM)9(S(8
MQ)''//$[1F3]WO4%3)\@.Y2*E@U_1WL9]4AUG29],MWF2YU&+4K*2PM7MF5)
MTN+P3M;0/"\B)*LDJ-&S!7 ) JPN=!29 ZD#\:Q++7]*U(R#3=4TS4#%(8I1
M8:C8WABE&08Y!;32F-P004?# @\<&K+W,)>$O-"AE)CA#RQ*9G,;OLBRP\Q]
M@+A$W-M5FQM!(+/L_N?^0KKNOO7^9IT5E:AJ%C91-=7>H65G:Q826XNKN"V@
MC?S)(]KS32QQHWF1R1[68'?'(OWD8"E::UI-_%-<6.M:3>P6SB.XFM-2L[B*
M!V?RE2:2&Y=(G:0&,*[*2_R ;N*+KNAG0Y'J/SHR#T(/XU31D8+AXW+#<I5E
M?<O!#*06W+AEY!(P1SR*6VGM[A4FMIH9X9%?9-!)'+$^U]AV21LR-M=60[6.
M&5E/(( %UW7WK_,N4444 %%%% !1110 4444 5/E&<X]#GIV/3ICIS@5"\D(
M?!9=Z@-MW*7VL<ABO)"L>59A@DX&1T>'1E!4AO4YR,C^]^)QZ8)]J^6OBA/J
M'C;XD>&?ADNK7^B^&FT2Z\5^(!I5P]M?:['#?+IR:)#=!E,5N\C^9,\?,4?S
MY7"D;X2$L5=M222E*6C:48WN]%HK7UO:V[ZGEYIF7]GX2&(@U*56<*2LXVO4
ME&"UO9+W[MZV2VU/J&*ZCER$=7P=CE64[2>"&P#M(]\'GMUHWQ2 JLL;9Z!7
M1A\Q9!T8D?,D@[Y*, 248UXKIWPD\*>#;V]USPJ-7T>7^P-0MIM*@UBYGT&X
M8VLB_:[VPN))I+G45.62[24 /S@]_'?A#\6O[-^&6C6UYH'Q#U*[AD\1P7.I
MV_AC4+Z&Y8:[K_E/#=('#6\ 4!6R ..H))WA@J=37"3C%*4;J\(M]7=.=FM+
M:/LK;7X*N<2P4)QQD)3C*$^9J,I)1Y9*3O&+Z7W2LKN[5S[(:>&([WN(57 V
MDR1*7QO&%_><Y*./EZF-N/E8B%;RTN-B1W41F,;7$:^;&6:W#K&TX3S"3"&9
M4\P IO=5+!F /YY7&M27WP&\)SZC)K>HPW_QCBMM6MH+:[?7-0TQM6UDC3'@
MA87*;)1$SQJ<*(BI !KW[X<:5X"M=;U"_P##_@CQ9H.L6.GRK%J6NZ;K%I8-
M#-*D-U:V4M[*\+2"":5FC X4Y4YZ;RP,XQ?/4A9R]FO>@F]5'1.4;J7-O&[[
M(X:7%D*^816%H5)X;"Y=/$5)0A4E[L*<YN-X0G"]J>JE*+UO8^F2R*';S
M"S*RD;>QSDC:> 6Y'0X'.$+A53)+,1G:_ QE<'IT.1CUR,8Z#X=^!?CJ\\*6
MSZ7XWUB:[T'4[KQ7XG\+ZWJ$LGVBWN-.O[J34=$N)FD6,RVUBAFL[67=O4!(
MT)(%)H_BWQ/_ ,+ \=>.]1N;D0W/PRN=5\+^%+]W72='T?2S]KL+W48SR^I:
MJ9#>7L*D3+;I BL ^Y;AE-653$0G4@XX>+FFY+]Y:R4:;4O?;O>T7+YVL9KC
M#!K"864,'5G4Q6.4)494YKD3<VY55[-2A#1>_/EC:VJN?<7VF)"JR201EBVU
M6DC5G\L9E5%W MY:Y+_W ,M@4V6^MK?!>Y@CRVSYY0@W,5P!NQR25 49)W#K
MD5\C>#OA)X?\8>$K+QCXYU;7O%'BKQ5H6E>(KSQ*=3NM/FTP:W;W#Z?!X7TR
MU<1:9%:[([*T@>.0W #-)N(*#/T+PY:^*=-^(_@WQM?WGBR_^$^J:AI>C>)[
MJ\G2]O++5--&L6$=W<63Q0S7FEM$+6XW!W1XP'VE17/'!T?:<OM(\Z:32LW=
MOET5W)V;]5JWI<ZJV>9JJ,JU#*Z4*?+S1<Y<J:O'1\R2^%NUKJ]E?8^QEO[>
M9GCCN[5I(U:1T^T0ED13\[R+NRJJ!\S,NT9R2,&I%F*X9MA4C<C*8RI 4N26
M!QC8-P(ZJ&(R <?#7A+P;HFE_L[R^-;*TND\1W?P\O)[F]%[J$T[R2-+<><B
MR3G<T9&[@9V)@]>>I;XNQK\(6MV\/^/8]1?X=RV\.J?\(GJ,L$=ZN@F,:@E^
MJ[(XY6FBD65F"R>:AW8!-;O+N>\8VG[ZA*/*HM:J[OS*Z5V_-)I:BPW%#LEC
M\NITUR2G[2G+FV4G%+E3=W))66MGV/KN6^MT6)I+F"$2Y\HO+$JRC9YA*,S+
MYF(QYF4S^[R^2"<,34+212RW5K*%8(S)<0-AO+:3:=I8*2BO)@X.Q6?&U3CX
M-\3WMK<Z5^SQ'XB'B76M,O\ 2+A+VQT=]7DO]0G'A])9)9+33&5Y6C"R*P<A
MT&X*0"U>GV6G^$[#X>?%#5O _ASQ+X:OSX.UTP?VU9:UIFHRWL6AZE_9[64N
MLNV))9)HT@:' ,I!#%@0)GE,*<>>R>MO=C?>?):_/>[?]V6GH<F'XJEC*E;V
M5"#5"-2<:5>7LTXQINHY^^HJT8N+O?1N[:6J^J%NX'<QJT+/M5MJRQL^QRRH
MP7!.URCA6(PVQ\'*M@WIEW+8RNT!2O)'!' &2"3D8!'&?0_G6;/X5:=\+?#V
MM^&_%-S9_$:31M%N=#DT/7KS4-:UCQK-%"LUDNG&X<:C/>WR7-AJ*I&1!%9R
M,-C0L']B^*>K77B6Q\%_"O4M8C\/ZKXPTF/5_&E[8:F+6]TK3]+MTD+Z=+))
M"RB76?*BEDX5PLL>21D"RR4IJ,%9N[;<791@N:3Z7T2M:[O9)-O0PO%JKX/%
MXFI1PD84XNDI8>O2JMU)RY8TGR3ERR;C*Z?9=FSZS,Z(N]F 14+L[D+M5!EV
M)/&U5/S,<!0PW$<&H(KV.3>L4D;F)V24)(C&-L\APN2A&02'P<$>O'Q_>^-K
MG7_V>/B1:W^IPGQ%X4T#Q#X7\1W>FS^;*=1TI(X(KV.>!B8_M-E'%<Y5B=LN
M_HN*X#7(?ASH'@OPOKOPXUZ>+XI"'P^VCP:)K%YJ=YJMU=KIGV^&^T]Y)HKF
MVN(%DGF>2,"-V=@0!L#GE;C&7UA<T54]G%<O-:?)SIZ--)PEI)-[KS23XHIU
MY8548I..#E4GJDW:I"#@D[WG?[#LWRW2>Y^@RO'(AE%TJ@;R^'4H@1B'+%<A
M0F#O)P%8$-CK3TD1MR"1'9 &8!D+ '[K.-Q(##^+ !P2"0:^/=9\7:S\%M;U
M$7D.H:CI/CZXM;WPS;3/-=-8_$'4D2*\T:2=2#'IM\X6XMH,;5<2H@  (]U^
M%GA;5/#_ (:B'B&[N-2\0:S?7'B+Q#--(\BIJ6J;KJXL;+<?EL;25S%;QC 5
M(\#H*Y*^$E0A&?-%TYNT%>-TU'FV3;VNKM?.YZ>7\00S'$K"0H5H5:"52K*5
M*I&/+*2II*3IJ+]YW^+9/9JQZL!NCV^F#C\.WX]O4U,O0?0?RJ",.JIE<,%4
M,!D@' R >XST/XU..@^@KF;T2\_T/I'%*<I]9)1?R;:?X_>+1114C"BBB@ H
MHHH **** "BD+!1DG Z<TWS$_O"C?;4:3>R;]$W^@^CIUJ,2QDD!U) R1GM3
M6FB(8"1<['/7LH^8GV&1GZT-I.S=F]D]&_1.S?R0FTFHMVD]HO1OT3LW\DQL
MI#%=I5L;MV"#CIUQTS@CH3Z#CB(MLY"@[N">.-IV\D Y/.2,C!!/ICG=<\1Z
M+H%I/J&JZG8Z=;6T<L\ES>.J1Q0IEI'W.R 87&#D\@8![_G%\:/V[K6V^U:+
M\([*/5KS,D;^)]2A;^P[5D;RVEL((R)-2G09*!2J!@%8-G%?1</<(\0<48ZE
MA<JRV51.:B\3*G-4XWW<ZKIJG!*[UE.]E=(_/N.?$KA3P^P>)Q.>9I3HXB$%
M*6!^L4%B%>"G!1P\JT:RYX<LHKV2YE+F5TTW]Y_$;XL>!_AAIDNL^,?$-KI<
M2P%HK(-#-J5_RZJEC9C_ $NY=I%= MO&Q+KC((P?RH^,_P"VQXT\<QW>B_#L
M3>"O#TCM VHA8O\ A)M1M@7&&^U 1Z/YB.I!?;<J3(68J4S\?^)O%GB;QKJM
MQK?BW7=4\3:A<ON6;4GE2"$DEQ]FT]6 L;='=Q' 1O!W2$X8"L-8E(8ML#,Y
M+;(R@S@#@'J #PW?&!RH-?U;P-X&Y%DDZ68<4\N;YIRQG3P22J83"U6W:G&H
MKTY124&Y.5E)RC]G3_/?Q8^E1Q/Q0GD_!G-D^1UIRISQ\>:.+Q-"7NNI5BN6
M<9<SK+EM'W8Q>JD/>>^EOO[3:\NQ?K*)UU:/5735(9U;<9GN))!)<R.XW.8F
M:(\ 8'-?97P;_;7\;^ A%HGCBUF\<>%4(62Z#*NNZ;B0[9%BD!EU154B0K$K
M.J  %:^,L*ORJ<]<D9XR<<@DYY. #Z$]Z='$N'8X (SR !@#L.^[G\!@  "O
MTK/N".#^(,'++<RRV-+&3@X8"-.$N6A%*U.%"45RNG!+1QD[7T;UO^%<*^*'
M&G!V=O,>'>(\3'EK.>9RG=/$UFTZTY1E;GYG+6Z:?XG]%'PT^+W@CXGZ''J?
MA'7]-U$CFYM&VQW>GO(S'[/>6P<3VTZY((FB5CPV&1DD;U*-E*/D(.@!+80L
M>REC]XD]" 1TP#R?YE]!\0ZYX0U2VU_PWK5[H6JVL@:*]T^2>02X;<8+JP1Q
M%/"Y&&E9"57.2#R/T=^"G[=+226GA_XM626D\K):6WB[2-DUD&8KM2]A;<;<
MG(,DF< E@5# $?RIQYX(9MP]2Q.;9)C(9GEN'<WB\'6G"$\,XRDIP:G)1E"G
M*\5-..B7NO5G^@7A1]*?(N*ZN$R+BJA'*,XJTJ5*EF2Y:<<94Y(0=:7.XN-2
MK).HXQYK.;O%'ZA(9D\YI%3[S"-5 Y^8[<D<G !Y)R3SUSC/O=2MM-MY;O5K
MRWL+6 >9-++)%"D" $AYY9"L<$87^.4JH[$@''SA\1_VJ/AQX&TU)M*U%/$^
MJWUDDEA8:7/'>6X\V/?&]Y+$6$'+*)"V3R1@=:_./X@_&+XC_&?6+6POI[J#
M2[IW;3?"VE3R06\LBDN7:^C*M=LJ$%X#\BX.0<5_G1XN?2J\.?#"K/*J&(GQ
MGQ="=2E#A;ARI"AA:=6E5J4:V'QF.I2J86G6HU:52C5YJW.ZM*I>,-8K_1+@
M;P?XCXT^KYMBY3R'AMTJ%59A7IU*2Q="K2I5J6)I*I"A&HJ]&I1K1G*<*;59
M2YJB:<OM?XM_ME>&] 2YT;X;O#XHU55*W&K2QRMX<M K%7!6,FYN&R"':W+(
MWWE9E937YR^+O&_BCX@:E=ZMXLU6\UJZE.Q4FG;^SK%N/W=K8VI*@MC&-N_@
MY4Y!"Z+X*\4^(3<KHFDW%Y_9]X;*^,$RV06\9MJ6DDDH(,Y8 *"<D@'&35*Q
M\*ZOK%SJMC86#SW>@0WM]?VT@>.53IA":C)*H 95L68+<,<B,D9!R,?Y5^*?
MC3XW^,F84L3F=3%</9=7G..#X1PT,1/*<13C.HJ?)75)T,35C34%/V56H^:,
MGHW8_L3@C@3PTX#PM:&#J8'-\XP\%+$XS,*^&A*@I./\:56K&GAH2<DUS\B?
M,M'%)G8?#+XT^.OA??O<>&=57["\@\_0-2^T7>GW6'W.L$Y8IILI7(6V)4NV
M%*@\5^FOP?\ VJ_ WQ&:#2-5D'A/Q4Y ?3=0GA2RO9BRH#9WTQ2$/N*C[()!
M-G*A&[?F#-\+?'X;34E\//))>O)+LBN J6$;H7!U&0#%O\@+;Y,% H/:N5UW
MP[J7A.\>QU*#[->V\4<]DL<TDKE)S@3V5]$07920T<F2H8*W0 CZCPP\?_'G
MP0=..99:^(>!9U:48X/&4J\9PC.I2YG&%2E&2ER.;2BOBMUT/+XR\/O#?Q,Y
MJV#K8/*>)>2<H5<!7PM55*JC)05;V%64)0=54H5)34;1E.5U%7/Z$A.LR1E7
M0B0 JZLK+(#CYDQG<N&X*D\$'.*=_$H41L <M@KN&/7J1@^GT/)P/QK^$O[4
M'C[X<?9M(U=G\4^%RT:BTU";.J6*$_O#!(Y9YE5,LB.22P&-I)-?H=H7[2/P
MDU;P7>^-=6\7Z+X8T31K62ZUD>*+^PTP::MJHFG>3[=+$DRQA254;G<X$?SE
M!7^HO@S])/@'QDC#+\CQE>AQ?.,8XSAK%IT/JDISC#GPT*KIRK*GS7C&G2G4
ME-*,4W))_P ?\<^%O$O >(G5S3+X5\&HRFLPP\)5<,J<8RE*;JQA*$'&*;NZ
MCAIS<T4G;Z*+IM\Q06&TD;#&"5P02I=E3C()+, ,#D$C/S=^T?\ M7? 3]E#
MP1-X]^//Q.T#P/I#0&?1-/O+FV?Q5XDGC*?\2SPYH0N5O-<U&XEDCMX8K>![
M>*23S+V:&VCFE3\"OVW_ /@X,\-Z!)JG@']BOP_:>.=>$5S:7_QF\9:==6?A
M/2B)5M]_A#1B4U+7;JRN=TL,VI1C2TDV72K*(0K_ ,M_Q2^*_P 4OCCXTU'X
MB?&CX@^*?BCXWU- D_B#Q-J$^Q1YOF"VL]'B<:58V-M%^YM!;6Z$!(^<CC^Q
MN'^ \=F'LZF8N=+#1G&5>$TX5IT4TZBA"<;J3C=*+C.5_L]#\4S'B3#8=N-&
M/M'_ #0M*/K>#?SM9=>Q^V/[;W_!>3XV_':/5O O[,5E?_ OX5W)FM)/%5Y"
MEW\5_%EC,&A=+ED)TKP1:W"[W:+3+N^N]KHLMQ'M%?@W-=ZO<ZO'XBFU;69/
M%279U)?%$GB'55\3/J?F>=]HB\1B7SK;4-QD\F\EE73XQOAD<226X:K($.TH
MC*0"/E'R#@>F,GTSR!R,5/O C'S<^F.1RW/IWR?7CFOV+*^'\HRZC*CAJ+A2
ME'EJ1<6I25M;Z<SZ6OM;:VA\1C\UQ^*J>UI5(QI1UE"ZYFNJ46T]VMKO1O??
M]T?V'?\ @NQ\?/V?$T7P'^T;8:A^T!\)(FALX==$EI!\5?!VFHT,:P[[MX+3
MQ8+:-9,?:[J SH1)#.942-_ZW_V9OVN?V?/VNO",/C;X%?$30_&-F8TDU+1D
MN8K/Q;X:D)7SM/\ $GAR[F75]/N(96:-IFM3IKLK+:7DY5B/\TIE$@V!GC!(
M)=&4,A5@P.T\2!B NP'/1L$ BNV^&WQ*^(7P5\9:?\1/A!XV\2?#?QMIMVEW
M8:]X4OKVU*R(09TO]*:;[#?6]\O[JXCGA<%=Q4!B2?F,_P" L!F'M,1EJ]AC
ME[U%\J4)3<ES\T6E9N#G:4>63=D^9-GI9?Q+6H*-+&1=3#;5(V][EM[MNME+
ME;3OHM+61_J0))$"@#*2Z;XPK*=R# 9UP<LH+J"PR,L,X)%21O&Q949690C,
M RE@K[MC$ Y"MM;:2,-@X)P<?RL_L0?\'!NEZI_9'PX_;B\/VOAJ_N#;:=:?
M&SPK9RWGAB]NF,D5N_C/P_ IN-*9F$4D]_"?L8=I&DB0(9!_3AX*\=^$OB'X
M<T[Q=X!\5:)XS\+:Q:Q7>FZ]X>U"UU+3;J.4%BT5W:22PX *CR&830$,DN3T
M_'LSR;,\HQ+I8RE645)KVCIS5*6CY6I^SC%IO9-IKL]&?<X#,,-C*:="<(IV
M_=N<%/:_P.7-II>T6NIW=%5HI@=RNP#@CY2<M@CCC'3T(R.O/%3AU.<,#@X/
M(X([5YZU5UJNZU7WH]%Z;Z>NGYV'44W>G]X?K2@@C(.0>]&VX6%HHHH *X+Q
MVSKX-\8L)3&5\->)0JP.(;H7 TZ_EMWM+D%3'=+&-X5273<).!C=W1D0$@L,
MC@UR_B'3_P"V-,UK2DNI+)]6TJ^TW[=%%YLMN;Z"^LA/!"Q"--:),)"6.&7;
MN!! IJI"$HJ2;<G[JBN9OEM*3M9NRB[MI.VCTN)M*,FVDK;MI+KO>R^]G\VO
MBP_%SQ7^P5_P3*M_AE\2/$7A[XLS_M&ZYJGAO6Y-<NKM?%FJ>&_%?Q(U%/!G
MBZZBD;^U-#\1V=H=*8.SQ0F.PM0I?8A^P_C]^UWK'[0G[*5I\,?@E?WG@'X]
M_M$_#;XVZ'\1;R*.==7_ &:O#'PN\(:^OQW\6ZC 46]TKQ+:ZX;/P3\-H]2B
MM9M4\3^)K#7K!KC2?#M^\/T7X<_83TW0/A5^R+\,%^).IR+^RK\4KOXEVNL'
M25$_BZ2ZOO$VIS:7=H6"P0-)XHEB,Z@%A:D#E3GVY/V1?@KH7B;]H_X@>#?!
M\'AOXB_M/^$E\,?$OQ7:O-=B[MDT+5M!MY=/TJ1S:V;00WS:GJ5KIRV_]O:B
M+>2\=YPDD?;/$X>$:3G3<6ISDFTXIJ4TXQES*UK=5:\DEU9Q7E4G)4:D7HN9
M1E&3MK9KED]FFM=+:WT/QD\86WQO\5?LJ_\ !%U?@7\0/$.B?%+3?%.J^+_#
MU]J>HZG<K\3[GX<?LL?'CQ9I_A#XF799H-0L_B%-X=L4\=O<DQW?B&[LTT0N
ML\2U[Q^V%^UGKG[3G[(5_P##_P#9I\0:OX*\:?&3X&_%#QU\1O$6G[8/%_P
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M0+ILH9D%M;ZVWE^;,.+:[LH+90?,8"[^U'\ (OVE/AQ8^ )O$]_X1BLOB%X
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MX#WR^!M-\,Z/XG:QU;1_'1\:Z?K-Y9BYC2=[NZN3!):HR^<H6\GBV!@ 2KY
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M=R6]QN&$C; +?LE;3Q_+M8D2>64VCS%=6AC82++'N$D4AW%;ERJ.00#\O/\
ME9-% \T,Y62*>!\PW5NNV[LV #+/8W(>*6QNTDY2Z@W2K@8&,5^Q_P"Q!_P6
MJ_:1_91FTKP-\27U#]HGX+K'#8Q^'/$&J1CXC^$=.MG3SKGPMK4KF;Q D=NA
MV:7J *F5[ADP[(R_E_$'AU7IJIB,JJ1EAVU55&,TY)W;48R5_>:T49W4K<JD
MKGVF5<5QKJ,,="5.<?<52:<4]$D_>2O?NO/0_O&+1_>!# C@CD$?4<D9^GUX
MIZ2*?E) ;TQ[X'8=<CTZ]*^-?V2_V[/V:OVS_"P\0? [XAV6MZM;V\5SXA\!
M:N8]&\?>$GECC)M]:\,W(BO8H%D8QQZC MS87$BS"*Z9HI4C^ODD!<R,-@7A
MF8$( K*2P<_(R[0275BHQR<FOR^M1Q.'Q,L/B:%6E4II_P 6G.F[:7TDDM?*
M]]S[.A56(IJO3JPJ4FK+DE&23Z:IOSW2\S1H)P"3T')IH=6&5.1C.1G!'J/4
M>F.O44-RC8YRK8_(TD[[:^AMY]"'KD^K,1]"217A_P >?B3=_"7X;ZWXVT_3
MX-5O--,<D=E=S-'&Z22K&Q4J#@!CM"GGD'.,5[<&#<+\Q].1U!/4X[ U\C?M
MIJQ^ 'C-RN/+1%&2  /MJ!".1U(. 2,8!.T<U\!XJ9MC<@\.>-<[RS$T\)FF
M6<-9OB<NQ%2<::I8F."J\LE*5DFG&-G=-.S6MCZ'A# 8;->*^'<LQE-U,)F&
M9T,+B(VNG"K.$>673WG)J*?Q-679_&J_\%"_'TF /AYX>C9E5MAU:?<H89PY
M\C:",X.#C(.#CFG+_P %#?'C 8^'GAGED3/]KW@R\C%4',(Y<\#''K@=/B_P
MQX"\4>+-,U74M*LQ)::/;"=GDO--MGU!BF?LBQWM[:SVZJ?E^T3Q1V[X#I*R
M'=65X0T^WUS5YM,U!3$D>A>*[G:"JB*]T6S%S&GG*=C&%-TGF*S1L(RL;N7
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M'A[2-*TE5FN9(+4:A'LEFN3&K3R>?<2!V(&%=GY)Q7]'UE-'*S; V/*A.Y@
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M35M0O]2U35+[6WFFUI;F[LM6N)X1;RO>VTS)-FU"PK;(S#<D*1%0,'S,G%9
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M_P 6<?\ "? V$C5S;'1EC'%.."=93Q$I63Y84[RT3YDDM4ET29\E>'/"^O\
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MW3M1@CO=.NK:6(B2&XL+I98)(Y.4V$<*S8(Z5^0'[<W_  03^#?QEFU?Q_\
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MRM"ZITXR44X04'R];7]YZ+5[OKYA1115%!1110 4444 %%%% !1110 4444
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M;J6OHU%RLU\[Z=145E)+8YQC&>V?7ZU)117WQX84444 %%%% !1110 4444
M%%%% !1110 4444 %%%% #)/N'ZK_P"A"J\G27ZG] #5B3A"?0K_ .A"H9!\
MLI_WOY'_  J9_##_ *^TO_3D3&NFX/\ Z]UU_P"4F?SJ?'P_\7K^)>-H+>(9
MT#.Q14)$>6+JK%/E#*&52V6  .>/2_V9]4TJUN=1L[GXC:EX:G.M6LEAX$2_
MCT6RUEDV-]HN->\F]N(K>4AO,C:",%2&,N]1&WFOQ]4_\+I^)/\ $3XCGV(%
M)WOL&U< ' /.2>!CGG%>A? >/P*VB:F?%=KX6GGFUJ.VUI/$VD7^H/+H<MM.
MLEG936B%K2ZCNA9W4=PC@K!;W$6#YN#_ '9Q+3C+PKR"I)Z4L%EWM&DGRIPI
M<K=XM).V]KKO'<_R+RB.+7C9Q%["OAE'^WL\2P]6+<^;VDKRORN-I:<JYNCN
MNC\B^)4VH7_CWQ@^HZ?_ &7>'6+I)+8,US"B-*6@:/451([Z.XB F2;9'(RD
MLT8Y-<%!:27-U:V443SS7EREM;Q1QHX>ZE81V\3RO+$\*2/N#M&LC.%Y0A<'
MK_'#+:^,_$=NJVB1FZBELH=/@N8+2/2C;1MI)@-VYG9#92J&,J*Y=2RDJ<UF
M^%7">,?!TC+O5?%FBNZ$G#)]M"N!@CYAO!3H,Y)ZU]S@\3+!\)O%4W98;)\-
M5HR6TF\*I:?.*WM?O;4_*LQP$LQXZQ67XOV>'EF'$'L:[@N6"IO$J$7:-[-P
M;;^YH^]_@E^PK>ZR+/Q#\7[R*WMV\B:#PCHY;[/Y3^8S)>W<EO;2.\BB$LH5
MR#O4')R/TV\+>"_#7@S3[?1/"^AV.CZ?;QHD<5A&(BP1=H,DNQ78D8R3N<$G
M,F!FN@L(3LB$2QI!%;VJ(&+&0_N%9BV/E'+#&"<Y;.*U0"."JXQCMV^G//'K
M]!7\"\4<8YWQ/BZTLQQ>,E1E4GRT*=:<,/249.G%1IJJ[^[%-R:O>\DDV[_[
M">'GA?PGP'E>!C@,LP.*Q\L%AI5,RJ8:E/%<U6C3JR;JRI*22=7ECR:J$8QW
M1$J_(RCL\8 SN"X9> V S#W89[=J_-3_ (*+#'A_X=@]M>OQ^5A-TK]+ &0-
MNVGYH\!<_P!X#G/X=.,=LU^:?_!1<Y\/_#L^NO:@1^-A,:_C3Z8\(4_HX^),
M(-N,<#@5%N3DW^_B]9/5N[>_ILD?U+X#<_\ Q%O@;G<9/^UL7>4%:+_V9VLG
M9I)66VZ9^7*]_P#@'_HJ.G4U>_\ P#_T5'3J_P">*6[](_\ I%,_UKI?PX_/
M_P!+F5IY/*1GQG+!2,9)ZA3SCTZYP!T!/3ZM^ G[/7C7XOV=MJ%M-'H?A1KB
M1KC7&F(NG6!@);>*$02QDM_!YDT>[JQ7Y:^4;A0X5?\ IH 2?H6QW&,-CD5^
MV?[$*/+\!?#^1$%&H:E'*I0?OD^U%%+$=6&[)8X) (.:_J[Z'GA-PUXN^+=;
M*^,85<3E&4911QL,%AI^S]K-4H->T>B;E;WI6;NW;N?SW])#C;->"N L+B,G
MC;,LRS-X-8F-E.AA[U-8OFB^;EY;7=K1=U>QZA\*_P!GGX>_"^WWZ1IRWFLR
M!9+O6-21+NZENRN9IXBV5MQ+('D\J%MB%@JLP4&O<1"PY!CRJ["[ 8^7@X52
M#G/4$*OO@9J>*,J%/R[=HP ,8&"1QT&,\ 'C%<;XX\86?@W3["YN[*2]GU?6
M=,T'2+.-HPUWJ>J.R0!B[ ".-T_?$Y<K]U"QX_WKX9X-X8X,P-' <*Y+@,LP
M].A0HQ=.C"%1PI4:-&#JU%!3G4<*4/:2;YI3YY.3<G?_ #+SC,,;G6)EC,UQ
MV.Q]:3<Y.=:<VY2E*<DE*:22E*7*H\L5=:=5U_VF-&2*0%6?A"SP_O$".S2J
MBRM)Y8V%2=F=S+@%<L//OB?8>*=7^'GBW2?!6N2>'?&-]HVIQ:)KT<$UPUAJ
M,3"5QY4=M.T(F0!(IEB+'S!*$4A0WQ[XS^,/QR\+_M6?!WX0/)8+I7Q=^'7Q
M(\5VEI%HXG\+:-K_ ($OO#UY::'J_B4H-0M+G7],OK]+"..*2)YK&\#%5C0D
M^.?B+]J[XTV6H_";]F#4/"7P/U;2/$FG:!\6/C1\1-+C\9Q>$M-33DU&^MOA
M9X%BFCM_%6O7<;-"EUKMY8V5N)/,<LP5E^F.+^M=_GYGT#^SE?\ B36/ #ZU
MXD\0VVN3:WXBUZ]T.W^T1ZIJ&BZ7'?RP#3=3UF,QMKMY!(A2>ZN;>S* IP?E
M(^B"P8 94;\+MWIO^8A<?*Q'&><$G!R,D$5\*2:KX_\ V4/ W@WP#:V6I_&B
MR,5V8_&%^1H>KR2H]QJ>K7OB :59/I[:CJ#D+I%K <75TR17)B#[D^P_"5_?
MZGH.AZE?L\=QJ=A;:J;:YL_LUY'%J$44RVUS;-B2WN;0S"*Y!&T2+)M9EP:3
MV>[T>BW>CT6JU?35:VU6Z#4OM TS5K&\TO5['3M3TN_AFM;W2[NSCGTR\L[E
M&CGM[NPNA=6UT)8F:*;=$HDC9D("D@_B1^TI_P $&OV0?C'XZG^)W@9/$?P>
MUR[>2YUSP3X+NK2#X:^*;EG#N;_PZUFGV"6Y9F-U<V<RD@E8X5'%?NF00"<+
MP">!SQSWJE<(\D; D(,9+  D $$X'0D@$=NN:PJPJXG XW+H8G,<'1S#"8K
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M&<'@@$@42ZS806IOIIXHK$*9&OI)H5LTB52TDLESYAA18RKH07W&1#&!NP*
M-6BH4EWMM*E2#@Y(.#\V>F<X*D5-0 4444 %%%%  >AQR>PZ9KY3_:!_;@_9
M2_95O_#FE?M#?&[P?\*M4\76>H7_ (9TSQ*VK#4==L]*F2WU&YTNQT_2[ZZO
M(;29Q'-)'%A3R 1DCZJ<X5CD#"DY/08!.3RO ZGYE^HZU_,3_P %C'\0>&?V
M]?V(OB3:>(?BK\-O#WA_X,?&G3M3^+'PY_9<\7?M667AV_O]2M!INE:EX*T3
M3KK1[5=<>4?\3'4?$-JFG0(9)H+JW&X ']"OP4^/WPE_:+\ 67Q2^"?C*P^(
M?P^U&]U+3+#Q/HEKJ\=G=:CHM[<Z=J]I'!J>FZ?>[[&]M9+=W:V6.1RA1O+=
M9&R?C1^TG\)OV?[SX6V'Q1UZ70KWXS_%#1O@[\.;2.QN+RX\1^/M?M+N^TO2
M;6.%?N3VMC=2/<D^7$8F1OF!Q_.%X^TK5_VN/$W_  1S\#>&/B7^TKKOPD\8
M^._VP?#WQ\^)G@CX(?$7]C?Q'XUC\-^'/"#(_C7PG:Z#/%\.M'U'698ETV[U
MR;2[CQ);Z5K-SX3UY[K4(YK+YB\1_!CXP>+_ ((?#[]ECQ8W[4^N?#SX._\
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M0"1R4 /R(FYY%8;MFU?,8K@Q+U"M=%-@>"0O(6P$Y55 #;G>40A0%.6X)7#
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M"UMX8T2Q\+M:-J<D_BJ?Q;J*WLEJIBFCL($:.<;"F]JG[3GPT_9C\7^-]?\
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M2V0+$/,2%'#*6)R!&'BW)01MO(9F9V(R79R"S,DGF0 M\XDQ;[!O8P1V[<T
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M_$G_ (*X?MFWOQ@L)+GQ1X5\9^&O@SJ<VL:UX+A\2ZQ#='4O#_@Z\%KI.B6
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M69$U/5;VX2ZUJ_O+NXNE%RUK^_*"W*(@'#_ 7]C3]FS]F#7/'7B7X$?";0/
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M.??'0]\'M[5_F].:<ZC4:G\?$0LZ<D^:G7J0EH];7BVGM*-I+1G^V6#E%8+
MJZ;6"P:?*^;E_P!EP_Q6OR^KZ:C9N2RGC]VI^O[S_#/^17Y'?\%/)Y+9_A%(
MC'(U76%9<D!@+"ZQD<],C\#SQ7ZW!C(S%MN<I'@9Q@ECDY'4$'&..^*_(?\
MX*BR,3\)!@?\A/6#G!S_ ,@^Z]_85_+OTS&E]'GQ"@[\TL#@5;S>(3WZ;G[O
M]&ZE[?QGX(I/EDGF>.JJTDXRIQPC;]Y771JV[:MH?F;I_B%=L<-T9#+LC/F8
M&P(8TVCTR.G7/ZFNIBO(ID#1.7!Y!&#UZ@]>AR.N!^%>7HIV1@-P(HB,@=T&
M02,'GO[=,5<L[VYLWQ$V8T((0YV_,=S8 YY))//) ^E?\^U?"N45%I<RC!.[
M6_LZ=]>J\^A_L#B,JA./-ATFVYOE<E%-^TJ?S+3;NET/2R Q0,=I?+'VXV=/
M<#([GT'?]M?V'SCX!Z$!VU2^Y]CJ(%?A-9:[%<$+<$1R)E&*DA2#D@@L3R01
MD^J\=#G]U?V'9(3\ M!PY .HZ@WF,1M#"_+Q@GC[Y&,C=GG&:_O#]G70K4/&
MSB!NC5E1_P!7:*6)IP=3".2H13H_6$U3]O%W4J"YJD9*2=FG?^)?I@T:E'@;
M)I5(N,%G=2GSN_LXSBZL6G.W*DFFKO33[OM)"3E>R8 /J 2O/_?-253MY7;E
MPH9@"VPDJ#AV.TGDC.<'N/0\58:0#H1GWX_PK_;J[M?EF_)1;:]5>Z\UW/\
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MCQZE)>ZUXMTU+;3M&TVTDNB9 ,#]*/V>/^"0?B'X0:!XS\*^)_B_X(\:6J?
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M@[5/$?Q3\3ZMX*NWLO&UK'X5M8_/B3P=/%,WB"\,AL[*"&2<SO&C$=M\*O\
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M "BBB@ HHHH **** "BBB@!K'"L?12>06' _N@@M] 03TS7XT?M\?\$P]?\
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MAC,96A0PF%P>&J8BOB9R5.$72A24W*,I+W977FD?[58K'X3*L#7QV:8BGEV
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M$?>?M(WMJM)QN[_<?Z?\?5/J/U+FK*?='X_S-5TQE,'MGZ'./3W8583E0?\
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M"I5@1C:<  Y&79\\*HR,8YZYXIAF8G #*,Y+NA"J$*@@9.6,I)6/C/4@' !
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MMOT>_;+_ ."L'[:'[;F@:;\-O'7Q'E\$_ ?PK:66C>&O@M\-+RYT#PS:V-C
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M]1TNXM[O3=35XY(IX=5T^XT^SDL=4AECU"T\@+!<QHTBOC^&/@S\+_!PTO\
MX1_P;IEJ^AWNIZCHDUW)?:Q<:/>ZS EMJMQI=QK5WJ,]@U_!&D5T+62))5!W
M+EF) /S[\*_M _M$?$OXFZ)J/PPTKP+<75Q^SM=>)_%G@WQ1XAU&+PYI/C+1
MO%HTB/2]$FLMLTJ:Y<+(L&HZ@X%K;W"N\R@ FY=?\%"8Y-1^#>N:%IOA_6O
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MCXS_ !'L[[1_A[I5GNF\Q]*OFCCG\4ZC(;:1H(=)CDAMS$L=PVZYAW?UH?\
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MCI=AKLL3WMK%>:'<6-VUOJ MK9KVSDF^R7,D"23QRR1QE/H_ )#$ L 0#@9
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M  6/S8+8 )([9R<'MTJ; ]!^0I< = !4N2=]-7;J=*2C&R7HPHHHJ0"BBB@
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MO$1(C;V@A@<1Q*8\(NWW*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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?HP,DX&2<DX&21T)]Q110 8!Z@<]>/3I^5+110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>forms-1_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 forms-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (] D # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BDS29H =29I,TF: 'YHS3,^YHW#UH =FES3-U+F@!U%)GTHS0 M%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 444AH 6DS2&FDT .S32U,+4PMS@#-
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M?]\T?\)9IWK)_P!\T_[1PO\ .@^K5OY6;M%87_"6:=ZO_P!\T?\ "6:=ZO\
M]\T?VCA?YT'U:M_*S=S29-8\'B73IW"B0J3W88%:RLLB!E(93T(K>EB*5;^'
M*YG.G.'Q*P\'FEI!UI:Z" HHHH **** "BBB@ HHHH **** $)Q2$T$TTF@
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M(<BDDCBM6TG6O%_@Z:TU2T2RU%) \,>[AL#'6N8N= \9Z]I^G:%?Z>MO:69
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M;S8TXQSM_A/8UI1337,S#$N,D^1# A0[HW96'<G/YUN:"[26<CXPA<[1_/\
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M %HHHH **** $/>F-TIYIAH A_C!]ZM9JJ]6%Y4&@!U)2TE "TS%*3Q29XI
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M#=:996RZC?WSV,T4K?)'(IP3GTS6OJO@K5DUZXUCPYK"V,][ L%VDD>Y6*C
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M !1110 4444 %%%% !1110 4444 %96B\+>#TN&K5K*T?B:^'_3<T :M%%%
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M>S>@;T- &D7H!9N@-3K&B]!3J *XBD/;%'D2>HJS10!6\AQZ4GER ]*M4<T
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MC9.1R*%;BK!J&2+'S*/J* ' T\&H%;WJ0&@"6BF@T[- !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 AK,@_Y&&Y'K$M:9K,B&/$4_O"* -2BD%+0
M 4444 %%%% !112&@ -1DTXFHV)H :QZTZ*//S-^%-1=[\]!5@=* "EI*0D
M$G@"@!<BC-<UJOBN*U=H;-1-(."W\(KG)]>U2Y/S7153_"@QBMX8><M3*56*
M/2:3(KS&/5M1B^Y>2#GN<UKV'BZYA*K>H)4[NHYQ5SPLXZK42K19V^12U6M+
MRWOH1+;R*ZGK@\CZU9S7+JMS8**** "BBDH 7-&:2B@!:*2@=*0$,L>T[EZ=
MZ:K58-5G7RW_ -DTP)@:?4*FI!0 ^BD%+0 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 &LQ>/$3^\ _G6G69T\1_6#^M &G10** "BBB@ HHHH *;2FFG
MO0 UC4+'/'>I&/6DB7<^X]!0!*B[% _.GT44 !Z5R/BO6&3_ (E]NY!(S(X/
M0>E=5/)Y,#R'^%2:\LGF:YN99WY:1R3[5U8:FI2N^AC6G961&  ..E+4<LL4
M"%Y9%1?4U3_MNQ#8WL??'%>JH-[(XN9(OT5'!<PW2;H)0X[XZBI:&NX%W2M3
METF[$T8_=L<2)GJ/6O2()DGA26,Y1P"#7ED<4D\@CC7+'\A[UL_V[-IU@EA9
M2ARGWICV/H*X<11YW>.YTTYVW.\>1(QEW51[G%1+>6S'"SQD_P"\*\QEN;BX
M8M/<22,?[S5&.,X8Y]C4+!NVK&Z^NAZQN!&001ZUSFK>*8;.1H+1?.F'5OX5
M_P :Y2WU*\M04CG=HB,-&QR"*<\$%U&TMGN64<R6Y[#V]:(X7E?O@ZMUH6)_
M$6J7#9\_RQZ(*ACUO4X_NWCGZ\U0&#2UV>SAT1AS2[G36'C"6,A+^+>G_/1.
MH_"NMM;F&[MUF@<.C#((KRRM#1M6DTF\#Y9H&XD3^HKFK89-7B;0JO9GI5,D
M7>I'Y4D4BRQK(ARK#(-/'(KSNIU%93SSU%3*>*BD7;)GL:<IX% $N<TZFBE'
M2@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S&X\1Q^]N?YUI&LV3CQ)
M!_U[M_.@#3HH%% !1110 4444 (:8>E.]:8>E $;GBI85Q&/>H&ZX%6AP *
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M>)+8^L##]:U*R[GCQ!9GUC84 :8I:0>M+0 4444 %%%% #3WIC=*D/>HFZ4
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MMR&0Y!H EHHHH **** "H9UX#>E34UAN!'K0!"AZ5*.E0)UQ4RT /%+2"EH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0TM)WH
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M6JPQ7=C):6BOF660C@#L/>O>R1GJ ?K6'XF\467AJR66Z8F28[8HUZD^OTH
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MX:Y)[>[^VJC!OM3G<"3R37A8W-50DH4ES/J=^'P3JKFD['I'6G"N>T36_/\
M]#N_DN$X!/\ %70KTKU,/B(5X<\#DJ4Y4Y<LA:***ZC,**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *3O2TAH 8W2H
M9!P:G;I4+CWH G0Y0?2G5%"?DQW%2T %%%(30!6U"^MM-LI;R[E$4$2Y9C7C
M?B+XG:IJ<[Q:4QLK0'Y7 ^=O\*M?%C6I;C5X='CD(@@7?(H/WF/3->>T 3O?
M7TCL[W]T78Y)\YJ2YO+N]$8N[F2?RAA/,;.T5#10!I6^MSPVD=K/:VM[!$28
MUN%Y7\1S46HZM>:JR"X=5AC_ -5!&NU(_H*I44 &,\$<>E>E?"CQ#]GEN='N
MIE2#'F0%SC![BO-:0C/<@^QQ0!]2I(CKN1@P]0<TH.:^;-*\1:OHDZ2V-[(H
M4_ZMVRK#T(KW+PEXKM?%&F^='B.YBP)X2>5/J/:@#HJ*3/-+0 4444 %%%%
M!110: *\O^M_"G+S49.Z0GWJ5* , >')3X\EU]ID:VDL!:& KDYW9S]*YOP_
M\+4T:^\2QO=B32]6C\N&$9W0J23C/U->AR3Q0+NFE2-2< NP _6E,\0&?,3&
M-V=PZ>M 'GNB>$?%&D265GYFA2V5JX_TDV?[]XQT'LWO45WX%\26IUG3=$U2
MUBT?5Y6DD\Y"9("_W]OKFO17N;>-%>2>-%;[K,X /TI9)XHDWRRI&G]YF 'Y
MT >>ZE\/]0MM2T:]T.:RF_L^R%EY&H1[TQ_? [-4-M\-]57PS+I]SJ5JUW+J
MZ:BTD<15  <E0.U=[J.L66F:/<ZK-*K6MNA=W1@>!Z56F\0PC3;*^M+>2\CN
MF0 0D$H&[GGM0!1O/#$UUXZLM>^T(+>"RDM7BQ\S%NX-<Y!X$\01>&-8\,MJ
M-F^FW(<VLIC/F(6;.&]17HLEQ#"RK++&A;[H9@,_2E>6./[[JO?YF H \K\2
M6B>%=7T34(O$,.FZG'8"TF:>W:2&>-?IT.>E9_A/P=>^)_!.JO=SF*XNM6-_
M97,L6 S+T8H?X3Z5Z^T=K>1JS)!<)V) <5.JA0 H  Z #I0!Q6BZ#XFCOI'U
M+^PX;<V[QD65KM=W(P&SV'M59_ %ZWPSB\+&^B^T)*KF?8=I ?=TKO\ '-+0
M R-"D2*>2J@5%<B4P2K"0)"IVD^M6*0BIDN9- M#G='T!X)C=Z@1)<$\#J!5
M.Z'_ !6<//'%=;CBN2NO^1VA'L*\+&8>%"G",%]I'H4*DJDI.79E_6M"^V-]
MIM<)=+SZ9K6TY+B.QB6Z(,P'S$5/@TX=*]6GAJ=.HZD=&SDE5E**B^@M%%%=
M1D%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %!HHH 8>E1N.M2GI3&'6@!D)Q(1ZU.*K'A@?2K(((!]: %I#UI::>M
M 'SYX\#_ /"<:CO)SD8SZ5SU=3\1;NTN_&=RUJ#NC CE;/5A7+4 %%%% !11
M10 4444 %;/A'59-%\46=S&Q5'812C/#*?6L:I;5&DOK5$.&,R8/XT ?4"X(
MR.AY%+4<(*PQ@]0@S^524 %%%% !1110 4UVVH33J@F;)"_G0 Q/YU,M1H.E
M2CTH \HU2WT_7_BOJ6F^+9@FGVMDC:?;RR^7&^?O/UY855N]!TC5OB+H>APW
MMP^CKI,AC6*Y/[P ]V'45Z?JOAS1]=\LZIIUO=-'PC2+DK[9J6VT33+.6"6V
ML+>*2WC\J)D0 HG]T>U 'C>M:6U[X^O]$G2P:QT^QCCL+74;MHE52#F1,=3Z
MU9O_ /0? WAW0=8DL=;NKJ\9+:X>Z(MD"YQN?O@<8KU75O#6C:ZR-JFFV]TZ
M<*[K\P'IFFS^%M"N=)CTJ72K9K",[D@V#:I]1Z&@#Q:QM<Z/\0]#DDMYK.WM
MEGC@M)"T43XS\IK:N;71]-\ ^&7T29%%QJ%F;AHIMV6.,@\\?2O4K#PYHVEQ
M2QV.F6T"2KLD"(!O7T/K4=KX5T&RA:&VTJUCB,HF**G&\=&QZT >97%MHVO>
M*O&;>++@I<:><6*R3&,10[<AT&>3GO5"U@?Q//\ #ZUUJ>Y99[:8N#(4:90?
MEW?A7KNI^%M#UJZ2ZU+2[:YG3@.Z9./0^HJX=+L6N;>X-G"9K92L#[1F,>@]
M* .'^'MM#I'B;Q7H5DS+I]I<1M#"S%O+W+D@9[9KT0=*K0V%K;W,]S#;QQSW
M!!ED5<%R.F?6K- !1110 4444 %<O<6EPWBV&58F,8&2W:NHII6N7$8=5TDW
ML[FM.JZ=[=0%**0#\Z45TF0M%%%, HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0BFMTIYZ4TT 0L*6%L$H?P
MI6%1L"#D=10!:J*X8K;RL.H0D?E3HW#KGOWI64,"#R",$>M 'R]/(TUY<3."
M'DE9F!/.<TRM7Q-IDFD>)K^T>(QIYI>+T*'TK*H **** "BBB@ HHHH *[#X
M<>'I-9\0)>O&3969W%^Q?L/>N;T>Q_M37+"PP2L\P1L>G>OH[3=-M-)LTM+&
M!(8$Z*H[^M %L"EHHH **** "BBD)H &8*I-5A\S9-.D;>VT'@4(* 'J*>*0
M"G"@!1THHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3J "BBB@ HHI* %J&63^%3]3222Y^5/SIBK0 JKQ4JBD48%/ H !TIPI!2T
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %-Q3J0B@!A&:85XJ:FD9H @P5.0<5(DP/#<&@K3&3/:@"R#Q154%
MT/RFI!./XA^5 $U%-5T/0BG9H **** "BBD) [B@!:*B,J#W^E,,KMP.* )G
M=5')J!I&?V%(%)Z]:>JT -5:D"TH'%.Q0  4HH%+0 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!2$4M% #< TTBGFC&: (BHII2IB*3% $!3TH ([FIL4F* (LO_>-&Z3^\:DP
M*,4 1_.>I-&TD<D_C4N* !0!&$]J<%J3;S1B@!H6G8I0*7O0 @%.Q110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
G 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>forms-1_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 forms-1_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &S D # 2(  A$! Q$!_\0
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MTHP/2EHH 3 ]*,#TI:* $P/2C ]*6B@!,#THP/2EHH 3 ]*,#TI:* $P/2C
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M% [,M4E58=2LKF3RX+N&5\9VHX)I)=4L8)#'+>0(XZJT@!%%PLRY25 EY;O
M9TGC:$=9 PVC\:A36--=@J7UNQ8X $@YH"S+U%5I[ZUM2HN+B*(MT#L!FN;T
MSQ5)J&NBR1K=X_-=28VR0!T- 69UE+5%M7TY&*M?VP*G!!D'%3/>6\< N'GC
M6$])"WR_G0%F6*2JD6J6$\@CBO('<]%5P2:6;4K.VD\N>[AB?KM=P#0%F6Z*
MKPWEM<1M)#/'(B]61@0*@&LZ:3C[?;9_ZZ"BX69>HJ":]MK9%>>XBB5ONEV
M!ID&HV=U)L@NH96QG:C@F@+,MT52DU6PAD,<E[;HZ]5:0 BI5O+9K<W"SQF
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MB_W11L7^Z*=10 W8O]T4;%_NBG44 -V+_=%&Q?[HIU% #=B_W11L7^Z*=10
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>OK1O7UIV!1B@8W>OK1O7UIV*,"@!N]?6C>OK3L48^E #=Z^M&]?6G8HQ]*
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MZ9+V)T^\N3T->@U<][DPV%HHHJ"PHHHH **** "BBB@ HHHH **** "BBB@
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MD$@,C$-@>]>CTI)+8J+;W'4445)04444 %%%% !1110 4444 %%%% !1110
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M0BF[S_=:@N?[IH XCQJ]Q9>)- U2.QN+J"V9_,$"[B,CBIO^%@+_ -"_J_\
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M'.CLQ1^-<9_;_C'_ *%9?^_XH_M_QC_T*R_]_P 4<C#G1V7XTHKC/[?\8_\
M0K+_ -_Q1_;_ (Q_Z%9?^_XHY&'.CL_QHS7&?V_XQ_Z%9?\ O^*/[?\ &/\
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M&7_N?K3Z* (\O_<_6C+_ -S]:DHH 9E_[GZT9?\ N?K3Z* &9?\ N?K29?\
MN_K4E% $>7_NC\Z7+_W/UI]% #,O_<_6C+_W/UI]% #,O_<_6C+_ -S]:CO+
MR"PMFN+F01Q)]YCVK+'BW12,B[_\<- &QE_[GZT9?^Y^M8__  EFC?\ /W_X
MX:/^$LT;_G[_ /'#0!L9?^Y^M&7_ +GZUC_\)9HW_/W_ ..&C_A+-&_Y^_\
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MI]>UV2&19$,J893D?=KI* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#"\6@'0R& (\U
M.#]:U([6V\I#]GB^Z/X!67XL_P"0(?\ KJG\ZDUB\U6SL(7TFP2\E. R,^W
M]:!,TOLEM_S[Q?\ ? H^R6W_ #[Q?]\"N2_MWQI_T+,'_@11_;OC3_H68/\
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M97=W)=B?85UNF:M;ZO:_:;42B/./WL90_D: )GM+8(W^CQ=#_ *R/"*A='8
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MS'5=QVKDXR?2@"3%&*A@N8KD.87#A&*MCL1VJ7F@ P*6DYI: "BBB@ HHHH
M*,444 &!1110 4444 %%%% !1110 444F: %HI,BC- "T49HR* "BDR*,B@!
M:*3(HR* %HHS10 449I,B@!:*3-+0 4444 %%%% !1110 4444 %%%% !111
M0 5A^,0#X/U8,/E-LX/Y5N5!>VD-_9RVEPF^&92CKZ@TF!Y%:;H_!+^# QW.
M@*#/_+N5R3^=:7AZ6^U"TL-&M=1;3K:STY90R $R'.!U["N['AO2Q?)>BV'V
MA+;[*'SSY>,8JM<^#M%N;>V@:V9%MT\N-HW*G9_=)'44P..LM7UKQ%>65O\
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MO8$+&G]YCT%8GBCQ=)X=T^SQ )[^=T#1KT12<%C[5+XYA=M)M;D*62TNXYY
M.Z@\US_B[PIJ^H17NHZ;J'FF\>$K$5R50$' /IWI(#L#K#0^(+?3IHP([J'S
M(7]6'4&M@9[UQNHP37'BCPW:;]\]JC2SN!T &.?K79"F M(>E+2'I0!S6E^*
M)=3\6WND?8GA@MX1(LLG!D)..!Z5TPZ5S<5C<KX_N+XQ'[,UBL8?L6#'BND'
M2@ I#2TAZB@#E+_Q>;=-1E@A$D=M*EK'S_K)F[?2FV_B+58FU"QOK>+^T;6
M7"",_+(G<?45A+I5U/I&L:=$@:]L]3%XJ'_EH =PK2MFN;C4M4\27UH]G;K9
M^3'')]YCCG/X\4 ==IM_%J>G6]["?DF0,!Z>U6ZY[P5:2V?A2RCF!#L#)@]@
MQR!^M=#0 5SWBSQ')X<TY;B&SDN9'<* O11GJ370UA>+K2>^\-75O;1EY7QM
M4=^10!KVTIFMHI3P70-^8J:J]FC1V,",,,L:@CWQ5B@ K)UO5CIB6T<2"2YN
M91%$A[GUK6KE/%*-!K>A:@^?(AN-LGHN>AI 5+CQ=J*375Y#:QMI=G,(9F)^
M=C_$1["MVRUKS]:FTZ10K>6LT+#^-#_6N1NM.U:&'4M AL7DCOKGS8[H'Y%1
MCDY]ZU[>W,GCZV$)W1V%CY4C#H2> *8'84444 4=7U*/2=+N+Z0%EA7=M'<]
MA6%I'B'4GU2ULM6MXH_MT1FMVC/0=<'WQ6KXDTZ35=!N[.(@2.GR9]17.Z1!
MJ.J:[I=S<V,EI%IEN8V+_P ;D8X]J0'<44@Z4M,!K, "2< <FN1G\77+VRM9
M6Z-)<W1M[3<>&QP6/M7574;36LT:G#.A /X5YU96EU_8&F3VUNTUSI-X_G0#
M[S GG'X4D!N1>*;V*POC=6R?:].E5;E4/!0_Q"NJ@F2XACFC.4=0RGU!K@I8
MKA-'\1:M>6[0-J6(X8&^]CH,^_-=EHEM)9Z'8V\O^LC@56^N*8&A24M(: .0
MU/Q/J27U\-.M8I+73@#<LYY;UVUT]A=I?V,%W']V9 X]LUQ.IVFJ:??:Q;6U
M@]S'JF/+E7HA/!W5V.D6;:?I-I:.<M%$%8CUI("]1113 **** "BBB@ HHHH
M **** "BBB@"GJM^NEZ5=W[J76WB:0J.^!FN6@\;W:VMA?:AH[VVGWCHJS[\
M[-_W<BMSQ6CR>$]62-"[M:R!5 Y)VFN:\.^#GNM"T9M4U"ZFAA2.46C\*&'(
M!^E %@>-M0F749[70I)K2QF>)Y!)@MMZD"I#XVGO=2AL]&TQKSS+-+O>7V@*
MW 'UXK$\.>&+W4X=;$^H7EG!/?RAH4X#*3V^M3?\(Y<?\+"D@L+BXL+2WTN*
M)'B'#8)XH V(?&K75D/L^F3/J/V@VSVN?N.!DY/I3)?'+"RB,6G.]^U[]A>V
M+8V28SU]*IZM*O@32(K73HIKF^U"<EKIUW;6/5V^G:LJYTJVN]+T*#3Y;J7=
MJRR7=UM*N7P<M]*0'6Z?XGFDUU-'U/3VL[F6(RPG?N#@=:GT?Q3::WK>HZ=:
MQR?Z$%W2,,!B?2N>TK3)M \?M%>^??0WD)^R7DOS&'^]&?K6II]FZ^.];(B:
M*%[2)5=1@9YSCWH Z2.[@ENIK9) TT./,7NN>E6*X?1?!DVG^+-0U"2_NFA<
MQF/<^=^!SNKN*8"=JX^^\7:II^J6EG-H;'[5/Y,163)(_O8],5V!KDK&WFU#
MXA:C?7$3B&QA6"VW#C<>68?RI =:*6D%+3 9)&DL;1R*&1AA@>XK+CU2WBU4
MZ3#'A;>#S)&'2,=A6O7(^'E\OQAXEAG'[R25)$SWCV@?SH M:/XMM]<.JBQ@
ME(L&V_,,>8<9XK1TJYM-5MX]5@0>9(FQF[K@\J?H:Q?#D#VWBKQ([Q>5"7C*
M$C"D!><4O@%7&C7<ASY4E],\0_V=W6@#K**** ,#Q-XC'A^&TVP">>ZF$4:%
MMOXFK^D7EQJ%@EQ<VX@=CPH;<,>N:Q/%IL8[O39M3TQ[JU1SF5 3Y+=B1Z4W
MP';W$-A?.R2164MTSV<4OWEC_P ,T@.MH/2BBF!GZS?6NGZ5/<7:AX0N"A_B
MSVK!N_%ATZ5K:VTN25+.%9+LJ<>0I&<>YQ3_ !VK?V792D$PQ7L3S8_N \UC
M:G</I.K>(XY+::7^U85-HT:Y#G;MV^U) =1::M8SZS$B1 27EL)H9O\ GHO<
M?A6V*X!;&>UU'P?8#BZMXF:7'\*XY!KOQ3 6F2.(XV<@D*"<"GU'.SI#(T:[
MW"DJOJ?2@#FK#Q:\^J6UI=Z;+:)>%A;,QR6V]<CM74BO-?/;6/%VD:C96=U#
MJ,<A2\CE!V1Q]#^)KTF@0M(:6D/44AG-7OB/3["XU&Y%N7:UVPO(O620]$%1
M)XD%Y:W]OJ&F/'=6L:S26K'.Z,\Y'TKF39W,OA_5HTB:2[L]76YE0?>90<\?
MA6K:7*ZKK^JZXL3QV$=AY6Z5=N\XR1^% ':6=S#>6<-Q;G,4B!DQZ58KG/ T
M4L7A"R$V02"R@_W221^E='3 *PM<UVXTN5([;3I+H[#)(P.U44=>?6MPUR?B
MZ^@"/INHVER;*XB)$\&<[_[O%)@;^E:E#J^F07T 81S+N ;J*O5S_@N&[M_"
MMI%>(4=<A%(P0F?ES[XKH*8!65KM]:V=FBW$(G,TBQQQ?WF-:M<GXG#)XA\/
M7#_\>Z7!#$] Q'%(!+CQFMO=RA+&1]/MY%AGN@>$8^WM6K87UI)JUW:1PB*X
M $I;_GHIZ-7$7/VBUL=7\.FTF:[N[PO"RKE65CG.?:MZ&%U\?6,:'/V;3]DY
M'3/09I@=C1110 R1UC5G8X51DFL30?%%KXAO+Z"UCD"VCA"[C&X^U;C '@C(
MKE_#]N\/BO76\DQQ,R;#C /':EU$=4!BBBBF,0URLOB>TM8I[BSLFDEFN?(B
M5#CSW]?PKI+M7:TF6/[Y0A?KBO-K5)(?#VB7XA>0:?>R?:4499<MR<4@.E_X
M26VNM/EFOK!EELIPEQ"W/E$]&]Q74HZNBNIRK#(/K7GA)N--\4ZN\3QVUZ D
M D&"V!@''U-=GH$<L.@:?'-GS5@0-GUQ3 TJ*** ,#7/%=GHE_9V,B223W4@
M10HX7W)K>%<MXSMFE736A@WN+M2Q5<D"NI6CH M%%% !1110 4444 %%%% !
M1110 4444 (0".10!@<#%+10 @ '0 48&<X&?6EHH :T:/\ >56^HS2+$B#"
MHH'L*?10 TJ"02!FEP,YQS2T4 %%%% !28 ["EHH **** "JATZW.I+?[,7"
MIY>X'JOH:MT4 0SP)/!)"X^612K8XX-):VL5E:QVT"!(HU"JHJ>B@ HHHH 1
ME### $>A%      QZ4M% !1110!!=VL-[;26\Z!XI!M93W%+%;QPPQQ*N5C
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> #-&:** #-&:** #-&:** #-&:** #-'>BB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>forms-1_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 forms-1_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "? G # 2(  A$! Q$!_\0
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MF_O#\J/M<W]X?E0!I45F_:YO[P_*C[7-_>'Y4 :5%9OVN;^\/RH^US?WA^5
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M_/Q=_P#?XT 5Z*L?V-#_ ,_%W_W^-']C0_\ /Q=_]_C0!7HJQ_8T/_/Q=_\
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M+>'YU$D9##N&V!\GU/%/N_#?B*._@6QDVVL=X9D<7)#JF].'S]X%0W'7)ZT
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M$>U:XKS!)'CD5T8JZG*L.QKMM#UH:C'Y,HVW*#)]&'K7T^49O]8_=5OC_/\
MX)Y&.P/LO?A\/Y%V?_D+VG_7.3_V6KM4IO\ D+VG_7.3_P!EJ[7TAY04444
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M5]+E64QPBYZFL_R]#R<9C77?+'X?S*4W_(7M/^N<G_LM7JI3?\A>T_ZYR?\
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M#D9IPK4ZGP.XI0E'=%3.I_W+/_OIO\*,ZG_<L_\ OIO\*NT5J24LZG_<L_\
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M$T+9$DG:$I+U/\3$'\*%A*'*HV#VU2[9UQT&!D ^T2Y;(D;(_>9.2#6L-J@
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M*6WG_P  \G,,9#E=*&MR:U_X](?]Q?Y5-4-K_P >D/\ N+_*IJ^U/ "BBB@
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MU@LMQLO)%,T8Y,:%T<*HWAB,C[@XZ5/=^"K#4;=X[F[ED,SRR,Z[1N9U4$C
M[;0<5G1^!+I$9WNTFNF#1O.9'1WC, CV[AG'S#/_ ->H;7P/JT7V3S+FS#1;
M=LB%@UL%<L0@  8L" Q('3I0!L0^"[*.VG@>Y)>XMS;NT<:)D%RY( '7FJUE
MX/TU-=N9AJDMQ=1RQRNC!2R .74,<9/.1SV%4G\ 7,<NF&WN51+>!$EV3.I6
M4'+2J<'<3T(..@[5H>&/#>IZ#//(1IX\_P E)?+9R75 P:0Y'WV)!]* )(O
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M3?\ 0.NO_'?\:O44 4?[0F_Z!UU_X[_C1_:$W_0.NO\ QW_&KU% %'^T)O\
MH'77_CO^-']H3?\ 0.NO_'?\:O44 4?[0F_Z!UU_X[_C4]M.\X8O;R0X/ DQ
MS^1J>B@!.U8LVFWCC4(D,/E73%@Q)R#@?X5M5CRQZL=?C>.2(680Y!!]1UY^
M]Z5E4H1K*TG:W^5@]LZ6RO<-/TJ>V5_,N6CS('VQ'KQW)'-1-I-S(MXH\A!-
M*LJ!2<9!'!^N*AU:TN)-;66:UN;JT\D+$L$FWRY,\D\C\ZH06_B&SMYUMA)\
MZRLJ/@A&W\8/J5)HCEU%P44_Q[F,\?4C-WBW_P  OOH-RR'#P[I0P<'.$RV<
MK70K\J@>@Q7)'_A)'MEV27 94=AE%!8[AM!S[9I;@^)(U*(9W"R2!'55W,>-
MF[_9ZUI1P%.BWR-:^9$\PE->]!_<=;D<49KCGT[5Y+MU9[H'[8LHD!!55V=5
M_'C%2QR>)3<69E$@7RUWX0$$\[MWIVYKI]BNDD8K%OK!G69I<UQ\_P#PDL=C
M:F-KA[AP7DP%PASPI'ICO2)=:W<7-Z8KB5(HFE4NRKL7 !7'<G/7VH]AI\2&
M\8D[<C.QI:R?#\]Y=Z6MY>'#W!\Q(\?<7L/Z_C6M6,ERMHZZ<^>*DNI3U)KE
M+"62UC@>9!N59R0G'/8$UR:>,%CL+:[UC3X&:>WCND2W!?:'.U=S, !CN3Q7
M7:E=V]AIMS=W9/V>*-FDP,DC'0#U-<Q=MX;:YM-)O-/F@E:P#*J[@(HERPB+
M*>N QV]\&I++(\6Z5<WLME):2D^9%&=Z*0[.0%XSDCD?-T]#1%XRTB35+;3X
M;><RR,$)6+B([F1<_7:>>PQ6"]UX:FT>351X;OI;-TCC5XRIVQDKL* /\G(7
M@8(.,U>TV30CK$5K8Z%=Q75@@5@KA?+;!<*XWY;[QY((RW6@"Y>ZS]@\1Q:?
M)IUI;62NABGG1E$K,"3Y;!=@8'C#$$TRR\;Z3*2+:PN1*\[(ZQQ+V3>7)!P5
MVG.<FK]KINB>(1!K9M#(TRAMLK-@,/E^9,[=PY'2K-AX8T;3&5K2Q1&4DJS,
MS$97;W)XV\8]* ,@^*M+CM 6T:Y2WG0W)'D)@P#'[XC/3YAQU]J)/&FFM.T3
MZ7>M"KY\XPJ4*K((R_7. Q';/>M$>#M!"1I]@4I&^Y5,C$#I\O7[O ^7IQTJ
MV= THJRFRBPRLI'/(9PY'XL : *^C^);/6=1O;*!9%FM,%BV"KJ20"I!(/*F
MMJLS3/#^F://--86HADF&'(8GC).!D\#+$X'K6G0!GW7_(7M/^N<O]*XS3+:
M"ZOY$N2PB5'<E3@\5VEU_P A>T_ZYR_TK@5EDAE=HW*DY4X[@]:^6S^<(3HR
MFKI7T/7RV,I1J*+L]#:.AP1-'YC,Z^6\K;#]\#[N/P-5[.+3KN5E^RSIB)I.
M9?3L.*H+?72F+;.X\D8CY^Z/2E:_NGF,K3-YA4IG_9/:O!>+PETXT[>5DST5
MAZ]FI2_$T8-.LY[>$A)5>X61T._(CV] ?6D_LZTELXWMU,C@()2).4)./NXK
M.CO;J&W:".9EB;.5'OUI6U"\>%8FG?8N, <=.E-8O!\NM/IV!X?$7TGU[FU)
MHEF9HQ&7V!W5]K[L[1G!]#4"Z;9/Y<H# 2PB1(&DVDG.#\U9KZE>R.CM</N0
M[E(XP?6C^TKSSS/YY\PKMR0.![>E:/&X&]U3_#_@D+#XFVLS:CT.S6XFCD9B
M!,(TW/MXQG ]35&"QM9[2Z&R19X58\O\Q(/]WTJE%J%Y#N\NX<;VW'/.3Z\]
MZ/[0O#;F#SV\HC!'J/K4O&8)VM3[]/N*6'Q&OO\ 8OWVFVT%K<>4)!+;%-SE
MLA]P].U8]6);ZZGA6&69FB7&%/MTJO7G8RK2J33I1LK'7AX5(1:J.["BBBN(
MZ KH=)U>9[.>PF#2#R7V/UVC!X/M6):VLU[<+! NYV_(#U-=I#I<.F:/<HGS
M2-$V]\<L<']*^ER'#XB5;VL':*W\_(\C,JM)0Y)*[_(T[7_CTA_ZYK_*I:BM
M?^/2'_<7^52U]Z?.!1110 4444 4I_\ D+VG_7.3_P!EJ[5*?_D+VG_7.3_V
M6KM !1110 4444 4C_R&U_Z]C_Z$*YJX\/:RJ:K8VALA!?3R7"WC.PFC+#[N
M .?3<#PI]JZ4_P#(;7_KV/\ Z$*Y#^R-6T^^U;6HHGDG;4 8XUCW2FWW)NVD
MM@@J&P,"@"%O U_<VS+-)##A9#;V\=Q(5MF9T(VG@GA6Y_VN*CE\'ZF-8CM[
M=56UCS)!<F=P+8&;<%0=VVY'/&#4]G9Z[>:]8:A=VMRBF9&?>0NU 9\;@#CH
MR?F*LZZGBE9;^>QGN1!]JCC2*.-"1!L!9TXR6W<=>F>* ,V3P!J<K"*6ZC>%
MK0P#$S*L1V,"NW;\RDL">1^E//@K66NC)%<I:YM1%"(;EMML?+V[ -N64GG.
M1U]A38K[Q;-?W,5K+=S75N@5UD@1+?F -GU\S>1QG'X5*UKXJU*RNK=;K4[>
MU^SW!@:18TGD;:NQ7./E^8OC&.* +]AX7O[;POK%A$+:RN+V8RQ1P2NR("%!
M4L<'G:<D>M9J>"=61(?*-I;#SGD6.*=\6A:16WIQ\S8!7G'7TS6CJ^F:CJ_A
MS0K>".9Y!.C7'V[((4(P)D"D$\XZ'TJE%IGB/19;N2TFOKU=QCV,R@3*+< 2
M G)#%P!0!6D\#:W) \?VF/R?M#2>2+E@[[EQO:3;R0>1QD>O2MWQ+X;U'5I=
M,:"Z8QVR%)(_/,9W';B0-@Y(VGMWK%M;CQKML=ZWDI$TB['B6/<F1L9VYX S
MP<$COFM[PB^N-9W9UQYVDRN%DAV%6V_.%(/S#/2@#&7P=JZSSL_V:XM6NC,;
M6:X?,^0W+2 9X+ @$'IUZ4D/@W73J=U<S7-HBR2QR!5=BA*2[@=N./EXZDFM
M?04U&#P7>Q107L5]&;G[.+KF0DLQC.23GJO6LN6R\6);W*FYO+M3NC6.58\,
MIA#;N .?,R/TH KV'@?5HIHKB[^QSO'=><L1F;:A,91G7CCDAMOMUJ0^"=:(
M>,WD)<P>6UR)I [#RE3RL= H(+9ZUHZ!%K4GBZ6YU*.]"I;RQ'S H@4F12@C
MQR?E&2361<Z=>7-_JL\6CZC;VS3Q"6U7/^EQ++F1\[N68=%&/E'OB@#;OM!O
M+'P=K>G62F1II7>TACD8%4)7Y<]1SNZ>M9L/@6]+?:&D@AF09MDCF<BU/G*^
MU6ZD8!_$GM4=GI]\NH:$D^F:A$UOF1KP9<B/>^R _-QA2-Q.>@'/4:W@6PN=
M.BO8)+69+<,@BGN8_+FF.#NW#<<XXP>,YH Q7\$Z_)%J1DF@+7,J2+&EPRQE
MU9SN*[<8(9<KSG'7I6GI7AK6],UJYU!YXKF5T.QC.RQG.WY"FTX"X.#D_J:[
M:B@ HHHH **** "BBB@ HHHH **** *]Q>6]J5$\@0MTX)J'^UK'_GX'_?)_
MPJ]10!1_M:Q_Y^!_WR?\*/[6L?\ GX'_ 'R?\*O44 4?[6L?^?@?]\G_  H_
MM:Q_Y^!_WR?\*O44 4?[6L?^?@?]\G_"C^UK#_GX'_?)_P *O44 4?[6L?\
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# __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>ex1-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex1-1_001.jpg
M_]C_X  02D9)1@ ! 0$       #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  V 2P# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBDR!GG
M/.?7&?Y#O29]SD8[>PSP.><\^A]*5_Z_K^M0'44A['\_IW//TQ]#D4F<YY(Q
MWQ]>?QX[8QTZT77]?U<!U%%(?YCCL?\ /ZCT-.X"T49_S_CZ=Z9DYY)QNP!P
M<Y/KZ=1@<BE>P#Z*0'/OC'I^?M].OM29]^>?3C/0D>W 'U]Z+V5V ZBD!!Y!
MX^O&>!Q]"/S)'7. GOVXY&/\X]3Z47 6BFJ>W/U)YSU(/3D=O4<TI]CCM^)X
M_3T]>N*+_C_6H"T4T'KST)X[^P[=3T_+KFE'USU'U/?C\*+_ -?UW &. ?Z\
MC\:_(S_@K1_P53\#?\$SOA'H=Y:Z)8_$7]H+XJ_VS8_!SX7W5S-::5'#HT,$
M>N_$CX@7EI)%=V?P_P#"EW?Z19RZ;IL\/B/QGKNKV'A_09-.LD\3>+/"7ZY-
M]T\9XQ^=?PN_\% ?"'A/]JW_ (. OBKX"_:1U-)_V>_V6/A!X.\6>)]#DU-]
M*CUOX3?#?]GGPG\?-2\"?VC>7L5GIQ\<_$_XJW>CW[PRZ<-1TW6)=*M9;76[
MZVU-?MN <DRS.<\KSSN-:KD^293CL^S'"X9M8C'TL"\-3H8"BXN,E+%XW%X.
MA+EG3DZ=2<54AS2G3^*X\SG,LGR6E')W2IYKF^8X/)<#BJ_+[# U<:L1.MCJ
MW/>+CA,)A,56BG&2]I&#<9<JA/X U/3_ /@LM_P5M34OBGK>K_$_QI\)-3U0
M:7!?:_X_\/?L^_LO:6VIZG%H=AHO@OPMXC\4^#?"?BN*;5[BS\+6USH&E>/_
M !7JNL&#1=:UK6-;1\]7^SI_P2C_ ."H'A_Q[\*/$'P*\;7%A\(?'/Q1\)^$
M?$_[2/['/[6?@_Q'X4\%Z7?^(].TOQ1XCN[[X9_$+3-=U.]\*Z8]Y<FWL] U
M8)J=MI^F78234;&.X]?_ &T/V\M*\):[X3/Q)\,7'Q+^*RV7A'QK\//@)X>U
MOQ#\+/@)^RW\-3XK\*?%?X4>#=3TQ/"'@KXAZSK-OJOPX^#/C/PMX=T3P+^R
M_J>L?#[X=_ #XB>/O#/A'Q]KOQK\._'3Z/\ V#_^#E>/X-67PP^!'Q[_ &7_
M (:>!/V=/!NB>'?A]X=\0_LW1>*]+NOA)X/T*RAT;2KRZ^&GB?5_&4_CS1M+
ML8[6;6UT'Q/H?BH6=MJ.HZ7H_C#7;J#1KK]^GC_$.MP[5K\,<&\.4,CJ4ZZI
M9-1R[!-?4UAZT%B,/'$UH8C-<51:4J=;^SHTJ]7#SEAZ6,I^QJ5_P6CA. H<
M04:'$G%6?3SJ-6E*>;ULRQ5Y8IUJ4_95WAJ<J.586OS27U=XR=:C2JTO:5,)
M-U(4O[=]'LCINFV-@US=7ILK.SLS>WT\EU>WAM;:* W5Y<S,\UQ=W!C,US<3
M.\LTSO)(S.S$Z=<]X4\2>'_&/AO0O%WA/6]+\3>%O%.C:3XC\->)-#O;;4]$
M\0>']=T^VU31-;T;4K*2:TU'2M5TRZM;[3[ZUEEM[NTGAN(9&CD#'H?_ -?X
M=_\ /:OY,M)74DU).2DFN5J2E)23C:/*U)24H\JY9)QLN6R_JV#BXQ<6G%J+
MBT^9.+2<6I7ES)Q<7&7-+FBU*[4DV44GOV_3MS_GWI-Q]#]X@'CMG]#CTX'?
M-*_]77]?+<=QU%'^?\FDSR1_GZ]<]\>F0:+H8M%)[=\ _P">OI_]>@G@D=@?
M3VS^(_Q%%]+@+13%R>YX..W0<@]^O?USP<4XYQQQ[GM_//I0G<5Q:*0?_KZ>
MGM_]:@GKU[>F?H!_CU)XH;MO^@Q:*3/7J>_'MCC\?3ZTN0/\_K]/>B]U< HI
M.X]L_P"3_3^O.$)Q@#))''/7UZ^GZYHO_6P#J*3(ZY[#\.^?;-+3W ^:_P!K
M;_A<T?P#\7W'P$T/5_%?Q$L]8^'6HMX1\,^)=%\&>,/&7P\T_P")G@V^^-'@
MSP+XO\17.FZ/X6^(/B_X,V_C[PU\/]?N]<\+'2/&>J:%>VOC/P7>06_BS1OF
M+]BCXQ?"_P")?Q)^+-KX+U7]K'X:>+=(\$_#J]^(7[(W[8.F?%"S\=?#6^O-
M:\>)I?Q6\'7?Q6\1^-)=0T#Q^L6H^#_$5W\+_'_C/X3:AJ?P]T75=(ETG7;_
M %C4O&/VM\:/AKJ?Q1\%IH/A[XA^+OA1XLTOQ)X9\7>$OB%X)71+K6= UWPM
MK%KJRVMWI/B73-7T+Q!X3\5Z=#J/@KQ]X<O[..77O GB3Q'IFD:SX:UZYTKQ
M-H_*^ /@GJ6F>/[KXR?$WQE;?$'XL3^!XOAO8ZCHWA.#P-X)\'^$&UQ?$FNZ
M5X#\*3ZWXS\0Z1_PF^M6?AW4_&]WXA\?^+KK6+OPAX6CT^31M,TB'33WT\1A
MEE^(P]2GS5ZCG*C5A.I"IS.6'<:=>G.C4PN(H2A3J.G4A5PV+P<U-4YU(8B4
M#RZ^'Q4LQP^(I2_=0455A4Y)0=/EKISHSC5IUL/6C.I!2INEB,-C(<KJJG/#
MTF5OVN[C4K3]E?\ :.U+1M:U_P -ZQHOP,^*GB'1-?\ "NOZQX6\1Z+KOA[P
M/KFMZ+JNCZ]H%]I^JZ==V.J6%G<H]M>1).D3VMVEQ93W-O-\5?LB6OQ?N/B%
M^S]XG\'>,?COXA^"OBW]DPZU^TO:?';6_B7XI\,S_'V\L/@Y=_"_Q3\%?$?Q
MIAU+QJ^JZYIMQ\6T\;Z7\-O%-Q\!WT*ST35Y-#L?'&H6.IZU^A_QN^'$_P 7
MOA!\3/A1;^([CP@/B7X&\2> ;SQ/8Z99:QJ&AZ3XMTJZT#6+_2]-U*5--FU>
M+2-0OAI$NIQWNFV>IFTO=0TO5[2WFTN[;\%?AU>_"?X3_#WX8:AXED\92?#S
MPGHG@JT\57&D66A7^M:1X8L8=%T"[U33-.GGTR'6ET&RTV#6KG3%L--U+5H;
MS4]/T?0K.[AT:PFGB*=++ZE&U.=:KBJMZ<Z7-;#U<OC1]JJCIM7IUX<]*"JP
M<*UJ]M+3*V$J5LRIUG[6%&GA*352%;EYJ]+'RK.BZ:J*7+4H2<:LW2FITFZ%
MU=.'H.J:IIND:7J&K:OJ%EI.DZ597.I:KJ>I7,%EINEZ?80/=W^H:A?74D5M
M9V5E;1RW-W=7$D4%O;Q22RR)&CL/R"_8U_;,U7XD?M<^./!?B;XG6/BWP?\
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M3^'_ !+\8/%GCCQEIMCJD26LU[HH\22:'%>VHO-.TVQN;W4I+WD?VK?CA9?
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MP'X#\::)XOT8Z3XLTCQ7X T.#P'XD74;2Z@2ZLGU/4?#UQJB(GEP7-K?6]U
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M2M^67_!4KP'J?A#]F?\ :8_:8\+_ !:_:$\)?$GP3\-]%G\ IX#_ &@_C/\
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M3*]"HKCLNVQZ!Y[O^*W_ #Z?#WIC_D(>).G_ (+*/,^*W_/I\/?_  8>)/\
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MH_Y<_AY_X,/$A_\ <77"Z!^T=\.?$M_X(33)?$)\._$_4'T[X6^/)_"VM1^
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DW*+35U&;BVG'F2CS)N*;],&<<G)I:**:V-@HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>ex1-1_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex1-1_002.jpg
M_]C_X  02D9)1@ ! 0$       #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  J R # 2(  A$! Q$!_\0
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M$FF^$=.^"VI_#K4[:Q\2Z7\2K[7M:T>&U\/:G9V8ET?5+#Q:+L>#[RWU]YO
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MX8MGU+2?$NM3:=#JNB3IX66?Q++>V=AX>UFU%S'I5K7U;\._^"A'[,OQ1?\
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MMM;ZA9/-INL6$@@U&PN+:>2"SN6N+*W\X_X*0_$3Q9\*_@CX&\7:+I_C?6O
M4'Q^^%.F?';PC\)M;O-%^-7C;X-:QJ&KZ=JWA?X.#1M0TKQ5K_C"]\6W'@J_
MU;P9X,O[/QKXW^'MGXU\*>%KC[?JD!/V3\*/A/\ #;X%?#WPS\*?A!X'\-_#
MGX=>#; Z;X6\&>$]-@TK0]'LY;F:]N8[6TM@5,]U?W=U?7]W,\UWJ-_<75_>
MSSW5S-(WSU^U=\(_BIXRUS]GCXP?!VUT#Q-XX_9L^+6K_$6#X8^+M?E\+>'_
M (F:!XP^&7CGX0>+-%@\5Q:9K*^$_&.B:!XYN_%/@76;[2+_ $F;6-+;PSJY
MTO3M=GUW28IO"O,'.G2]GA?:U'&G7EJH^_[.$YNZ4FN2*G;W)N%1)J&LUH8M
M95*DYJKC/9PC.="'*G->S564:<;1Y%:I+V4+1<%.C%VJ'PK^R=J'A[]M#X3?
MMG^#_P!G7]HGXM^ _@!XC^*?@KP'X ^T^+/&#_M&_ :]T/1/"C_M$>&K&'Q]
MK4OQ4^"L'CB6SU+3OAYH_C*ZAU?P;J&L>(?B#X8T<>%]0\/:3-Z#^SY^SO-X
M/_:%_:F\(?"C]H7]J7Q!X4\%_!+0O@YK/B/XW_'?Q]\>-,\,?M _$RQ;XB1Z
MCX4T;QGKAMM.\2_"WX=WGPUUR^>TNM.N-2A^)UEITD]J;:26;Z-_9[^!GC#3
M?VA/V@_VLO'_ ((T/X3^)_COX5^#/P\/PST7Q%8^*;Y=$^"TGCA[/Q_\1?$.
MBVMKH.K?$+Q-_P )RWA^&STA]:M/#_@OPCX8M9/$FJ7MY=Z;HV+_ ,$YOAC\
M7?AE\"/&O_"_O"<GA7XQ_$/]IS]J?XM>,[676-$US^T[;QU\</&E[\/=7M]0
MT*]U"U&GR?"B+P-IVE6D\R7]AIFG6EE=6EHT MH^NMBHJ&+>%K0Y$\'%492I
M59^V<Z3K.2Y>:K/!>PM&M&T:M2I[::=YI^5AL+.<L$L5AW[>+Q<U6ITZM.$:
M-&4W@XP@[NE3Q<:K]K0;?L805&E;E@X_./PA_96L/@E^V?\ !+P5\/OVF/VP
M?B7<?#3X.^-_B;\=K#XW?M,?$CXJ>%M7T/Q/I-U\*/A7IVL^!];O'\+VNO\
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M^4O;(RNTY).5]#SUZ#/7'%+L'J<_7KW_ "R3QGN>:^5?$'[</[(OA/PS\/\
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M?KWE>-+4WL'ASQ=;->:#JECI00ZKK<,]NDG]H1Z#9:G<Z%-#<6NNP:9=6\D
M^O?A[\2/!GQ7\&^&?B-\-?%/AWQW\/\ QIHMGXA\(^,O">K6FN>'?$6BWT8>
MVU'2]4L9);6ZMI1N&^-]T<R2VTR13P2I14I5*=G6HU:?*[*52E."4M+)-Q2Y
MG?1;M*5M(NRIXK"UO<HUZ-7X5RTJD)M*4VDVH2;4>9N\G91<E=KF2.V,2D$'
MG/7Z\G/KSGUSQUIC1HJMG<00>!G&<'=D_P!TX&><#G-8M]XGT?3;_2])OM5T
M>QU;7);V+0]+OM5L;/4=;?3;>.ZU%='L9YDN]4?3[:1+J^2RAD:U@=))@L9#
MML>:&A9W 52LC!6SDI@]5*@@D9W#!"Y(!? -9S335H-S7-./-&:2]YTY2YE'
M6]I*R<DU9NVA:=*HDTXRC-13LU[T6O:I;MK6TFFHOFON[CL1Y(5E&% ." =H
M^7.03DC."<#D]R::8XF.XX)ZABV0 >H/. 0.2!QCGM7YN^"?VM?'6B_\%&/B
M7^Q+\6KWP=J.@^(?@IX9^.'[.GBWPWX,UWPK>S3IXA\6V/Q*^#_C75+[Q5XE
MT/Q1XU\.^&;?PKXTT2_T*R\,3WWA:YUR_O-!C\A"VM=_M:>*O$'_  4B\,_L
M9^![?2;;P7X._9T\=_&SXR^*M6\,:OJEUK'C&R\2_#/P[X5^%/@;Q!'KNCZ)
MHFL>&=#^).B_$#XC75QI/BMX]%\6^!M&@CTJ?5[F^AZ)X"O3DU*G!IT(8Z,X
MN;I>RFDXR22O&2G!)M6<9))KF:OPK,L)*,9\TE+ZV\#*$HQYE5IR2E!N4F[*
M,O:\R5G2;FGRQ;7Z'JBG  P"?FP<[L9(]<@9)QTZ9)XIWEJ >O+!C@X]0?7C
M!Y!R,<<"O*=0^./P>T6X\9V.K?%CX7Z5=_#338-9^(MKJOQ#\)V5W\/]%N&,
M,6K>.8+O5X9_"NG/+F)+[7TL8))\0K(SMD9E_P#M'? +3IM8LM4^./P9TV\T
M#Q5H?@3Q#:7WQ3\#6ESH7C3Q2'/AKP;K$,^O12:7XL\11J7T'P]>"+5]7 =M
M.L[A4)/-"DW!6H26B]V,)\JYN622DXII/G@VMHN^GNR3[55I*T'6AS)SBN:5
M--)2:V4[-))+6]^6VFJ/94DB;.QT*_Q,I!7@$YR.A Y.3P#DC!%3[<CGH1]W
MIZG!Y]_;M7YU^(/VF5\ _MV^,?A7\0_C-X#\"? [1/V9_A'XGCL?B)JG@/P=
M$/CG\7?BK\1?"_A'0-!\6ZP=$U2_OM4\)_"W7+^/PE+?:S<7=]J0FL(X(8HK
M$?;.I_$OP)H7BCP[X%USQKX+T7QOXM$Y\*>#-7\6Z#IOBSQ.EM#>7,S^'_#U
MY?1:OK*PV^FZE/*=.L;D1PZ=>SR!$MIQ%I4HSI\BJ0O[6A"M#EC5:=.?/)1E
MS)^^E3;DD[OW6TKHSHXNE6]H^=1=*O4HM2E2OST_9J4UR2TC+VT%'F2L^9+6
M,CN!"@+$ #=G/!SSUYST/I_^NFM&I;Z 9)/&!R<D\>G8]3TKS?PO\9?A9XXU
M"VTOP1\2OAWXSU"^\,P^-;*Q\)^-_#7B2_O/!T^L7WAV+Q9:6.BZI?75UX9E
M\0:9J&A1>((8GTF76K*\T>.[;4;2XMX[#_%3X>+XP?X=R^// \?CY8)9Y? \
MGBS0HO&*6ZZ7_;32GPQ)J UI8TT0KK$DCV2*NDJVJ'%B5F;.<7JG"<7SP;O3
MDG>^DK-*^R:E;LVS6-3#^[^\I6VBU.+3?O/EC)2E'FNI>YSJ5U+W=+'>9B.T
M^8NT_,H\Q-I/48YY!&>G'J"!3I"C?*9%0D9(#+S@8['=GYLYP<$9YXKX-_9T
M^/>K?M+?&'X]Z_X-^)7@F]^!/P3^(>L_ G3?!7AS3]$\2:QX[\1:/X7\":YJ
M_P 6=1\=VNM7%SH6FV7B[4O&?@;PSX=LM+72-9TSPM=>(9[Z:6XA6P^>H?CG
M^V)XI^-__!0/P%I/Q\_93^%W@_\ 96U_X<Z9X"UOXG_ 7Q5J-M<V?Q5^#.@_
M%_3V^(?B6+]HWP78VEIX;N/$2>%I]5L-)A75+:QDUA]-L[QWTY>F.!G.52E[
M2G%4Z5*<HS52T8RG"/+[M*I)5KUJ>BC*BH-N;YXRY>*>84HQC5C3G4A*I4A!
MTW1E*]+GY[.4XP=)>QE&2;6(=6/)&,HM.7ZZ[X\?>!VA0=S#;D8;<PP.0"&)
MSG:0<X(--8HKE<[N-N=PSN^\0' X*X/RMTP>F./S.\(?%G]KGQ9^U=^T!^SA
M?^-?@;H2?#S]E'X#?%;PKJ%K\(_%.NRZ-\6/B]K'CK0=5L]>O7^+>C+XK^'_
M (8U+X4Z[>:78V.E^#=>U/3_ !=:1W.M07/AY;C5L[]A7]NW5_VXO@5J6E&W
MT?X _MB>$_ WAG5/'O@'Q/X:U#Q'X?L$\6V$%_X*^.'@'PU-XC\.ZIX_^ ?Q
M-M0VI^%K^R\5P7.BW37_ ()UK7!XD\.W<UR3RVO""J1J0J4X*E*HZ;]I&G1K
MI<E2I:C2E"G>/+.7))0DXJ;4I1,J>;8>I5]DZ<X59NM&FJJ495*N'UK4H6;B
MZL$XM*\6HRYH.,5(_43Y.BD,5^\ 5(4.!DDCK\I!&3D C'7-/(7Y5)&0K94E
M0V%(5L+G/RDX)QU;GDXK\:(?VI?VP=;\)_\ !+*33_&_P&T3Q%^W.=:TCXIZ
MBGP0\6:UIG@[68/V??B5^T/IM]\.M*D^.>G2QZ;8VG@>V\!W5CXCU'77U2&X
MD\4VU_87$\.D#[ _8U^-WQ9^*MK^T'X4^,=KX U'Q?\ L\_M#^*?@8WQ%^%6
MGZYHOPX^*VG:5X2\$>,[+Q1HV@Z_K_BV_P##/B#1(_''_""?$7PO'XM\3V?A
M[XB^%/$^EVNJ"*W6QL2IA*D**JIPY)\TN7WIRFN>5)U$Y1LH\\6E'XE:_+L:
MT,PH5JJI.,H2C:U2HH1C34J<,1&G-1;::A6A+VK]Q3G;FYKW^U@L8)4$;F&-
MI89(7J"I).-K+D8(^89X;EZQ!>F1ST/(Z8^7/08Z#''3L*_.7QO^VOXC\'?M
MV?"G]GV3P39+^S_XS'B#X,>)?C5>3^6NF_MA:QX,LOC1\,/A#8.ER;=+*]^#
M7AWQ9=:S)>V:_;_&/BWP'H>EZC#J4&H:?J7Z+1S[H]X3:"%.!\Q+/R, 9W9&
M!@=3PO/)PE1E15)N-Z<Z*G&22D[^TE%MI+F4W=*SC=*SLDT=5+$T*T:O)=<E
M65.;;=G.FGSJ][2<+M2:LE)2C>31(8D!X"C<02>%RPXYX).>..>?PII\L@@R
M*<#!(887D8SV &!@-C..,\XQ]$\1Z-XD@FO-"U?1]:M+:\O--FO-&U2QU:SA
MU'3[E[34-.EN;":XBCOK&YB:&]M9#'<VLH6*XAAEWQI^>/Q)_:GUB^_:W\:?
MLHZ-\<O@S^S3XC\)?"WX=>/O!\GQA\*P^)?$WQTO_B-?>,K.[G^'.FZS\2OA
MMI>J^#?AO<>%M/TCQC9>&Y=?\4WWB'Q###<ZAX(L;73IO%+IX>5:K5IPI>]&
M*JU-*KE%1E!*<H4X.:Y92B_AD^5\]E&[66(QE##TX59R3C.I&C3]ZG'G<X74
M(3JU(44G&.KE4A"\7!RYVHR_2-FAZAT)&>-RYXZ' /3H">W7IT8=A.U@#NVD
M'=C)91\I.<$$EAQUSP#CC\N_'WQR_;,^'6L?\$\?#GCEO@3X3\:?M"_M :_\
M"?VB-#T?P-XH\5:$O]A^ /BW\4K'QE\&]</Q4LKOPQ:>*?#/PB>ULM*\71^,
MKS1HO'4-SJ)36/#%QHVH\9K7[0?[;NK_ !Z_;\\ _#OQQ^R_9Z!^Q]H7PD\<
M>"=(^)?PF\;Z19^/=#^*?P^\5?$6\\+>/OB=I_QQLK3P/+X=@\+-HEM\1;#P
M;?Z79I?2^(-<\'74=H^GC:EETZT?:PG0A&4/:PE.<U%2^L*A=7B^6;K22?-&
M+7-SZ13:Y*V9TJ3<9TZTFG[.HH0IMRC]6>)LE&;?+&A"5X)_'!P5Y2BG^OH1
M& R_. #R,?>SQQC@],9]!B@!6VJ6'REF5"5)'(W$!3NR"#CC(Y7(R:_,+X0?
MME?$S]LC6/"/AG]G[1]'^#D.G? #]GWXZ?'CQ3\5_#&I>-M<^'6N?M(^#I?'
M?@CX!>%/!MKK_@6UU#XA:=X1MI/$?C?QCX@U*;0?"^D:MX/M+3PGXBU3Q+<#
MPW])?#'5_P!I_P /_&/4OA[\6M,\ _$'X57?@:_\6^#OCUX'T:_^'VI:=XFT
M[6](TR[^%?Q%^&]]XE\:6TFKW>G:O-XH\.>/_#>O:7HNLV=GJ^A7O@_1]2T9
M+_6\IX2='GC-T55HP<I4I3J^V44Y12A!IQE-WE*G!R;G!\].\;G51QU&I[.=
M*G7E3J3<858PING*4HP<E*7-S1BFXQFX1485$Z<[2@SZO0'!;<26))));@$X
MQSGIC\,#I@!CN4=02F&QD,ZH N3N;#$YRQ53V&1R"<''?Q'HL6M0^&VU72E\
M0W.FR:S!H)U.Q76YM'AN%LY]6@TEI_[1FTZ"Z9+:6^CM7LXYV$4DZ.0I^+O^
M"B?QM^-_[./[+_BWX]_ 31/#?C'Q?\+_ !!\/]7UGX;^(O"FN^*;OXF^#-5\
M;^'_  UXG\%>$1X>\2>'=0T+QUJ.GZ]-)X0UD1>(K4ZS:V]A=^'-0CNLPNAA
MZF(K8?"TN2%3$5*=*E4K7A23J\UIRFDHJ,N24/:7]FISC>:LTM*^)I8>C5KS
MM45"G*<X4WSMJFXPE%)<SDX\]U!VJ2C'F46E=_=0< C<>23@,0">N0H.#D ?
M='. >V#4.5^<%OE+ $LZE3\QQD9XRV#CC)'<U\-_M ?ML>#_ (=_L/>)?VR?
MA78)\6=-U;X0CX@_!#PWI)+S_$W7_$_AB;7/ F@"-)(Y[2%I +WQJ^Y9/"OA
MS2O$VK:B($T&\:#Y]U']L_Q=H]A^Q)X$^(_QL^!OP/\ %_[47P$NOC%J7QJ\
M=>"[G2_A[XF\56NF> M43X.?"/0O$?Q/T[0M)\9S6'C@ZQ*/%OC?Q%=S^%?#
M<@T?0M2U77)K_P ,U2P.)J04_9N$95ZD8<W-+WJ%/VE2$HKFJ2E2IRC*:C"3
M:DN5.TE'GJYEAJ=2=)24I0H4JLI0G",.2M-4J%YSE"ES5IJ7)4E.,;1DYRBK
M.7ZSDHT9RX"$$."5"E6./FR< 2;CSD [OESQEJK !B/!+\DHP*\Y'!&1T!R/
M3&<YR/R>^._QK_;F^"WPG^'^IZCXG_9KG\2^*/VTO@-^SKI_C?3?A?XLUGPG
M\0_@I^T9\2/AC\-O"GQ4TGPI!\;;:]\%>/\ PCJ'CC5Y]<T*\\3>(/#&OW?A
MNXFTA;#1]1TVY7W']F_XQ_'OQ+\:?VJ?V</B_+\.?$VM_ JV^%.L>$?CA\,O
M">O^%O"VO6/QB\,:SJ]GX0\<_#W6/&GC$:)\3/ %QH4&KZ[I^E>.7T_Q'X(\
M5>#-;_L[PQ_;2Q7#>#G[+VO/1<8J=W&4^=QA4A1FXQG&,>52J0@XS<:CUY82
M46R89G0G5^KNE7C)*\DXTO9J=6G.M1O*G6G4;E"G.K"=.-2BX<LG42DC[R$2
M<<_-@+N#= I+#(&1]X'D_P 65&,8J0A"<,P&W&%# $8)48*G<.01QM^8%<]1
M7X3^!/VX?VQ8?!6B_%+Q1XM_9C^*/]G?MQ^*?V1/%_[/_@CX9^,O WQ7\4>&
M-&_:0O/V=X/B3\*=2NOC=XYNV\5:)9P1_&'Q9X.UGP/K.D-X'TOQ3]EUK1;;
M3(M<3]'OV[/BI\2?@#^R#^T1\>?A#=^"X?'7P2^%'C;XJZ39^//"VJ^*_"FO
M0^ = OO$-YX:U+3-#\7^"=3MDU^UT[^SH-6M->BDT>247AM-0C1[24J8.:JT
M*/-24ZM648R;GR.:E2AS-VC.*YZM.TXQ?,G=:1=G3S+#5*.)KN-2"PU-5)Q<
M:,I.G&G6J6O"K45X0IU92CI*&TE>:O\ 6RB/:$0KLX "NA4!B,$*&ZY "XRP
MQA,9H BC+;"OW06 ;)8%@=WS%LDL=S,V69SN))K\UOA)\>OVDM*_:;^%/P.^
M+VH?"KXK^$_C7^S)XG_:!TKQ;\-?A]XE^&_B[X4:OX,UKX:Z/?>&_B%H>I?$
M'XCZ/J_A#QS)\1&@\$^)89/">I1ZOX9UC2KFPUXHUWI_E>A?&;]N3QUX_P#V
M[O"OASX[_LE^"H?V:OC+H/PQ^&-S\1_@%XQ^Q^(!XX^#WPV^+/A"#QKXCA_:
M1T"#3;Z75?BEI7P]EU'3-$O1J-SIAUZST/[5J\&@VMQRR?-4A[;#1C3LYSA4
MJ\CC[25/V<4Z522G&2]Z,J:E*#C/FY6F\99SAVJ;5.O*56;2I*%/FC&,(U/;
M7YU&I1G"<7&5.=2*D^2<(R3BOV PBCGC/7#?>XR#GH>V!GK@C)-,5D"@[L+(
M6^\V&!#="6/! /3Y2O.>IKX1L_CO\6OC/\<OBG\!?@S>>#? T7[-^G_#O3?C
MU\4O$_AC4/',]Y\4/B3X0A\<:;\,?A7X6A\4>%;"(Z!X3O=&\1^,/'7B_5M6
MM;6/Q+HOAW2?"6IW<NJ>(]!W?">H_MEZ9XP^)OP^^(__  JC6O"<?PR;Q7\'
M/VE?!O@K6]%3_A,O[2NM*N_ /Q/^"VJ>/];$VJZ#:?V?X@M=>\,>.=,T3QEI
M,][:IIOA*_TZ6&XPCAI148MTHS=J:C*<Y-J4TU)\M*"=TU)+E3L[ZG2\=3?/
M4M6E!P;=54XJ"=-/F@I7:7)*+BW:RFN6]W8^SC'"KYXS]T@N2%+GH4)V[QL#
M#(W9&4Q\Q,C>23M:1=S;2,R+EASMX+9/&<#D'!QTK\4/AW_P4+^(FH?L9_L$
M_&_XU_$3X$?!GQ7^VMKS:9K_ ,9/$'@O7-,^!GPGEO/"/C?QIHGA6UTK7/B8
M$3Q1XM;PK'X7\):MXX^(VEZ!=:K)>7NHQZC?P:/X3U?ZNBE_;XUNPU#3/!WQ
M0_96U33+KQMX6U7P-^T(?A;XH\0:1K7P;OO"/C"?Q/I.I_"_P_\ '&SAU7XB
MZ9X]L/!FD67B31?'6A>$=1\)>(;K6(= &L:;>:9#N\%53<I2A3C*I.%&JXU7
M2E.'.I2C4E2]G/EY)P=*,W6DW&?LI1G&;R69T)<RA3J2E"E&O4IQ]@YPA*$7
M%RA[7VBC*G74DXTW!<TX\T91G%?H)LC&T I@G@9'.>. 20>G'7G/!J,N@;!<
M 8!4F1&R"1A@I)R#T!QP1SC&!^0G[/?Q>_X*'_&SQ%^T!;'XF?LA?8_V;?VM
M]5^ >K>'T_9Y^*^@7GQ*\*>$;/X>>(O$VKV7BJ?]I?Q+%X!US6?#7C/48M#1
MO#/C&VTW7-+L);G^U+"\N(H<GX5_'+]O'XK+^UK#I/QV_9%\.:Q\!/VLO%'[
M-?P_TCQQ\!?&6FZ?\0)-#LO NJ>'+?5O$,'[1MN^B^(?&]QXZMO"EJNF>'=:
MBBU>"&[T[2;T78TZ%RRV:=5NIAY*A[.=24)5+)S4/9WM'2ZJ1LVFE>SY;-K%
M9Q2M2OA\2I593A"*A13DU*HJB@G5CSN,J4^=1O)63>DHI_LJ'0?QA<G&795!
MP,Y7GG'7OP#NZY+7,1.2P+*"<AEX&<'.">X..#C&.V*_';QY^T?^V0WQ]_X*
M!_#[P#\2OV8/#'A7]COX1_!7XW^#KCXH_!CQO+I_BG1_B]X=^-?B74/"7Q+\
M9Z?\>-!3P_;^&XO@_P#8#X]T?08D$.OR:IJ/AFX;2S8WO:?M$?M5?M#6?[+/
M[&GQ_P#A':^#?@QXF_:+^)O[(O@CQ[X"^-7P^UKQ]>^!;#]JS7_!?A>>R$&G
M>-_AC=VGB3X7ZAXK-S=0ZDJV^O"SN+&^M-!D1I[86 J.5*+G13JN*Y)3JWI-
MTG6CS14&_?@G:2YDW:+2;-_[5I<M:;IUK48RE%J-.4<1"E5]E5E3E>49<K3]
MU\DFES14X^^?JL'0'9OP 5"G<,-E1PI[Y.!M7^+U[H FX*/E#,5(!4*SY#M@
M$$DY!X'/7.!T_*_X^_&+]L/X!_LU_MU_&<?%?]E?XEZY^SO\'[GXG_#5M"^$
M?C/2;:R\2?#WP3XI\??$7X8_&/P;;_'CQ+J$)\1>&K7X?W7A/7-(\8Z)K%E;
M>*KJ^N?#MY:VFCPW^W\9?CO^U-^R?\*;7]I_XBZC\+?CY\!O!>@Z+XQ_:!\.
M>"OA;XH^&'Q5^&_P[NH["X\:?%OP%J;?$SXA^'/&V@_#+1KS4/%GB?P!KGA_
M1-;OO"FBZO>Z7XZ_M&S73;^8X&=G'GHR<JGLXPO4C*I)J-2*@ZD8*,4I+2;B
MI2=D]@IYE1J3?[JLDZ<:DI.$)0I0NXR4E&3;;:;]Q2Y(ZOL?IR8E)).>>O8]
M,8!Z@>W/;T&&FWC.,@_*<CD@ \8. ?8=?TJM8ZC:ZE:6M_8W-O>6-[;P7=E>
M6L@FM[RTND2:UN;>5?EDAN+>2.:)T+(ZN"KL"&.A7.DMN6W*VK.*3B]5)/2Z
MDM5)/572>CL>BG"I[T6I_"U).Z:LG"2>UFK.+6C2NM5<8$VX"D@#MU[D\\^]
M&P<<G@YXX^G3J1Z_I3Z*&D]TG;:Z3_-/^O16JRUTWWU>OX^7]:W9Y:\GG)&.
M?\.F/;I1LYSG.1@YZ=,' Z#(XSC/ICN^BAI.R:32=TGJD[6O9Z7MI>W^862U
M2UM:_6U[VOO:^MK[_<,\M2 IZ 8&,CCCKZGCK3?)3(;&"IRN"P&>>JYVMC)*
M[@0I)*A223+1197O97O=.VS2LFKWLTM-+#M_7];_ #N1^6,$=B .>2,8Q@G/
M/%)Y*]>?0<\8^G3WR,'-2T465K65FK-66WW>;^]]Q62V5M9/RO)6D[;>\M'I
MJNQ&(@,8)SQDGO@8 //IUYP>XH\M2I4Y*D$')Y(.<@GJ<@D=>GN,U)11RQM:
MRMIT[--?<TG\D"26R_JW+^6G=K=O<A$"*NU1M'4CL3SR1^)/& #C & *40H,
M<9(QDGG."2.OUY]>X-2T4<L==%K=/3=.7,[^LO>>NKU!Q3U:3]=?FD[J_G:_
MF1F)2023\I4J,\ KT..A_+@9 XI!$H.1CC:0,=U^Z>O49.2,9R?6I:*3A%JS
MC%IWOHNK;?1;MMOS;?4=E^-_GJOR;7HVK6"BBBJ **** "BBB@ HHHH ****
M "BBB@ HHHH *#T.>G>BB@#\&?VR/^"?7Q<^*/[=FI>(OA.B:-^SQ^WI^S1X
MB_9T_;_U^&YLUN_"^E?#'4_#VJ> ?''A?3[];NUF^)GC;P7J&N_"'P[J=SI>
MK:?X?TZ75/$5U:0W=C9-<>I?\$R_V3OC?X8_9FU?PG^WAI6E>*/'J?#R?]C2
MQT2ZAM+B"\_94^#.I>,_!'A*>_O+>\NKBXU'XPVFL:IXMUN]-_'/JWA@^ 5U
M&"+5]$>8_L#"JL K*&5YB'4@%6&)&PP/#?-\W(/S<]>:1^$<C@F(L2."69#N
M8GN6P-QZG STKMGF>)>$HX:2I\D8PM*,>6H^32/-.[D_W<:=-K9PI4H[03?S
MZR; K%U<QM6=2K.NI0<[T[8BRJ14-()*?-.%HW@ZE6S_ 'CM_)AX9_X)T?\
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ML?#_ (V\7^ +NTM_%'A?2-"^*%EH>IZ;?:;>:=#NFZK]I'3_ -J#]I3]C/\
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M9))+M%?#%:*T8K2,=>5:)V"BBB@H**** "BBB@ HHHH **** "BBB@ HHHH
"_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
